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I. Introduction 
Differentiated thyroid carcinoma (DTC) is a rare disease with an incidence varying from 2-
10/100.000 (1-4). The prevalence of DTC is, however, high because of the good prognosis. 
In general, 80% of the newly diagnosed tumors are differentiated tumors originating from 
the epithelial follicular cells. Median age at diagnosis is between 45 and 50 year with a 
female to male predominance of 2:1 (5). 
DTC is associated with an excellent prognosis, with reported 10-year survival rates reaching 
90% (6). This is because of a combination of the favorable biological behaviour of the tumor 
as well as the availability of effective therapy, consisting of total thyroidectomy followed by 
radioiodine ablation. After initial therapy, all patients with DTC are initially treated with high 
doses of thyroxin aiming at significantly suppressing thyrotropin (TSH) levels, resulting in 
a subclinical hyperthyroid state. The rationale of this approach is based on the potential 
harmful effects of TSH on tumor recurrence (7;8). However,  long-term TSH suppression may 
be associated with potential harmful effects on various systems, including bone metabolism 
(9-11), glucose metabolism (12-14), the autonomic nervous system (15-18) and quality of 
life (19-23). 
According to protocollized follow up, thyroxin replacement therapy can be transiently stopped 
in these patients to detect residual or recurrent disease by TSH stimulated thyroglobulin 
levels. As a result of this standardized procedure, patients become overtly hypothyroid within 
4-6 weeks. This may reversely affect the systems influenced by subclinical hyperthyroidism, 
mentioned above.  
DTC patients are an unique model to study the metabolic effects of thyroid hormone, both 
depletion and excess, on physiological systems, because these DTC patients are treated with 
total thyroidectomy and therefore don’t produce any endogenous thyroid hormones. Thyroid 
hormone levels are well documented in these patients and can be exactly regulated by 
changing the thyroxin dosages. During clinical follow-up, patients are sometimes withdrawn 
from thyroxin, which creates a state of controlled hypothyroidism, whereas many patients will 
be treated with TSH suppressive dosages of thyroxin, thereby creating a state of subclinical 
hyperthyroidism. Moreover, there is no interfering effect from thyroid disease, like in patients 
substituted with thyroxin for autoimmune thyroid disease. 
In this introductory chapter a general overview of DTC, thyroid hormones and the clinical 
consequences of exogenous subclinical hyperthyroidism and thyroxin withdrawal will be 
provided and the questions addressed in this thesis will be introduced.
II. Differentiated thyroid carcinoma
Pathogenesis
Genetic alterations are involved in the pathogenesis of thyroid carcinoma. The analysis of 
these genetic alterations is important not only for the diagnosis of DTC, but also for the 
understanding of the pathophysiology of thyroid disorders(24-26). Mutations in one of 
the three RAS-genes are frequently found in follicular adenomas and carcinomas. Benign 
hyperfunctioning nodules or adenomas are associated with mutations in the GSP and TSH 
receptor genes. 
The recent identification of mutations in B-RAF, which are present in 40-60 % of papillary 
thyroid carcinomas (PTC), has improved the understanding of the molecular pathogenesis 
of PTC. B-RAF is a component of the RET RAS RAF cascade that activates MAP kinase. 
Almost all patients with PTC have rearrangements and mutations of B-RAF, RAS, RAF and 
TRK (neutrotrophic tyrosine kinase receptor). Translocations of RET, that are found in DTC, 
give rise to a chimeric protein consisting of an activated RET tyrosine kinase domain (24;27-
01
 
G
en
er
al
 in
tr
od
uc
tio
n
12
42). Transcriptional and post-transcriptional mechanisms are thought to regulate MET 
overexpression as a secondary effects (43). 
The genetic pathogenesis of follicular thyroid carcinoma (FTC) is less clear. However, it 
was found that FTC is related with rearrangements in PAX8 and PPAR-γ genes, which are 
traditionally associated with thyroid development (PAX 8) and cell differentiation and 
metabolism (PPAR-γ) (44). The chimeric protein acts as a dominant negative competitor for 
PPAR-γ. A downregulation of the PPAR-γ signaling route has been observed in experimental 
models of DTC (45).
The genetic alterations that are involved in the pathogenesis of DTC, result in proliferation 
by multiple pathways and the loss of thyroid specific proteins. Thyroid peroxidase (TPO) is 
believed to disappear in an early phase, followed by the disappearance of NIS. 
Diagnosis
Fine needle aspiration (FNA) is the procedure of choice in patients presenting with thyroid 
nodules. The sensitivity of FNA is 90-95 %. The specificity of FNA is lower, 60-80%, when 
all patients with a non-benign FNA are referred for surgery (46). The distinction between 
benign and malignant follicular tumors is difficult to make by FNA, because the essential 
criterion for FTC is capsular invasion which can not be determined by cytology. Another 
problem is the differentiation between follicular adenoma and follicular variant of papillary 
thyroid carcinoma (FVPTC), because the essential criterion is the aspect of the nuclei. As 
a consequence, the frequency of FTC in hemi-thyroidectomies performed after suspicious 
outcome from FNA is only 20-30%.
The Tumor-Node-Metastases classification system is based on pathologic findings. This 
classification system divides patients into four stages, with progressively poorer survival with 
increasing stage. Recently, the 6th edition of the TNM system has become available (47). The 
most important difference with he 5th edition is the fact that the dimension of T1 has been 
extended to 1.5 cm and that tumors with limited extrathyroidal extension are designated T3 
instead of T4, which has implications for the prognosis of DTC (48). Therefore, some experts 
propagate to continue the use of the 5th edition. In the studies in his thesis the 5th edition of 
the TNM staging system is used (49).
T0 No evidence of primary tumor
T1  Tumor 1 cm or less in greatest dimension
T2 Tumor > 1 cm, but nor more then 4 cm in greatest dimension, limited to the thyroid
T3 Tumor > 4 cm in greatest dimension limited to the thyroid
T4 Tumor of any size, beyond the thyroid capsule
Nx Regional lymph nodes (cervical and upper mediastinum) cannot be assessed
N0 No regional lymph node metastases
N1 Regional lymph node metastases
N1a Metastasis in ipsilateral cervical lymph node(s)
N1b Metastasis in bilateral, midline or contralateral cervical or mediastinal lymph node(s)
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Figure 1. TNM classification system 5th edition, AJJC, Adapted from (50)
Initial therapy
Initial therapy for DTC consists of near-total thyroidectomy followed by radioiodine ablation. 
There is still some controversy about the extent of thyroid surgery. However, there are strong 
arguments in favor of total or near-total thyroidectomy in all patients (51). Only very low-risk 
patients (T1 (< 1 cm) N0M0 (5th edition) DTC, unifocal) may be treated by hemi-thyroidectomy. 
13
In tumor stages of T2 and higher a total thyroidectomy is indicated (52-54). Near-total 
thyroidectomy results in lower recurrence rates than more limited thyroidectomy because 
many papillary tumors are multifocal and bilateral (55;56). In addition, total thyroidectomy 
facilitates total ablation with iodine-131 and reveals a higher specificity of thyroglobulin (Tg) 
as a tumor marker (52-55). Complications of total thyroidectomy are laryngeal nerves palsy 
in 2 % of DTC patients and hypoparathyroidism. The latter occurs in 1/3 of patients after 
total thyroidectomy, but persists longer then 3 months in only 2 % (50). 
Controversy also exists about the routine use of iodide-131 ablation of thyroid remnants. 
However, many clinics give postoperative iodide-131 ablation for three reasons. First, 
iodide-131 destroys any remaining normal thyroid tissue thereby increasing the specificity 
of detectable serum Tg levels and positive whole-body scintigraphy  indicating persistent or 
recurrent disease (5;54;57). Second, iodide-131 may destroy occult microscopic carcinomas, 
thereby decreasing the risk of recurrence thyroid carcinoma (8;54;58;59). Third, the use of 
large amounts of iodide-131 for therapy permits post ablative scanning to detect recurrent 
disease (60;61). A meta-analysis showed that the use of iodide-131 to prevent recurrence 
or death is uncertain (62). A beneficial effect is probably only present in patients with high 
risk or irradical surgery (8;53;63;64). Many authors are more careful advising I-131 ablation 
since various papers reported a relation between I-131 therapy and non-thyroid carcinoma 
(65-67). 
In patients with a very low risk of recurrence/mortality (T1 (<1 cm) N0M0 unifocal) I-131 
is not indicated. I-131 ablation is still the treatment of choice in patients with a high risk 
of recurrence/mortality 1) T3 or T4, 2) any T N1, and 3) Any T M1, and incomplete tumor 
resection (68;69). Controversy exists about patients with a low risk (T1 (>1 cm)N0M0, 
T2N0M0 or T1(<1 cm)N0M0 multifocal) of recurrence/mortality (50).
After initial therapy, all patients with DTC are treated with high doses of thyroxin aiming at 
significantly suppressing thyrotropin (TSH<01 mU/L) levels. The rationale of this approach 
is based on the potential harmful effects of TSH on tumor recurrence (7;8). One study 
demonstrated a preventive effect of TSH suppression on tumor recurrence or progression 
only in high risk DTC patients (70). However, long-term TSH suppression may be associated 
with potential harmful effects on various systems including bone metabolism, glucose 
metabolism, the autonomic nervous system and quality of life. The recent European 
Consensus on thyroid cancer (71), recommended that not all patients with DTC should be 
indiscriminately treated with TSH suppressive therapy because this represents in effect a 
state of subclinical hyperthyroidism, as defined by suppressed serum TSH levels (below 0.4 
mU/l), in the presence of normal serum levels of (free) thyroxin. A recent analysis of our 
institution showed that TSH levels are positively associated to thyroid carcinoma related 
death and relapse (72). This effect became apparent at TSH levels above 2 mU/L and is in 
line with other studies (73). 
Follow-up
The purpose of follow-up protocols in DTC is the early detection of tumor recurrence or 
metastatic disease in order to optimize additional treatment. Most patients during follow 
up have been cured definitely, and, as a consequence, have a low pre-test probability for 
recurrent disease. Therefore, the sensitivity of the diagnostic test must be adequate to 
detect the few patients with evident thyroid carcinoma, whereas specificity must also be 
high to avoid unnecessary treatments in patients without recurrent disease. In addition, the 
burden of diagnostic tests for the patient should be kept at a minimum. 
a. Thyroglobulin
Thyroglobulin (Tg) is produced by normal or neoplastic thyroid follicular cells and Tg 
production is stimulated by TSH. In patients treated with a total thyroidectomy and I-131 
ablation, Tg should be undetectable. The clinical interpretation of Tg is hampered by the 
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following analytical problems: 
1. lack of universal standardization of the Tg assays, which results in considerable inter-
assay variability (74), 
2. a high intra-assay variability, which results in a poor comparability of results obtained 
within one patient during follow-up, 
3. “hook” effects may be present, which affect IMA methods in particular and can lead to 
inappropriately low- or normal range Tg values in sera with very high serum Tg concentrations, 
4. the presence of Tg auto-antibodies that can lead to lower or higher Tg levels. 
Despite these analytical problems, Tg measurements are still the basis in the follow-up in 
DTC. Several studies have been performed on the diagnostic value of Tg measurements. 
The interpretation of these studies is difficult, because 1. heterogeneous patient groups 
with respect to initial therapy are included, 2. the time points of Tg measurements after 
diagnosis are not clearly indicated, and 3. fixed Tg cut-off levels are used, without receiver 
operator curve (ROC) analyses. The application of ROC data is essential, as a chosen cut-off 
level is a subjective choice based on the balance between a desired percentage of missed 
recurrences versus unnecessary therapies. Therefore, in the recent European consensus 
paper, it was recommended to define institutional Tg cut-off levels (71). In addition, most 
studies provide data on the diagnostic value of Tg for tumor presence, but do not give data 
on the prognostic significance for recurrence or death. The few studies that were published 
on the prognostic significance of Tg measurements used fixed cut-off levels, contained 
selected subgroups of patients, and included either Tg measurements at one time point or 
at undefined time points (75-79).
We, therefore, performed a study on the diagnostic and prognostic value of Tg in a 
homogeneous group of DTC patients with respect to initial therapy, using Tg measurements 
at 5 defined time-points after diagnosis, in combination with ROC analyses (chapter 2). 
b. Thyroxin withdrawal versus rhTSH 
Serum Tg measurements, I-131 ablation and diagnostic I-131 whole body scans are based 
on the responsiveness of DTC to TSH (80). TSH stimulated Tg measurements have superior 
diagnostic value in DTC compared to Tg measurements on thyroxin replacement therapy 
(81).  High serum levels can be achieved by thyroxin withdrawal or injection with recombinant 
human TSH (rhTSH), which has less impact on quality of life (82). rhTSH is an adequate 
method to detect recurrence or metastases (78;83-85). A rhTSH stimulated Tg level greater 
than 2 mg/ml predicts persistent disease (78;83;86), whereas a rhTSH stimulated Tg 
level lower than 0.5 mg/dl has a 98 % likelihood of detecting patients free of tumor (78). 
Whole body scans performed after rthTSH-injections have a similar sensitivity and negative 
predictive value compared to thyroxin withdrawal (83-85). However, more negative whole 
body scans were found after rhTSH-injections compared to thyroxin withdrawal (83-85). The 
sensitivity and negative predictive value of Tg values after rhTSH-injections are 96.3 % and 
99.5 % respectively by combining these measurements with a neck ultrasound (87). 
Several studies have reported that radioiodine ablation of thyroid remnants after rhTSH-
injections is as effective as ablation after thyroxin withdrawal (88;89). Radioiodine ablation 
after rhTSH-injections in patients with recurrence or distant metastases results in a 
beneficial effect in 75 % of patients (90;91). However, rhTSH has not been approved for this 
indication.
c. I-131 scintigraphy, Ultrasound, and FDG-PET
The result of iodine-131 whole body scanning depends on the presence and the ability 
of thyroid-cancer tissue to accumulate iodine-131 in the presence of high serum TSH 
concentrations. Diagnostic RaI whole body scintigrapies have a much lower sensitivity 
than ultrasound and Tg measurements. Therefore, the routine use of RaI scintigraphy in 
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the diagnostic follow-up of DTC patients is no longer recommended (87;92). Ultrasound 
combined with FNA had the highest sensitivity (even higher than Tg) for local recurrence and 
lymph node metastases in recent papers (87;93;94). Thus, ultrasound has an important 
place in he follow up of DTC. 18-F Fluorodeoxyglucose-positron emission tomography (FDG-
PET) may be useful in patients with elevated serum Tg levels, in whom no RaI uptake is 
observed after diagnostic or post-therapeutic scintigraphy. The sensitivity of FDG-PET 
is increased with elevating serum Tg levels and after TSH stimulation (95). Robbins et al 
showed that FDG-PET positivity is associated with worse survival (96). 
III. Thyroid hormones
The production of thyroid hormones by the thyroid is regulated by the hypothalamus-pituitary-
thyroid axis. Thyrotropin releasing hormone (TRH), which is produced by the hypothalamus, 
stimulates the secretion of thyrotropin (TSH) by the anterior pituitary. TSH promotes the 
thyroid to synthesize the prohormone tetraiodothronine (T4) in the thyroid. Iodide is actively 
taken up by the thyroid gland by the sodium-iodide-symporter (NIS) at the basolateral 
plasma membrane. The expression and activity of NIS are controlled by TSH. Thyrogobulin, 
which is synthesized by the follicular cells, is then iodinated with one or two iodides to form 
monoiodotyrosine (MIT) or diiodotyrosine (DIT). This process is catalyzed by the enzyme 
thyroid peroxidase (TPO). Two DIT molecules are then coupled to form T4 and one DIT and 
one MIT molecule are coupled to form T3. The thyroid secretes approximately 90 % T4, 10 
% triiodothyronine (T3) and less then 1 % reverse T3. The T3 molecule is the active form 
of thyroid hormone. The majority of the active form of thyroid hormone T3 is derived from 
conversion of T4 to T3 in peripheral tissues, such as the liver (see deiodinases). T4 and T3, 
in turn, have a negative effect on the TRH secretion by the hypothalamus and TSH secretion 
by the pituitary. Iodide is important for the synthesis of thyroid hormones. 
Deiodinases 
Peripheral thyroid metabolism is mainly regulated by the iodothyronine deiodinases D1, D2 
and D3 (97;98). D1 convertes the prohormone T4 in T3, plays a role in the breakdown of 
rT3 (97;99) and is expressed in liver, kidney, thyroid and pituitary and at lower levels in other 
tissues as skeletal muscle, spleen and lung. D2 is essential for the production of T3 through 
outer ring deiodination of T4. It is present in brain, skeletal muscle, thyroid, pituitary, brown 
adipose tissue (BAT) and aortic smooth muscle cells (97;100-104). D3 inactivates T3 and 
prevents T4 activation by innerring deiodination (98) and is present in brain, skin, placenta 
and fetal tissues (97).
The deiodinases adjust the thyroid hormone levels of individual tissues in response to 
various conditions. The peripheral conversion of T4 to T3 is increased during hypothyroidism 
(97;105;106). Extrathyroidal T3 production changes from PTU sensitive to PTU insensitive 
during hypothyroidism in rats, representing an increase in the conversion of T4 to T3 by D2 
and a decreased conversion by D1 (107). D1 gene transcription is decreased in liver and 
kidney during hypothyroidism (108), which is related to the presence of two T3 response 
elements in the human D1 gene (97;108-110). Thyroid status regulates D2 activity both at 
the pre- and posttranslational level. D2 activity is increased in different tissues predominantly 
during hypothyroidism by a decrease in substrate (T4)-induced degradation of D2 protein 
(97;111-113). Hypothyroidism elevates D2 mRNA in rat brain and BAT (97;100;114;115). 
D2 mRNA expression and activity were found in skeletal muscle samples from healthy 
subjects (103;116). This is fascinating, because D2 could therefore play a role in peripheral 
and intracellular T3 production (103). Maia et al. reported that D2 is a major source of 
T3 during euthyroidism and could therefore play an important role during hypothyroidism 
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(117). As patients treated for DTC have no thyroid tissue left, we hypothesized that during 
hypothyroidism D2 in skeletal muscle could be essential in promoting the conversion of T4 
to T3 (chapter 3). 
Several polymorphisms in D2 have been described (118-120), with most studies investigating 
the consequences of the D2-Thr92Ala polymorphism. This D2-Thr92Ala polymorphism has 
been associated with BMI and insulin resistance in obese subjects and type 2 diabetes 
mellitus (118;119), although this was not confirmed in another study (121). The maximal 
velocity of D2 in vitro in thyroid and skeletal muscle of homozygous carriers of the Ala92 
allele was decreased by 3–10-fold (118). 
IV. Bone metabolism
Thyroid hormone impacts on bone metabolism, ranging from decreased skeletal development 
in childhood hypothyroidism to an increased risk for osteoporosis in hyperthyroidism 
(11;122;123). Thyroid hormone indirectly promotes osteoclast formation and activation 
by inducing the expression of cytokines, prostaglandins and the receptor activator of 
nuclear factor NF-κB ligand (RANKL) (124-126). RANKL, the key molecule in osteoclast 
differentiation, binds to its receptor, RANK, which is expressed on dendritic cells, T cells, 
osteoclast precursors and mature osteoclasts (127;128). RANKL promotes the survival 
of RANK positive T cells (127), stimulates osteoclast differentiation (129-133), increases 
Figure 1. Structure of the iodothyronines and their activation and inactivation by iodothyronine deiodinase. 
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the activity of mature osteoclasts (130;134;135) and stimulates survival of osteoclasts 
by preventing apoptosis (135). Contact with stromal cells and M-CSF also promotes 
osteoclast differentiation (136;137). Thyroid hormone inhibits chondrocyte proliferation and 
promotes hypertrophic differentiation, mineralization, matrix synthesis but also apoptosis of 
chondrocytes in the growth plate. 
Overt hyperthyroidism results in an increased risk for osteoporosis (123), the pathophysiology 
of which is multifactoral (124), including shortening of the bone remodelling cycle (138) 
and acceleration of bone turnover (139). The effects of subclinical hyperthyroidism on 
bone metabolism are not clear. Several studies have addressed this issue, but there is 
no consensus largely because of differences in study design, including patient groups, 
methodology used, follow-up time and choice of outcome parameters. To study the effects 
of subclinical hyperthyroidism on bone mineral density, we performed a systematic review 
including all clinical studies on TSH suppressive thyroxin therapy in thyroid cancer patients 
(chapter 4). 
An interesting development has been the discovery of the TSH receptor (TSHR) in bone 
(140-142). TSHR knockout and haploinsufficient mice with normal thyroid hormone levels 
have decreased bone mass suggesting that TSH might directly influence bone remodeling 
(141;143;144). This is intriguing, because effects on bone metabolism that were previously 
ascribed to high thyroid hormone levels could also be attributed to suppressed TSH levels (143-
145). Abe et al. suggested that TSH inhibits osteoclast formation and survival by attenuating 
JNK/c-jun and NFκB signaling in response to RANK-L and inhibits osteoblast differentiation 
and type 1 collagen expression as well by downregulating Wnt and VEGF signaling (141). 
The same group found also that TSH directly inhibits Tumour Necrosis Factor-α (TNF-α) 
production and that TNF-α is the critical cytokine mediating the downstream antiresorptive 
effects of TSH on the skeleton (146). Other studies suggest that serum TSH activates the 
type 2 deiodinase in osteoblasts, thereby linking TSH and increased local thyroid hormone 
availability (142). Furthermore, in animal studies, low doses of TSH increased bone volume 
and improved microarchitecture in ovariectomized rats (147), without increasing serum 
thyroid hormone levels.
It was recently reported that the TSHR-Asp727Glu polymorphism was associated with 
2.3% higher BMD in elderly carriers (148). Although the functional consequences of this 
polymorphism are debated (149), the lower plasma TSH levels in patients carrying the 
polymorphism could point toward a higher sensitivity of the variant compared to the wild-
type TSHR (150;151).  
We, therefore, evaluated the independent relation between serum TSH levels and indicators 
of bone turnover in thyroidectomized patients for differentiated thyroid carcinoma receiving 
thyroid hormone substitution (chapter 5). In addition, we studied the relationship between 
the TSHR-Asp727Glu polymorphism and bone as these subjects are not expected to show 
compensatory lower serum TSH levels if they carry the TSHR-Asp727Glu polymorphism 
(150;151).
The consequences of hypothyroidism on bone metabolism are not clear. Various studies 
report decreased bone resorption (152-155) or bone formation (152), whereas other 
studies document no impact on bone turnover (156-158). Furthermore, it is not clear if 
the effects of hypothyroidism must be attributed to the increased TSH levels or decreased 
thyroid hormone levels. As mentioned above, TSHR knockout and haploinsufficient mice 
with normal thyroid hormone levels have decreased bone mass, suggesting that TSH might 
directly influence bone remodeling (141;143;144). However, other studies question the role 
of TSH in bone metabolism (159;160). Three studies in humans have investigated the effect 
of TSH on bone metabolism, but their results were not consistent showing either no impact 
on bone turnover (161), increased bone formation (162;163) or decreased bone resorption 
(163).
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To document the effects of hypothyroidism on bone metabolism and to discriminate 
between effects mediated by decreased thyroid hormone levels versus those mediated by 
increased TSH levels, we studied bone metabolism in eleven patients with differentiated 
thyroid carcinoma (DTC) during short-term thyroxin withdrawal and compared with eleven 
age-, gender- and BMI-matched DTC patients with increased TSH levels and normal thyroid 
hormone levels due to rhTSH injections (chapter 6). 
Although earlier studies on the role and functional expression of iodothyronine deiodinase 
enzymes in the skeleton have not revealed unequivocal answers (142;164-167), a recent 
study reported normal growth in mice with deficiencies in D1 and D2 indicating that D2 
may not be critical in skeletal development (168). This was supported by another study, 
which found that D2 activity is restricted to mature osteoblasts, suggesting a possible role 
for D2 in mature osteoblast function (169). Because it is difficult to study the role of D2 
per se on skeletal metabolism in humans, we choose to study the effects of functional D2 
polymorphisms on BMD and indicators of bone turnover. Canani et al. (118) reported that 
the maximal velocity of D2 in vitro in thyroid and skeletal muscle of homozygous carriers of 
the Ala92 allele was decreased by 3–10-fold. We, therefore, studied the relationship between 
the functional D2-Thr92Ala polymorphism, BMD and indicators of bone turnover (chapter 
7).
V. Glucose metabolism
Thyroid hormone has effects on glucose- and lipid metabolism (13;170). There is a relation 
between serum thyroid hormone levels and basal and insulin-mediated glucose metabolism 
in euthyroid subjects with preserved thyroid function (171-173). It has been suggested that 
T3 regulates insulin response after glucose ingestion in humans (174). 
Hyperthyroidism has been associated with impaired glucose tolerance and increased insulin 
resistance (175-181), predominantly at the level of the liver (182). The pathophysiology has 
not been completely elucidated, but it has been ascribed to a combination of multiple factors, 
including diminished pancreatic secretion of insulin (183;184), diminished suppression of 
glucagon by glucose (185) and increased adrenergic activity (186). 
Limited data are available on the consequences of subclinical hyperthyroidism on glucose- 
and lipid metabolism. This issue has been studied only by Yavuz et al., who reported a 
decreased insulin sensitivity index by oral glucose tolerance test in patients with exogenous 
subclinical hyperthyroidism compared to values after restoration of euthyroidism and 
compared to controls (187). Regarding lipid metabolism, most studies report no differences 
in lipid profiles during subclinical hyperthyroidism (188-190), with the exception of 2 studies, 
that observed decreased total and LDL cholesterol levels (191;192). Franklyn et al. reported 
decreased total cholesterol concentrations only in patients older than 55 years and LDL 
cholesterol levels were decreased only in patients older than 65 years (193). We therefore 
performed a prospective placebo-controlled randomized trial to investigate the effects of 
restoration of exogenous subclinical hyperthyroidism to euthyroidism on glucose- and lipid 
metabolism (chapter 8).
VI. Autonomic nervous system
The consequences of hyperthyroidism on the heart are profound, including tachycardia 
and/or arrhythmias, increased systolic pressure, increased systolic function, left ventricular 
hypertrophy and diastolic dysfunction (194-196). It is suggested that these effects are the 
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Result of direct effects of thyroid hormone on the cardiovascular system and the interaction 
of thyroid hormones with the sympathetic nervous system (195;197). Hyperthyroidism is 
associated with a sympathicovagal imbalance, characterized by increased sympathetic activity 
in the presence of reduced vagal tone, which corresponds with increased urinary excretion 
of catecholamines (15;16;198). Therefore, the current consensus is that manifestations of 
altered autonomic nervous system function play a role in the pathophysiology and clinical 
presentation of thyrotoxicosis. 
During subclinical hyperthyroidism, cardiovascular effects may also occur, but these are less 
well known and seemingly less severe. Regular findings during subclinical hyperthyroidism 
include increased heart rate, supraventricular arrhythmias and abnormalities of LV 
morphology and function (195;199-201). The consequences of subclinical hyperthyroidism 
on the autonomic nervous system function are less well defined. Several studies, using 
measures of heart rate variability, found evidence that in patients with endogenous 
subclinical hyperthyroidism a reduction of cardiac parasympathetic control is present (18), 
(200), (202). This is supported by findings on heart rate turbulence by Osman et al (203). 
However, in the study of Goichot (18) no differences in the ratio of low frequency power over 
high frequency power (LF/HF) were reported in these patients. The LF/HF ratio is commonly 
used to characterize the balance between vagal and sympathetic influences. To further clarify 
this issue, we performed a prospective, randomized, placebo-controlled study using heart 
rate variability to assess the autonomic nervous system in patients with DTC with longer 
than 10 years exogenous subclinical hyperthyroidism and investigated whether restoration 
to euthyroidism affects autonomic nervous function (chapter 9).
Hypothyroidism is associated with bradycardia, mild diastolic hypertension, increased 
peripheral cardiovascular resistance (194;204;205), decreased cardiac output and 
diastolic dysfunction (194;204;206;207). Hypothyroidism also induces sympathovagal 
imbalance (17;208;209). Nevertheless, current literature shows inconsistent results with 
either an increased sympathetic activity (17), a decreased sympathethic modulation (208) 
or an increased vagal tone (209). We therefore investigated the effects of short-term 
overt hypothyroidism, 4 weeks after thyroxin withdrawal, and restoration to subclinical 
hyperthyroidism on the autonomic nerves system (chapter 10).
VII. Quality of life
DTC is associated with an excellent prognosis. This may imply that quality of life in cured DTC 
patients may be quite normal. However, patients are treated long-term with TSH suppressive 
thyroxin replacement therapy, reflecting in effect a state of subclinical hyperthyroidism, 
which may impact quality of life (210-212). 
Quality of life in cured DTC patients is investigated in a few studies (20;21;213-215). However, 
these studies are limited by small patient numbers(21;213), limited number of quality of life 
questionnaires (20;215) or the absence of a healthy control group (20;213;214). 
Studies reporting the relation between the level of TSH suppression and quality of life in 
DTC patients are inconclusive because of small patient numbers, selection of patients with 
symptoms of hyperthyroidism or selection of patients with a long duration of cure (210;216). 
For that reason, we investigated quality of life in a large cohort of cured DTC patients 
compared to controls matched for age, gender and socioeconomic status. In addition, the 
determinants of quality of life, including serum TSH levels were investigated (chapter 11).
Thyroxin withdrawal resulting in overt hypothyroidism may also impact quality of life. It results 
in fatigue, anorexia, constipation, problems with motor skills and fluid retention. Quality of 
life during thyroxin withdrawal is also affected by a decreased motivation, productivity and 
quality of work and by interfering with family and social life (22). In addition, a decreased 
psychomotor function and an increased fear are reported during thyroxin withdrawal 
(19;217).
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VIII. D2-Thr-92-Ala and thyroxin dose
Several polymorphisms in D2 have been described (118;119;218;219). The functional 
implications of the D2-Thr92Ala polymorphism are inconclusive. One in vitro study found an 
association with a decreased D2 activity (118) whereas another study found no difference 
(219). So far no associations between the D2-Thr92Ala polymorphism and serum thyroid 
hormone levels were documented (151;218;220). A study of Torlontano et al. documented 
that homozygous carriers of the D2-Ala92 allele needed higher dosages of thyroxin in 
thyroidectomized differentiated thyroid carcinoma (DTC) patients, particular in the group 
with near-suppressed TSH levels (TSH values between 0.1 and 0.5 mU/L)(221). However, 
this study had limitations, because actual values of serum TSH levels for wild-type and 
homozygous groups within the near-suppressed TSH group were not given. It is, therefore, 
unclear whether TSH levels in both groups were indeed identical, which would be a key 
finding to ascribe the slight differences in thyroxin dose indeed to the polymorphism. The 
fact that serum T4 and T3 levels did not differ between the wild-type group and D2-Thr92Ala 
homozygotes is also remarkable. We, therefore, studied the association between the D2-
Thr92Ala polymorphism, thyroid hormone levels and thyroxin dosage (chapter 12).
IX. Outline of this thesis
In chapter 2, we describe the diagnostic and prognostic value of thyroglobulin (Tg) in a 
homogeneous group of differentiated thyroid carcinoma (DTC) patients with respect to initial 
therapy, using Tg measurements at 5 defined time-points after diagnosis, in combination 
with ROC analyses.
In the continuation this thesis, questions about the clinical consequences of exogenous 
subclinical hyperthyroidism and hypothyroidism on bone metabolism, glucose metabolism, 
the autonomic nervous system and quality of life in patients with DTC are addressed.
Chapter 3 evaluates the D2 activity and expression of deiodinases 1, 2 and 3 in skeletal 
muscle samples in DTC patients both during hypothyroidism and thyroxin replacement 
therapy.  
Chapter 4 shows the results of a systematic review describing the effects of TSH suppressive 
thyroxin therapy on bone mineral density in DTC patients. 
In chapter 5, we evaluate the independent relation between serum TSH levels and indicators 
of bone turnover in DTC patients receiving thyroid hormone substitution. 
In chapter 6 we describe a prospective study to investigate the effects of hypothyroidism 
on bone metabolism and to discriminate between potential effects mediated by decreased 
thyroid hormone levels versus those mediated by increased TSH levels. 
Chapter 7 presents the relationship between the functional D2-Thr92Ala polymorphism, 
BMD and indicators of bone turnover. 
In chapter 8, we investigate the effects of restoration of exogenous subclinical hyperthyroidism 
to euthyroidism on glucose- and lipid metabolism in a prospective, randomised, placebo-
controlled trial.
Chapter 9 describes a prospective, randomized, placebo-controlled study to assess 
autonomic nervous function in patients with DTC with longer than 10 years exogenous 
subclinical hyperthyroidism and to investigate whether restoration to euthyroidism affects 
autonomic nervous function.
In chapter 10 we show the effects of short-term overt hypothyroidism, 4 weeks after thyroxin 
withdrawal, and restoration to subclinical hyperthyroidism on the autonomic nervous 
system.
Chapter 11 describes quality of life in a large cohort of cured DTC patients compared to 
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controls matched for age, gender and socioeconomic status. In addition, the determinants 
of quality of life, including serum TSH levels were investigated.
In chapter 12, we studied the association between the D2-Thr92Ala polymorphism and 
thyroid hormone levels and thyroxin dosage
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Abstract
Objective: Most studies on the diagnostic value of serum thyroglobulin (Tg) concentrations 
in differentiated thyroid carcinoma (DTC) use fixed cut-off levels in heterogeneous groups 
of patients with respect to initial therapy and do not provide prognostic data. The objective 
was to investigate the prognostic values of serum Tg for disease-free remission and death, 
measured at fixed time points after initial therapy using receiver operator characteristic 
(ROC) curve analyses.
Design: Single-centre observational study with 366 consecutive patients with DTC, who had 
all been treated according to the same protocol for initial therapy and follow-up.  
Methods: Tg concentrations were measured at five fixed time points after initial surgery. Tg 
cut-off values with highest accuracy were calculated with ROC analyses. 
Results: During follow-up of 8.3±4.6 years, 84% of the patients were cured. Pre-ablative Tg 
levels were an independent prognostic indicator for cure (Tg cut off value 27.5 µg/L, positive 
predictive value 98%). Highest diagnostic accuracies of serum Tg for tumor presence were 
found during TSH stimulated Tg measurements, 6 months after initial therapy (Tg cut-off 
value 10 µg/L: sensitivity 100%, specificity 93%). 
DTC related mortality was 14%. TSH stimulated Tg levels before ablation and 6 months after 
initial therapy were independent prognostic indicators for death. 
Conclusion: Optimal institutional Tg cut-off levels for diagnosis and prognosis should be 
defined using ROC analyses for each condition and time-point. Tg measurements 6 months 
after initial therapy during TSH stimulation had an excellent diagnostic value. Tg levels are 
independent prognostic indicators for disease-free remission and death. Using this strategy, 
high-risk patient groups can be selected based on Tg levels, in addition to conventionally 
used prognostic indicators.
35
Introduction
Differentiated thyroid carcinoma (DTC) has an excellent prognosis with 10-year survival rates 
of 85-93 % (1). The purpose of follow-up protocols in DTC is the early detection of tumor 
recurrence or metastatic disease in order to optimize additional treatment. Most patients 
during follow up have been cured definitely, and consequently have a low pre-test probability 
for recurrent disease. Therefore, the sensitivity of the diagnostic test must be sufficient to 
detect the few patients with evident thyroid carcinoma, whereas specificity must also be 
high to avoid unnecessary treatments in patients without recurrent disease. In addition, the 
burden of diagnostic tests for the patient should be kept at a minimum. 
Serum thyroglobulin (Tg) measurements are the cornerstone in the follow-up in DTC. 
Numerous studies have been performed on the diagnostic value of Tg measurements. We 
recently published a structured meta-analysis on the diagnostic value of Tg including 46 
articles (2). The interpretation of many studies on Tg performed so far is difficult, because 
in most studies 1) heterogeneous patient groups with respect to initial therapy are included, 
2) the time points of Tg measurements after diagnosis are not clearly indicated, and 3) fixed 
Tg cut-off levels are used, without receiver operator characteristic (ROC) curve analyses. The 
application of ROC data is essential, as a chosen cut-off level is a subjective choice based on 
the balance between a desired percentage of missed recurrences vs. unnecessary therapies. 
A recent European consensus paper recommended that there should be defined institutional 
Tg cut-off levels (3). Only a few studies have been published on the interpretation of Tg levels 
during follow up of DTC using ROC analyses. However, in those studies, heterogeneous patient 
groups were included and the time-points of Tg measurements were not clearly indicated (4-
6). In addition, most studies provide data on the diagnostic value of Tg for tumor presence, 
but do not give data on the prognostic significance for disease-free remission or death. One 
large study (7) investigated the prognostic significance of 1-month post-surgical Tg levels 
and found a significant prognostic cut-off level of 
10 µg/L. The few studies that were published on the prognostic significance of Tg 
measurements used fixed cut-off levels, contained selected subgroups of patients and 
included Tg measurements either at one time point or at undefined time points (8-12).
We therefore performed a study on the diagnostic and prognostic value of Tg in a homogeneous 
group of DTC patients with respect to initial therapy, using Tg measurements at 5 defined 
time-points after diagnosis, in combination with ROC analyses. In addition, we studied the 
diagnostic and prognostic value of Tg antibodies for tumor presence or death.
Patients and methods
Three-hundred-and-sixty-six consecutive patients were included in the study. These patients 
had received initial therapy for DTC between January 1986 and January 2000. All follow up 
data were collected until January 1, 2003. January 1986 was chosen as a starting date, 
because from that date forward, all relevant patient data were registered in a computerized 
database. Initial surgery and radioiodine ablation therapy were performed at the Leiden 
University Medical Centre or at one of the connected general hospitals. All hospitals are 
affiliated in the Regional Comprehensive Cancer Centre and use the same standardized 
protocol for the treatment and follow-up of DTC. 
All patients were treated by near-total thyroidectomy, followed by routine radioiodine ablative 
therapy with 2800 MBq I-131. 
Follow-up was performed according to a standard protocol. Serum Tg levels were measured 
at the following time-points: 1) after initial surgery during thyroxin withdrawal just before 
radioiodine ablation, 2) during T4 therapy, 3) 6 months after initial surgical therapy after T4 
withdrawal (‘off’) and 4) annually during T4 therapy. 
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Although additional TSH stimulated Tg measurements were performed in selected subgroups 
of patients at other time points after initial therapy, we did not include those data as these 
tests were not uniformly done in all patients, and calculations of diagnostic values would 
have been biased. T4 therapy was aimed at suppressing TSH levels (below 0.1 mU/L). Six 
months after initial therapy a diagnostic 185 MBq I-131 scintigraphy was performed after 
T4 withdrawal. 
Tumor presence during follow-up was defined as histologically or radiologically (X-ray, computed 
tomography (CT) scan, magnetic resonance imaging (MRI) scan, 18F-fluorodeoxyglucose 
positron emission tomography (FDG-PET) scan or I-131 scintigraphy) within a 1-year interval 
before or after the time of Tg measurements. Although we realize that Tg is considered 
the best parameter for tumor presence, Tg was not used as the ‘gold standard’ for tumor 
presence, as the diagnostic value of Tg was the subject of this study.
Disease-free remission was defined as the absence of thyroid carcinoma for a minimum of 
3 years according to the above mentioned parameters. 
The following data were registered: age at diagnosis, sex, date of diagnosis, histology, TNM 
stage, date of cure, date of recurrence, tumor localization, cause of death, Tg levels, TSH 
levels, Tg antibody levels and date of last follow up or death. TNM stage was registered 
according to the 5th edition of the TNM Classification of Malignant Tumors (13) because 
most patients were analysed before the latest edition of the TNM classification had been 
published. We used the following end-points of follow-up: date of death (82 patients), date 
of emigration (12 patients) and date of most recent contact (272 patients).
Causes of death were analysed in all 82 patients who had died during follow-up. Cause of 
death was investigated using medical records, death certificates, enquiries with physicians 
involved in the treatment of each patient, enquiries in other hospitals, enquiries of general 
practitioners and autopsy findings. Causes were divided into thyroid cancer related death 
and other causes. Analyses were performed in evaluable patients, defined as patients in 
whom all of four conditions were fulfilled: alive at time-point of Tg measurement, documented 
serum Tg measurements, documented serum Tg antibody measurements and documented 
gold standard parameters for the presence or absence of disease. If Tg antibodies were 
present, the Tg measurement at this time-point was excluded from the calculations because 
of possible interference with the Tg assay. The numbers of these patients are given in table 
2.
 
Measurements of Tg and Tg-Ab
Until January 1997 serum Tg was measured using an immunoradiometric assay (IRMA), 
the Dynotest TG (Brahms Diagnostica GmbH, Germany) was used with a sensitivity of 0.03 
μg/l. From January 1997, the Dynotest TG-s (Brahms Diagnostica GmbH) was used, with 
a sensitivity of 0.05 μg/l. Inter-assay variability was 0.3 μg/l. The comparability of the two 
methods is excellent: R2=0.99, slope 0.99, intercept 0.09 (14). Serum Tg-antibodies were 
also measured at these specific time points by the Ab-HTGK-3 IRMA (DiaSorin Biomedics, 
Italy).
Statistical analyses
Data are presented as mean ± SD. All statistical analyses were performed using SPSS version 
12.0 (SPSS Inc., Chicago, IL, USA). Data are expressed as number of patients (percentages), 
as mean ± Standard Deviation (SD) or as median (range). ROC analyses were used to find 
the cut-off value with highest accuracy. Prognostic indicators for recurrence or death were 
calculated using univariate- and multivariate Cox-regression analyses; indicators that were 
identified as significant for survival in univariate analysis were entered into a stepwise 
multivariate model. A p-value of < 0.05 was considered significant.
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Results
Characteristics of the patients are shown in Table 1. Mean age at time of surgery was 48 
± 18 years. Mean follow-up was 8.3 ± 4.6 years. Significant prognostic factors for cure and 
death are given in Table 4. 
Diagnostic value of Tg.
The diagnostic values of Tg measurements at the different time points are given in Tables 
2. The diagnostic value of Tg before ablation therapy was reasonable in our analysis, with 
a sensitivity of 87.9% and a specificity of 90.3% at a cut-off value of 27.5 µg/L. When a cut-
off level of 2 µg/L was used, sensitivity increased to 93.9%, whereas the specificity fell to 
45% with a positive predictive value of only 23% instead of 62%, and with similar negative 
predictive value. 
The highest diagnostic value of Tg was found during TSH stimulated Tg measurements 6 
months after initial therapy (see Fig. 1). The Tg cut-off value with highest accuracy was 
10.0 µg/L, with sensitivity and specificity of 100.0 and 93.1%, respectively. When the more 
commonly used cut-off value of 2 µg/L was used, the sensitivity remained similar, but the 
specificity fell to 82% with a positive predictive value of only 54%, instead of 77% (Fig. 1). We 
analysed the course of 9 patients with Tg values > 10 µg/L, 6 months after initial therapy 
during TSH stimulation: in three patients, tumors were detected 2-5 years after initial therapy. 
In four patients Tg became undetectable and they were considered cured. Two patients had 
Table 1. Patient characteristics
* Significant at univariate analysis, # Significant at multivariate analysis (see Table 4)
Parameter N Cured Patients N 
(%) 
Patients with 
Relapse after Cure 
(N, (%))
Thyroid Carcinoma 
Deaths (N (%))
Total 366 305 (84) 46 (13) 52 (14)
Gender 
(Male/ Female)
Stages 
91/ 275 72 (80)/ 233 (85) 13 (14)/ 33 (13) 13 (14)/ 39 (14 )
T1 22 21 (96) 1 (5) 0 (0)
T2 188 176 (94) 17 (9) 10 (5)
T3 56 51 (91) 9 (16) 8 (14)
T4 96 53 (55) * # 17 (18) 32 (33) * #
T unknown 4 0 (0) 0 (0) 2 (50)
N1 107 76 (71) * 15 (14) 22 (21) *
M1 52 19 (36) * # 6 (11) 27 (54) * #
Histology
Papillary 203 173 (86) 28 (14) 25 (12)
Follicular 72 58 (81) * 11 (15) 17 (24) *
Follicular variant 
papillary carcinoma
68 56 (82) 5 (7) 6 (9)
Hürthle Cell 23 18 (78) 2 (9) 4 (17)
Age (continuous) * # * #
< 55 yr 210 221 (95) 18 (8) 3 (1)
> 55 yr 156 84 (64) 28 (21) 49 (31)
39
persistent measurable Tg, but no tumor was detectable up to 15 years after initial therapy.
Tg measurements on T4, 2 and 5 years after initial therapy had lower sensitivities, but 
comparable specificities and negative predictive values, albeit at lower Tg cut-off values. 
Prognostic value of Tg
Disease-free remission. The prognostic value of Tg for disease-free remission is given in 
Tables 3 and 4. Tg before ablation had a high predictive value of 97.8% for disease-free 
remission at a cut-off value of 27.5 µg/L. Tg appeared to be an independent prognostic 
marker for disease-free remission (likelihood ratio for disease-free remission 43.2 for Tg < 
27.5 µg/L, p<0.001), irrespective of TNM stages T4, M1 and age.
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 Table 3. Prognostic Value of Serum Tg Measurements for disease-free remission and thyroid carcinoma-related 
death. Patients with Tg antibodies were excluded.
PPV= positive predictive value, NVP = negative predictive value, ROC=Receiver Operator Characteristics Curve.
Outcome Tg Cut-Off
(µg/l)
Sensitivity ± 
SE (%)
Specificity ± SE
(%)
PPV 
(%) 
NPV 
(%)
Pre-ablation Disease-free 
remission
27.5 84.4 ± 2.6 88.9 ± 5.6 97.8 49.1
Death 21.5 66.7 ± 9.6 81.3 ± 2.8 30.2 95.3
Six months after initial 
therapy, suppressed TSH
Death 2.5 72.0 ± 9.0 85.7 ± 2.6 40.9 95.7
Six months after initial 
therapy, stimulated TSH
Death 10.0 85.0 ± 8.0 83.5 ± 2.9 39.5 97.8
Two years after initial therapy, 
suppressed TSH
Death 2.0 85.0 ± 8.0 85.7 ± 2.5 38.6 98.2
Five years after initial therapy, 
suppressed TSH
Death 2.0 82.4 ± 9.2 92.8 ± 2.2 58.3 97.7
Figure 1 Receiver Operator Curves six months after initial therapy, during TSH stimulation to obtain optimal 
cut-off levels of serum Tg measurements for the diagnosis of active tumor in patients with differentiated thyroid 
carcinoma.
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Thyroid-Specific Death. The prognostic values for Tg measurements for DTC-related death are 
given in Tables 3 and 4 and Fig. 2. The negative predictive value was high for all time-points 
of Tg measurements. Tg was an independent predictor for thyroid-related death during TSH 
stimulation, 6 months after initial therapy (hazard ratio 10.9 for Tg > 10.0 µg/L, p=0.008, 
Table 4, Fig. 2), 2 years after initial therapy (hazard ratio 12.9 for Tg > 2.0 µg/L, p<0.001) 
and 5 years after initial therapy (hazard ratio 29.1 for Tg > 2.0 µg/L, p=0.001).
 
Table 4. Likelihood Ratios for Serum Tg values for Outcome (disease-free remission or thyroid carcinoma-related 
death) as calculated with Cox-survival Analysis. Patients with Tg antibodies were excluded. Tg Cut Off values are 
given in Table 3.
CI=confidence interval. M1= metastases, T4=extra thyroidal extension
# Likelihood Ratio for Tg value < Cut-Off, * Likelihood Ratio for Tg value > Cut-Off
Outcome Univariate 
Analysis p
Likelihood 
Ratio (CI) 
Multivariate
Analysis p
Likelihood 
Ratio (CI)  
Other 
Significant 
Parameters
Pre-ablation Disease-
free 
remission
<0.001 43.2 (15.0– 
124.3) # 
<0.001 29.9(5.2– 
171.5) # 
Age, M1, T4
Death <0.001 8.0 (3.4– 
18.7)* 
Ns -- Age, M1, T4
Six months after initial 
therapy, suppressed TSH
Death <0.001 14.4 (5.7 
– 36.7) * 
ns. -- Age, T4
Six months after initial 
therapy, stimulated TSH
Death <0.001 31.2 (7.1– 
136.7) * 
0.008 10.9 (1.9– 
63.5) * 
Age, T4
Two years after initial therapy, 
suppressed TSH
Death <0.001 30.9 (9.0– 
105.7) * 
<0.001 12.9 (3.4– 
49.2) * 
Age, M1
Five years after initial therapy, 
suppressed TSH
Death <0.001 24.2 (5.0– 
116.2) * 
0.001 29.1 (3.6– 
232.2) * 
Age
Figure 2 Prognostic value of Tg measurements for Differentiated Thyroid Carcinoma a) Proportion of patients non-
cured, Tg levels pre-ablation, four weeks after surgery; b) Survival according to TSH stimulated Tg, 6 months after 
initial therapy; 
Follow-up (years) Follow-up (years)
a. b.
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Tg antibodies. The percentage of patients with Tg antibodies decreases from 27 % 
immediately after initial surgery to 12 % 5 years after initial therapy (see Table 2). There 
were no significant differences in tumor presence between patients with and without Tg 
antibodies: 15 – 23% in patients without Tg antibodies and 16 – 33% in patients with Tg 
antibodies. The presence of Tg antibodies did not have a significant prognostic for disease-
free remission or death.
Discussion
In the present study we investigated the diagnostic and prognostic value of serum Tg 
measurements for tumor presence, disease-free remission and death in the follow-up of 
DTC by ROC analysis in a homogeneous group of patients with respect to initial therapy. 
The study differed from earlier investigations with respect to the homogeneity of the patient 
group with respect to initial therapy, the fact that multiple Tg measurements were analysed 
at fixed time points during follow-up and the use of ROC.
We found an excellent diagnostic accuracy of serum Tg values during TSH stimulation 6 
months after initial therapy (sensitivity 100%), with a higher Tg cut-off level (10.0 µg/L) than 
commonly reported (2;8;11;15;16). When we used the more commonly used cut-off value of 
2 µg/L, the specificity and positive predictive value decreased considerably. We also found 
that Tg cut-off levels are dependent on the time-point of follow-up, which is an important 
finding, as in most papers on Tg, the time after diagnosis is not considered.
Tg levels are not only diagnostic indicators of tumor presence, but also predict disease-
free remission or death. We found that serum Tg levels before radioiodine ablation are an 
independent predictor for disease-free remission, irrespective of the classical prognostic 
indicators. In our series a patient with Tg level pre-ablation of < 27.5 µg/L has an almost 98% 
chance of being cured irrespective of the prognostic indicators stage T4, follicular histology, 
metastases and higher age.
TSH-stimulated Tg measurements 6 months after initial therapy and at 2 and 5 years after 
initial therapy were independent predictors of thyroid carcinoma-related death. Negative 
predictive values for DTC-related death were high (95.3 – 98.2%) at all 5 time points of 
follow up, albeit with different Tg cut-off values. 
In the discussion about the diagnostic value of Tg, specificity is a controversial issue. It has 
been argued that the specificity of Tg is, by definition, 100%. Although from a biological point 
of view it is undoubtedly correct that Tg is only synthesized by thyroid cells, in clinical practice 
the meaning of measurable Tg levels is not always clear, and even less so with the advent 
of high sensitive Tg assays. A less than 100% specificity of Tg for thyroid carcinoma can be 
explained by the limitations of current imaging techniques to detect thyroid carcinoma. In 
this respect, administering a high dose of radioiodine to patients with elevated Tg levels 
has been advocated, a policy that we agree with (17-20). However, we also observed that in 
only three of the nine patients with TSH-stimulated Tg levels > 10 µg/L without detectable 
tumor, did a tumor become apparent during follow up, which is in line with the observations 
of Baudin et al. (8). Therefore, in our opinion, a potential solution to circumvent the debate 
about specificity of Tg is to consider Tg a risk indicator. The independent prognostic value 
of serum Tg values for disease-free remission and death are arguments to include Tg in the 
conventional panel of risk factors. A potential consequence could be to administer higher 
dosages of radioiodine for ablation in patients with Tg levels above the above-mentioned 
thresholds. As such we do not advocate that patients with Tg levels below institutionally 
defined cut-off levels should not be followed up carefully, but we belief that the elimination 
of Tg should not be a treatment goal in itself.   
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Tg cut-off levels are influenced not only by clinical considerations, but also by analytical 
aspects. Analytical problems include the lack of universal standardisation of the Tg assays, 
(21), intra-assay variability, “Hook” effects and the presence of Tg auto-antibodies (22;23). 
Another important point, not addressed in this study, is the observation that Tg increases 
may be more informative than absolute Tg levels (8;24).
The percentage of patients with Tg antibodies (initially 27%) is in line with previous studies 
(23;25;26). The percentages of active tumor in patients with and without Tg antibodies were 
comparable, confirming the lack of diagnostic value of Tg antibodies.    
Because our study involved a large cohort of patients studied before the introduction of 
rhTSH, we did not include rhTSH stimulated Tg measurements in our series. However, recent 
reports indicate that the diagnostic accuracy is comparable (2;3;15). It has been suggested 
that Tg cut-off levels for rhTSH should be lower than for thyroid hormone withdrawal (27). 
However, no systematic analyses have been published comparing optimal Tg cut-off levels 
for both strategies. Furthermore, in a large study, similar Tg cut-off values were used for 
rhTSH and T4 withdrawal (16).
Because our analysis is based on retrospective data, we believe that the prognostic Tg cut-
off values as found in our study should be interpreted with some caution, and they should 
be confirmed in a prospective study. We maintain, however, that the main message is valid-
that Tg cut-off levels should not be adopted from the literature, that Tg cut-off levels are 
dependent on the time-points, and that Tg has a prognostic value.
In conclusion, our studies illustrate the importance of the definition of institutional Tg cut-
off levels. We analysed the diagnostic value of Tg at specific time-points and detected 
an excellent prognostic value 6 months after initial therapy during TSH stimulation. Our 
analyses allow the definition of groups of patients with an increased risk for residual disease 
or mortality, in addition to conventionally used prognostic indicators. Based on our analysis 
we recommend subjecting every patient, who has undergone thyroid surgery and thyroid 
remnant ablation, at least once to TSH-stimulated Tg measurements. 
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Abstract
Context: The iodothyronine deiodinases D1, D2 and D3 enable tissue-specific adaptation of 
thyroid hormone levels in response to various conditions, such as hypothyroidism or fasting. 
The possible expression of D2 mRNA in skeletal muscle is intriguing as this enzyme could 
play a role in systemic as well as local T3 production.
Objective: We determined D2 activity and D2 mRNA expression in human skeletal muscle 
biopsies under control conditions and during hypothyroidism, fasting and hyperinsulinemia. 
Design: Prospective study.
Setting: University hospital.
Patients: We studied 11 thyroidectomized patients with differentiated thyroid carcinoma 
(DTC) on and after 4 weeks off thyroxine replacement, and 6 healthy lean subjects in the 
fasting state and during hyperinsulinemia after both 14 and 62 h of fasting.
Mean outcome measures: D2 activity and D2 mRNA levels were measured in skeletal 
muscle samples. 
Results: No differences were observed in muscle D2 mRNA levels in DTC patients on and 
off thyroxine replacement therapy. In healthy subjects, muscle D2 mRNA levels were lower 
after 62 h compared to 14 h of fasting. Insulin increased mRNA expression after 62 h, but 
not after 14 h of fasting. Skeletal muscle D2 activities were very low and not influenced by 
hypothyroidism and fasting. 
Conclusion: Human skeletal muscle D2 mRNA expression is modulated by fasting and 
insulin, but not by hypothyroidism. The lack of a clear effect of D2 mRNA modulation on the 
observed low D2 activities questions the physiological relevance of D2 activity in human 
skeletal muscle.
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Introduction
Peripheral thyroid hormone metabolism is mainly regulated by the iodothyronine deiodinases 
D1, D2 and D3 (1;2). D1 is expressed in liver, kidney, thyroid and at a lower level in the pituitary. 
This enzyme converts the prohormone T4 to active T3 and is very active in the breakdown 
of rT3 (1;3). Although D1 contributes significantly to peripheral T4 to T3 conversion, it is 
probably not the major source of extrathyroidal T3 production in humans (1;2;4;5). D2 also 
catalyzes the production of T3 through outer ring deiodination of T4, and is present in brain, 
pituitary, thyroid, brown adipose tissue (BAT) and, perhaps, skeletal muscle (1;6-10). In 
brain, pituitary and BAT, D2 is very important for local T3 production. D3 inactivates T3 and 
T4 by inner ring deiodination (2) and is present in brain, skin, placenta and fetal tissues (1). 
These deiodinases allow the adaptation of thyroid hormone levels of individual tissues in 
response to various conditions.
During hypothyroidism, the conversion of T4 to T3 by D2 is increased, whereas the 
activities of D1 and D3 are decreased (1;11;12). D2 mRNA was found to be expressed in 
skeletal muscle samples from healthy subjects (9;13). Since skeletal mass is a major body 
compartment, muscle could therefore play a role in systemic and local T3 production (9). 
Maia et al. proposed that D2 is a major source of circulating T3 in euthyroid subjects and 
even more so during hypothyroidism (14). In line with this assumption, we hypothesized 
that during hypothyroidism caused by withdrawal from thyroxine substitution therapy in 
thyroidectomised patients treated for differentiated thyroid cancer (DTC), D2 activities might 
be up-regulated in skeletal muscle. 
Short-term fasting induces a decrease in plasma T3 that is most probably due to a decreased 
activity of D1 and/or D2 and/or an increased activity of D3 (1;1;15;16). Indeed, the fasting-
induced decrease in serum T3 levels has been attributed to lower peripheral conversion of 
T4 to T3 (17;18). Since the fall in T3 levels (50%) may be larger than can be accounted for 
by a drop in D1 activity, and because D2 has an extremely short half-life, D2 activity may 
have an important role in the reduction in serum T3 as well (1). In contrast to fasting, insulin 
has been shown to increase both D2 activity and mRNA expression in BAT in animal studies 
(19-21). Moreover, a recent study demonstrated that incubation of human myoblasts and 
myotubes with peroxisome proliferator-activated receptor (PPAR)-γ-agonists resulted in 
increased D2 activity and also suggested a possible role for D2 in insulin signalling (22). We 
therefore hypothesized that conditions of fasting as well as hyperinsulinemia would affect 
skeletal muscle D2 expression and activity in vivo since these conditions affect insulin 
signaling (23). 
To our knowledge, no studies in human skeletal muscle samples have been performed to 
investigate the effect of hypothyroidism or fasting and insulin on skeletal muscle deiodinase 
mRNA expression or D2 activity. To address this issue, we analyzed D2 activity and mRNA 
expression of D2 and D3 in skeletal muscle samples in thyroidectomised patients with 
differentiated thyroid carcinoma (DTC) on and after 4 weeks off thyroxine replacement 
therapy, and in healthy subjects in the fasting state and during hyperinsulinemia after both 
14 and 62 h of fasting.
Material and methods
Subjects with Differentiated Thyroid Carcinoma 
Patients were recruited from the outpatient clinic of the Department of Endocrinology of 
Leiden University Medical Center, which is a tertiary referral center for differentiated thyroid 
carcinoma. Patients were included who had been diagnosed with DTC and had received 
initial therapy consisting of near-total thyroidectomy and radioiodine ablation therapy. 
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Additional therapies were allowed, as long as they resulted in cure. Cure was documented by 
the absence of measurable serum thyroglobulin (Tg) during TSH stimulation as well as by a 
negative total-body scintigraphy with 4 mCi 131I. The patients had to be on TSH suppressive 
therapy, defined as TSH levels below the lower reference value for TSH (0.4 mU/l). The 
adequacy of the TSH suppressive therapy was documented by yearly TSH measurements. 
 14 and 62 h of fasting. Patients who had diabetes mellitus or other endocrine diseases 
or had a BMI >30 kg/m2 were excluded. Patients who used any drugs known to influence 
thyroid hormone metabolism were also excluded. The ethics committee of Leiden University 
Medical Center approved the study, and written informed consent was obtained from all 
subjects.
Study design in DTC patients
Patients with DTC undergoing TSH-stimulated 131I scintigraphy were asked to participate in 
the study. Four weeks after thyroxine withdrawal and 8 weeks after subsequent thyroxine 
replacement, patients were admitted to the clinical research unit at 8 a.m.. All subjects 
fasted from the preceding evening (6 p.m.) until the end of the study day. Length (m), weight 
(kg) and BMI (weight/length2 [kg/m2]) were measured. Patients were studied in a semi-
recumbent position. A catheter was inserted in a dorsal hand vein to collect plasma samples 
for measurement of TSH, FT4, T3 and rT3. Muscles biopsies were taken from the quadriceps 
muscle (vastus lateralis) under local anesthesia (Lidocaine 20 mg/ml; Fresenius, Kabi, Den 
Bosch, The Netherlands) as described earlier (23). One skeletal muscle biopsy obtained 
during hypothyroidism was lost. Biopsies were quickly washed in HEPES-buffered saline to 
remove blood, inspected for fat or fascia content, dried on gauze swabs, and subsequently 
stored in liquid nitrogen until analysis. Serum samples were handled immediately and stored 
at –20 C. 
Fasting subjects
Six lean healthy men with a normal thyroid status who participated in a study on fasting-
induced peripheral insulin resistance were included in this study (23). Written informed 
consent was obtained from all subjects after explanation of purpose, nature, and potential 
risks of the study. The study was approved by the Medical Ethical Committee of the Academic 
Medical Center of the University of Amsterdam.
Study design in fasting subjects 
The experimental protocol has been briefly described earlier (23). In short, subjects were 
studied twice: after 14 and 62 h of fasting. Study days were separated by at least a week. 
Subjects were fasting from 8 p.m. until 10 a.m. the next day or 3 days later. They were 
allowed to drink water ad libitum. 
After admission at the metabolic research unit, a catheter was inserted into an antecubital 
vein for sampling of venous blood for determination of plasma TSH, T4, FT4, T3 and rT3. 
Hereafter, a muscle biopsy (vastus lateralis of the quadriceps muscle) was performed as 
described above. Thereafter a continuous infusions of insulin (60 mU/m2/min) (Actrapid 
100 IU/ml; Novo Nordisk Farma B.V., Alphen aan den Rijn, The Netherlands) and glucose 
20% (to maintain a plasma glucose level of 5 mmol/L) were started. Plasma glucose levels 
were measured every 5 min at the bedside. After 5 h of insulin infusion, muscle biopsies 
were repeated.
Thyroid parameters 
Plasma and serum thyroid hormone levels of DTC patients and fasting volunteers were 
determined as described previously (reference (24) and (25) respectively). 
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D2 activity
Skeletal muscle samples were homogenized on ice in 10 volumes of PED10 buffer (0.1 M 
phosphate, pH 7.2, 2 mM EDTA, and 10 mM dithiothreitol) using a polytron (Kinematica 
AG, Lucerne, Switzerland). Protein concentrations were measured with the Bio-Rad protein 
assay (Bio-Rad, Veenendaal, The Netherlands) using BSA as the standard according to the 
manufacturer’s protocol.
Skeletal muscle D2 activities were measured as previously described (9). Duplicates 
of 200 µg homogenate protein were incubated for 60 min at 37 C with 1 nM (1-2x105 
cpm) [3’,5’-125I]T4 in a final volume of 0.1 ml PED10 buffer. The incubations were done 
in the absence or presence of 0.1 μM unlabeled T3, to prevent inner ring deiodination 
of the labeled T4 substrate by D3, if present, and in the absence or presence of 0.1 μM 
unlabeled T4, which is sufficient to saturate D2. Deiodination of labeled T4 in the absence 
minus that in the presence of excess labeled T4 represents D2 activity. Reaction products 
were analyzed by determination of the [125I]T3 generated by HPLC analysis of ethanol 
extracts of the reaction mixtures as previously described (26). The samples from the DTC 
patients were also analyzed by isolation of the released 125I- from the supernatant after 
addition of albumin and protein precipitation with 10% TCA.
To rule out interfering effects of local anesthesia on D2 activity in the human muscle 
samples, we analyzed the effects of increasing lidocaine concentrations on D2 activity 
expressed in COS1 cells transfected with a human D2 construct (D2-COS1 cells) in 
pcDNA3 as previously described (27). To rule out the presence of factors in skeletal 
muscle homogenates that could inhibit D2 activity, we measured D2 activity in D2-COS1 
cell lysates with addition of increasing volumes (12.5-50 µl) of homogenate (50-200 µg of 
protein).
Quantitative mRNA analysis
RNA was isolated from skeletal muscle samples using High Pure RNA kit (Roche Diagnostics, 
Almere, The Netherlands) following the manufacturer’s instructions. RNA concentrations 
were determined using the RiboGreen RNA quantification kit (molecular Probes, Leiden, The 
Netherlands). All samples were diluted to 0.1 μg/μl, and 1 μg was used for cDNA synthesis 
using TaqMan RT kit (Roche Diagnostics, Almere, The Netherlands). D2 and D3 cDNA 
were analyzed on an ABO PRISM 7700 sequence detection system (Applied Biosystems, 
Nieuwerkerk aan den IJssel, The Netherlands), which uses TaqMan chemistry for highly 
accurate quantitation of mRNA levels. Sequences and concentrations of the primers are given 
in Table 1. The D2 and D3 mRNA levels are expressed relative to those of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) or cyclophilin A. Probes and primers for these 
housekeeping genes were provided as preoptimized control system (Applied Biosystems). 
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Table 1. Primers and probes used for the determination of D2 and D3 mRNA levels by quantitative real-time RT-
PCR
Primers and probes Sequence
D2 forward CAAGTCCACTCGCGGAGA
D2 reverse GACATGCACCACACTGGA
D2 probe ACGCAGGCGCAGTCCCTCT
D3 forward TTCCAGAGCCAGCACATC
D3 reverse ACGTCGCGCTGGTACTTA
D3 probe TGCACCTGACCACCGTTC
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After 4 weeks of thyroxine withdrawal, all patients were overtly hypothyroid. After 8 weeks of 
thyroxine replacement therapy, FT4, T3 and rT3 increased significantly (p=0.003), whereas 
TSH decreased significantly (p=0.003). Six patients had thyroid parameters within the 
reference range, whereas 5 patients had a TSH below the reference range with normal 
plasma T3 and T4 levels. 
Skeletal muscle deiodinase expression and D2 activity in DTC patients
Results of the quantitative RT-PCR analysis of deiodinase mRNA levels in skeletal muscle 
biopsies are presented in Fig. 1A. D2 and D3 mRNA levels were present in all muscle biopsies, 
but there was no significant difference between the hypothyroid and thyroxine replacement 
states. 
Very little D2 activity was detected in the muscle biopsies and it was not different between 
the thyroxine replacement and hypothyroid states (Fig. 2A). Similar results were obtained by 
HPLC analysis of T3 formation (Fig. 2A) and using the iodide release assay (data not shown). 
Little D3-catalyzed conversion of T4 to rT3 was observed in the skeletal muscle biopsies, 
and this was also not different between the hypothyroid and thyroxine replacement states 
(data not shown). 
Reactions were done for 2 min minimal at 50 C and for 10 min at 95 C, followed by 40 
cycles of 15 sec at 95 C and 1 min at 60 C. Following the manufacturer’s guidelines, the 
cycle threshold (Ct) was determined, which represents the cycle number at which probe-
derived dye absorbance reaches the calculated threshold value. Data were expressed as 
2∆Ct, where ∆Ct represents the Ct value of the housekeeping gene minus the Ct value of 
the target gene.
Statistical Analysis
Statistical comparisons were performed with the Wilcoxon Signed Rank test. Differences 
were considered statistically significant at P<0.05. The SPSS statistical software program 
version 12.0.2 (SPSS Inc, Chicago, IL) was used for statistical analysis. Data are presented 
as mean ± SE.
Results
DTC patients characteristics and thyroid hormone levels
Eleven patients were included in the DTC group (4 males/7 females). Mean ± SE age was 
45.5 ± 2.1 years. Mean ± SE duration of TSH suppressive therapy was 5.0 ± 2.1 years (range 
0.6-24.3 years). Mean ± SE thyroxine dosage was 197 ± 13 µg/day. Thyroid parameters are 
presented in Table 2. 
Table 2 Thyroid hormone parameters in DTC patients
Wilcoxon signed rank test. Data are presented as mean ± SE
Hypothyroidism 
(n=11) 
Thyroxine treatment
(n=11) 
P-value
FT4 (pmol/L) 1.4 ± 0.2 24.8 ± 1.2 0.003
TSH (mU/L) 142.4 ± 10.4 0.8 ± 0.3 0.003
T3 (nmol/L) 0.3 ± 0.1 1.3 ± 0.1 0.005
rT3 (nmol/L) 0.02 ± 0.00 0.29 ± 0.02 0.003
53
Fasting subjects characteristics and thyroid hormone levels
Six lean healthy men were included. Subject characteristics were: age: 23 ± 1.6 yrs; weight 
69.4 ± 2.2 kg after 14 h and 67.5 ±  2.2 kg after 62 h of fasting, P = 0.002; BMI 21.2 ±  0.7 
Kg/m2 after 14 h and 20.5 ± 0.7 kg/m2 after 62 h of fasting, P = 0.001 (23).
Plasma FT4 and TSH levels were not different between 14 and 62 h of fasting (Table 3). T3 
levels were significantly higher and rT3 levels were significantly lower after 14 h of fasting 
compared to 62 h of fasting. The T3/T4 (not shown) and T3/rT3 ratio’s were significantly 
higher after 14 h of fasting compared to 62 h of fasting.
Skeletal muscle deiodinase expression and D2 activity after 14 and 62 h of fasting
D2 mRNA levels in skeletal muscle biopsies were significantly lower after 62 h of fasting 
compared to 14 h of fasting in the basal state (p=0.028). (Fig. 1B). No differences in D2 mRNA 
levels were observed during hyperinsulinemia after 62 h compared to 14 h of fasting. 
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Figure 1. mRNA levels of deiodinase 2 and 3 vs. the household gene GAPDH or cyclophilin (*103) in skeletal 
muscle samples (mean ± SE). 
A.  In DTC patients (n=11) during hypothyroidism and during thyroxine replacement treatment. 
B. In healthy subjects (n=6) after 14 and 62 h of fasting before and after insulin infusion. P < 0.05 for D2 
mRNA expression in the basal state after 62 h of fasting compared to the basal state after 14 h of fasting and D2 
mRNA expression after insulin infusion after 62 h of fasting compared to the basal state after 62 h of fasting.
Figure 1b
Figure 1a
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Insulin infusion did not significantly increase D2 mRNA expression after 14 h of fasting, 
whereas insulin induced a significant increase in D2 mRNA levels after 62 h of fasting 
(p=0.028). D3 mRNA measurements were not reliable due to contamination with genomic 
DNA. D2 activity was low, but detectable in the muscle biopsies in the basal state and after 5 
h of hyperinsulinemia both after 14 and 62 h of fasting. However, no significant differences 
were found (Fig. 2B). Very little D3 activity was demonstrated, and also here no differences 
were found (data not shown).
Different household genes were used for standardization of mRNA mesurements in DTC 
patients and healthy fasting subjects. However, their expression levels were constant in the 
patients and healthy subjects during the different conditions.
D2 activity, lidocaine, and possible inhibitors in muscle homogenate
Addition of increasing concentrations up to 1 mM of lidocaine did not inhibit D2 activity 
expressed in COS1 cells transfected with human D2 cDNA (Fig. 3A). Although a dose-
dependent inhibition of D2 activity was observed after addition of increasing volumes of 
muscle homogenate up to of 50% of the total incubation volume, remaining activity still 
amounted to 60% of that expressed in D2-COS1 lysates (Fig. 3B).
Figure 2. D2 activity in skeletal muscle samples (mean ± SE) 
A. In DTC patients during hypothyroidism and thyroxine treatment. 
B. In healthy subjects after 14 and 62 h of fasting.
Figure 2a
Figure 2b
55
Discussion
In this study, we investigated the D2 activity and expression of D2 and D3 mRNA in skeletal 
muscle samples in DTC patients on and off thyroxine replacement therapy and in healthy 
subjects after 14 and 62 h of fasting and during hyperinsulinemia. Hypothyroidism induced 
by withdrawal of thyroxine substitution in thyroidectomised patients did not affect muscle 
D2 mRNA expression, whereas fasting for 62 h reduced muscle D2 mRNA levels compared 
to fasting for 14 h. 
Conversely, insulin increased mRNA expression after 62 h, but not after 14h of fasting. 
Nonetheless, skeletal muscle D2 activities were very low, and not influenced by hypothyroidism, 
fasting or insulin. 
D2 activity is regulated by thyroid status both at the pre- and posttranslational level. In 
hypothyroidism, D2 activity is increased in different tissues predominantly by a decrease in 
substrate (T4)-induced degradation of D2 protein (1;28-30). Hypothyroidism also elevates 
D2 mRNA in rat brain and BAT (1;6;31;32). We found no differences in D2 mRNA expression 
in skeletal muscle of DTC patients between hypothyroid and thyroxine replacement states. 
We measured D2 activity with a highly specific and sensitive D2 assay based on the 
measurement of radiolabeled T3 production (9;33), but found little D2 activity present in 
skeletal muscle samples of the DTC patients. 
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Table 3 Thyroid hormone parameters in healthy subjects 
Wilcoxon signed rank test. Data are presented as mean ± SE
At baseline (n=6) During hyperinsulinemia (n=6)
14h fasting 62h fasting p-value 14h fasting 62h fasting p-value
FT4 (pmol/L) 14.6 ± 1.0 14.6 ± 1.3 0.985 13.7 ± 0.8 14.4 ± 1.0 0.279
TSH (mU/L) 1.0 ± 0.2 0.5 ± 0.1 0.102 0.8 ± 0.1 0.5 ± 0.1 0.116
T3 (nmol/L) 1.6 ± 0.1 1.1 ± 0.1 0.027 1.4 ± 0.1 0.9 ± 0.05 0.027
rT3(nmol/L) 0.24 ± 0.02 0.44 ± 0.02 0.027 0.26 ± 0.01 0.38 ± 0.01 0.027
T3/rT3 ratio 6.9 ± 0.7 2.5 ± 0.2 0.028 5.3 ± 0.5 2.5 ± 0.2 0.028
Figure 3a
Figure 3
D2 activity in D2-COS cells with increasing levels of lidocaine. 
Figure 3b
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Furthermore, no differences were observed between the hypothyroid and thyroxine 
replacement states. The peripheral conversion of T4 to T3 is increased during hypothyroidism 
(1;11;12). In rats, extrathyroidal T3 production changes from PTU sensitive to PTU insensitive 
during hypothyroidism, representing an increase in the conversion of T4 to T3 by D2 and 
a decreased conversion by D1 (34). There is, however, no D2 expression and activity in 
rat skeletal muscle (6), whereas D2 activity has been reported in human skeletal muscle 
(14;35). Animal studies have shown significantly increased D2 activity in the cerebral cortex 
and pituitary during hypothyroidism (36-38). Collectively, our data on D2 mRNA expression 
and D2 activity in hypothyroid and thyroxine treated patients point out that changes in 
circulating plasma levels of thyroid hormones do not regulate muscle D2 activity or mRNA 
expression. Consequently, increased D2 activity in other tissues must be responsible for the 
increased conversion of T4 to T3 in hypothyroid subjects.
Since it has been shown that skeletal muscle expresses D3 mRNA and activity, we assessed 
D3 mRNA expression and activity as well. Furthermore, in the rat brain D3 mRNA was found 
to be decreased during hypothyroidism (1;39). However, there were no differences in D3 
mRNA expression or activity during hypothyroidism and thyroxine replacement. 
Between 14 and 62 h of fasting, plasma T3 levels decreased, whereas rT3 levels increased 
as has been shown earlier (15;40). Both the decrease in serum T3 and increase in serum 
rT3 may be explained by decreased D1 activity (in liver/kidney), decreased D2 activity (in 
muscle), or increased D3 activity (in the central nervous system) (2). 
D2 mRNA levels in skeletal muscle samples were significantly lower after 62 h of fasting 
compared to 14 h of fasting. In mice, fasting decreased the expression of D2 in the pituitary 
(36). In other conditions of insulin deprivation, such as streptozotocin-induced diabetes in 
rats, the increase of D2 activity in BAT after insulin was exaggerated compared to the normal 
response (19). 
A significant increase in D2 expression was found after 5 hours of hyperinsulinemia in 
healthy subjects after 62 h of fasting, whereas this was not the case after 14 h of fasting. It 
had been shown in rats D2 activity and expression are upregulated by insulin in BAT (17-19). 
Injections with insulin resulted in an increased D2 activity in BAT in diabetic and non-diabetic 
rats (19) and addition of insulin to rat brown adipocytes in vitro leads to an increase in Vmax 
of D2 (18). Martinez-deMena et al. found that this induction is not a direct effect of insulin, 
but that insulin improves the adrenergic stimulation of D2 activity (17). A role of insulin in 
regulating D2 in skeletal muscle is conceivable. Moreover, the lack of a significant increase 
after 14 h of fasting suggests that minor increments of insulin (i.e. postabsorptive plasma 
insulin levels) are sufficient to induce D2 mRNA expression.
Little D2 activity was present in skeletal muscle samples after 14 and 62 h of fasting and no 
difference was observed between the two conditions, in contrast with the observed changes 
in D2 mRNA expression. There are several possible explanations for this. The particular 
level of D2 mRNA expression in skeletal muscle may not result in significant D2 activity. 
Therefore, D2 activity in other tissues may be responsible for the decrease in T3 levels. 
In rats, D1 activity in the thyroid and liver, and D2 activity in the thyroid were decreased 
after fasting (37;38), whereas D2 activity in the hypothalamus was increased (39). In other 
conditions where T3 levels decrease significantly, such as acute critical illness, no D2 activity 
could be measured in liver and skeletal muscle biopsies (30). However, Mebis et al. found 
low but significant skeletal muscle D2 activity during prolonged critical illness, indicating 
an adaptation to the low T3 levels (11). This may suggest that our volunteers had not been 
fasting long enough. 
It is not likely that the local anaesthetics used for the sample collection could have influenced 
D2 activity, since we found no effect on D2 activity in D2-COS1 cells with increasing 
lidocaine concentrations. However, we cannot exclude a local effect of lidocaine resulting 
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in downregulation of D2 activity. On the other hand, Mebis et al. reported no differences in 
D2 expression and D2 activity in muscle samples taken under local anaesthetics or during 
laparotomy (11). 
Recent findings show that D3 mRNA and activity (catalyzing T4 to rT3 deiodination and T3 
degradation) may be increased in muscle and liver of patients hospitalized in the intensive 
care unit (40). However, we found no change in D3 activity in skeletal muscle during fasting 
or hyperinsulinemia. 
In summary, no differences were observed in the expression of skeletal muscle D2 mRNA 
between hypothyroidism and thyroxine treatment, although a robust decrease was observed 
after 62 h of fasting. Moreover, insulin restored D2 mRNA expression after 62 h of fasting. 
Little D2 activity was measured in skeletal muscle samples and no differences were observed 
between hypothyroidism and thyroxine treatment or after 14 and 62 h of fasting. Our results 
therefore imply that skeletal muscle D2 mRNA expression is modulated by fasting and 
insulin, but not by hypothyroidism or thyroxine treatment. The lack of effect of changes in D2 
mRNA on already low D2 activity questions the importance of a role for D2 activity in human 
skeletal muscle.
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Abstract
Patients with differentiated thyroid carcinoma (DTC) are commonly treated long-term 
with thyrotropin (TSH)-suppressive thyroxin replacement therapy resolving in a state of 
subclinical hyperthyroidism. The relationship between subclinical hyperthyroidism and 
osteoporosis is not clear. In this review, we systematically selected and analyzed 21 studies 
addressing this issue. Although multiple methodological differences between studies 
prevented a structured meta- analysis, our data suggest that postmenopausal women with 
subclinical hyperthyroidism are most at risk, whereas no increased risk was observed in 
men and premenopausal women. Based on these findings we believe that measurement 
of bone mineral density is recommended in postmenopausal women with DTC starting 
TSH suppressive therapy. This should be subsequently regularly measured to enable timely 
intervention with bone protective agents.
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Background
Differentiated thyroid carcinoma (DTC) is associated with an excellent prognosis, with 
reported 10-year survival rates reaching 90% (1). This is because of a combination of the 
favorable biological behaviour of the tumor as well as the availability of effective therapy 
in the form of total thyroidectomy followed by radioiodine ablation. After initial therapy, all 
patients with DTC are treated with high doses of thyroxin aiming at significantly suppressing 
thyrotropin (TSH) levels, the rationale of this approach is based on the potential harmful 
effects of TSH on tumor recurrence (2;3). One study demonstrated a preventive effect of 
TSH suppression on tumor recurrence or progression only in high risk DTC patients (4). 
However long-term TSH suppression may be associated with potential harmful effects, so 
a recent European Consensus Meeting on thyroid cancer (5), recommended that not all 
patients with DTC should be indiscriminately treated with TSH suppressive therapy because 
this represents in effect a state of subclinical hyperthyroidism, as defined by suppressed 
serum TSH levels in the presence of normal serum levels of (free) thyroxin. The question 
which clearly is to be answered is whether long-term TSH suppressive therapy is beneficial 
and safe in patients with DTC.
Subclinical hyperthyroidism has effects on carbohydrate metabolism (6), the cardiovascular 
system (7-11) and psychological well being (7;12). Whether subclinical hyperthyroidism also 
deleteriously affects the skeleton remains the subject of discussion (13;14).
Overt hyperthyroidism is associated with an increased risk for osteoporosis (15), the 
pathophysiology of which is multifactoral (16), including shortening of the bone remodelling 
cycle (17) and acceleration of bone turnover (18). Thyroid hormone indirectly promotes 
osteoclast formation and activation by inducing the expression of cytokines, prostaglandins 
and the receptor activator of nuclear factor NF-κB ligand (RANKL) (16;19;20). RANKL is the 
key molecule in osteoclast differentiation. It binds to its receptor, RANK, which is expressed 
on dendritic cells, T cells, osteoclast precursors and mature osteoclasts (21;22). RANKL 
increases the survival of RANK positive T cells (21), promotes osteoclast differentiation 
(23-27), stimulates the activity of mature osteoclasts (24;28;29) and promotes survival of 
osteoclasts by preventing apoptosis (29). Osteoclast differentiation is also stimulated by 
contact with stromal cells and M-CSF (30;31). Thyroid hormone also inhibits chondrocyte 
proliferation and promotes hypertrophic differentiation, mineralization, matrix synthesis but 
also apoptosis of chondrocytes in the growth plate. An exciting new development has been 
the discovery of functional TSH receptors in bone (32;33) because of the implication that 
effects that traditionally have been attributed to high thyroid hormone levels may be in effect 
related to low TSH levels. 
The relationship between subclinical hyperthyroidism and osteoporosis is not clear. Several 
studies have addressed this issue, but there is no consensus largely because of differences 
in study design, included patient groups, methodology used, follow-up time and choice of 
outcome parameters. It is of note that although the role of subclinical hyperthyroidism in the 
pathogenesis of osteoporosis has been the topic of several reviews, no attempt has been 
made to categorize the original studies so far published according to the various parameters 
above mentioned. In this review, all clinical studies on TSH suppressive thyroxin therapy in 
thyroid cancer patients have been systematically selected for analysis. 
Methods
Searches of Medline, Cochrane and EMBASE were conducted using the keywords: “thyroid 
cancer AND bone mineral density”, “thyroid cancer AND osteoporosis” and “thyroid cancer 
AND bone metabolism”. Our aim was to include all studies in which patients with DTC were 
treated with TSH suppressive thyroxin therapy. We restricted our search to publications in 
“English language”, on “Human subjects” and “articles containing Abstracts”. The last search 
was conducted on January 17, 2006. Of the initial 230 publications found, 32 publications 
fulfilled these criteria and were selected for detailed analysis.
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Each study included was scored semi-quantitatively by assessing the following: whether 
hormonal state of female patients was mentioned; whether they were estrogen-replete or 
-deplete; whether additional risk factors for osteoporosis were reported; whether a control 
group was included; whether duration of follow-up was shorter or longer than 5 years; and 
whether TSH concentrations were adequately suppressed. Eleven studies were excluded on 
the basis of insufficient data: Mikosch et al. (34) and Rosen et al. (35) did not report the 
duration of thyroxin therapy. Rosen and coworkers included patients who were taking thyroid 
hormone for at least 6 months. In one study patients did not have sufficiently suppressed 
serum TSH concentrations (36). Guo et al. (37) and Gonzalez et al. (38) did not report serum 
TSH levels. Mikosch et al. (34;39) and Taimelia et al. (40) did not measure bone mineral 
density. Subanalysis according to gender and menopausal state were not performed in two 
studies (35;41). In an additional 4 studies (40-43), it was not indicated if other risk factors 
for osteoporosis were investigated. The last 4 studies (38;40;42;44) lacked control groups. 
Twenty-one studies fulfilling all criteria were finally included in the analysis, the following 
parameters were documented: study design, number of patients included, age, gender, 
hormonal status of female patients, additional risk factors for osteoporosis, dose of thyroxin 
prescribed, serum level of TSH, duration of TSH-suppressive therapy, the presence of a 
control group and the final outcome based on differences in bone mineral density (BMD). 
The studies were categorized according to gender and menopausal state and subgroup 
analyses undertaken accordingly. 
Although we set out to conduct a structural meta-analysis, the heterogeneity of the available 
data did not allow us to do so. 
Results
The results of the analyses are shown in Tables 1-5. Almost all studies excluded patients 
with diseases and those using glucocorticoids or other drugs potentially affecting bone 
metabolism. Of the 21 studies included, 4 of 6 prospective studies reported a significant 
decrease in BMD with time on treatment, as in 4 of 17 cross-sectional studies there was a 
significant difference in BMD between DTC patients and controls. The results of the subgroup 
analyses according to gender and menopausal state were as follows: 
Premenopausal women
The effect of TSH suppressive therapy in premenopausal women is described in 15 studies, 
of which 12 had a cross-sectional design and 4 were prospective studies (Table 1 and 2). 
Two cross-sectional studies found a significant decrease in BMD in DTC patients receiving 
TSH suppressive therapy compared to controls: Jodar et al. (45) evaluated 37 DTC patients, 
significantly lower BMD of the distal radius was found in DTC patients compared to controls; 
although, this was still within the normal range for age and gender. There was a significantly 
positive relationship between thyroxin dose and lumbar spine and distal radius BMD. 
Diamond et al. (46) evaluated 14 DTC patients. BMD of the femoral neck in DTC patients was 
significantly lower (-10.6%) than in age-, gender- and menopausal state-matched controls. 
There were no significant differences between patients and controls in the other cross-
sectional studies analyzed. 
Two of the prospective studies found a significant effect of TSH suppressive therapy on 
BMD. Jodar et al. (45) studied 14 DTC patients for 18 months. He reported that BMD of 
the femoral neck was significantly lower in DTC patients than in age-, gender-, body- weight- 
and menopausal state-matched controls. There were no differences observed between 
premenopausal and postmenopausal women. Sijanovic et al. (47) studied 19 premenopausal 
women. There was a significant reduction in BMD of the distal radius after 4 years of follow-
up. 
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A significant negative correlation was found between thyroxin dose and BMD of the distal 
radius. Muller et al. (48) studied 23 patients: 8 with a non-toxic goitre and 15 DTC, who were 
followed up for an average of 1.5 years. There were no significant differences in BMD of the 
lumbar spine, femoral neck, trunk and extremities between patients and age-, gender-, body 
mass index (BMI)- and years of menopause-matched controls. 
Postmenopausal women
The effect of TSH suppressive therapy in post-menopausal women was investigated in 16 
studies (Table 3 and 4). Fourteen studies were cross-sectional. Four found a significant 
difference in BMD between patients and controls. Kung et al. (49) studied 34 postmenopausal 
women. The patients had a significant lower BMD than age-, gender- and menopausal state-
matched controls. Jodar et al. (45) studied 39 patients. Average TSH levels were 0.50 ± 1.28 
mU/l. BMD of the distal radius was significantly lower than the average of controls, although 
is was still within the normal range. Stepan et al. (50) studied 15 patients using both thyroxin 
and liothyronine. BMD of the lumbar spine was significantly decreased compared to matched 
controls. Diamond et al. (46) studied 10 postmenopausal women. BMD measurements at 
the lumbar spine, femoral neck and forearm were significantly lower than those of matched 
controls. There were no differences in BMD observed between patients and controls in the 
remaining cross-sectional studies analyzed.
There was a significant difference in 2 of the 4 prospective studies analysed. Jodar et al. (45) 
studied 13 postmenopausal women for a period of 2.25 ± 0.6 years. BMD of the femoral 
neck was significantly lower in DTC patients than in matched controls. Kung et al. (51)studied 
46 patients who were randomly assigned to treatment with calcitonin and calcium (n=16), 
calcium (n=15) or placebo (n=15) and followed for 2 years. At the end of the two years, the 
BMD of patients treated with calcitonin or calcium remained unchanged, whereas BMD was 
significantly lower in the placebo-group. In the other 2 analyzed studies (48;52) there were 
no differences in BMD.
Table 2. Premenopausal women Longitudinal studies
All values expressed as mean±SD unless indicated otherwise, DTR:  Distal Third of the Radius; FN: Femoral Neck, 
DR= Distal Radius, NS=Not significant
Author Patients
(N)
Duration
(Years)
L-thyroxin 
Dose
(µg/day)
TSH
(mU/L)
Controls Outcome
(BMD (z-scores) unless otherwise 
indicated)
Jodar (45) 14 5.4 ± 2.8 177 ± 43 0.61 ± 1.18 Yes BMD (z-score):
DTR: 
-0.84 ± 1.00 (significant below 0)
FN: (% year):
-1.50 ± 3.18 (patients) vs.
 -0.24 ± 1.32 (controls) (p<0.05)
Muller (48) 15 11.2 ± 0.9 200 ± 7 0.09 ± 0.01 Yes NS
Sijanovic (47) 19
(p<0.05)
9.4 ± 6.4 171 ± 30 0.07 ± 
0.062
Yes DR baseline: 0.670 ± 0.037
4 y: 0.657 ± 0.039
Karner (54) 19 9.4 ± 6.4 171 ± 30 0.07 ± 0.62 No NS
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Men
Eight studies selected for analysis addressed the effects of TSH suppressive therapy on bone 
metabolism in men in a cross-sectional study design (table 5). One study was longitudinal 
(table 6). Only one cross-sectional study found a significant difference between patients and 
controls. Jodar et al. (53) studied 49 men, of whom 17 were treated for DTC and 32 were 
treated for Graves’ disease. DTC patients had a mean TSH concentration of 0.20 ± 0.27 
mU/mL. Graves’ disease patients had a mean TSH concentration of 1.07 ± 1.85 mU/mL. 
BMD of patients with Graves’ disease and DTC were significantly lower than that of controls. 
In the longitudinal study (54), 9 men were studied for one year. A significant bone loss at the 
distal radius, but not the lumbar spine and femoral neck was found. 
Discussion
The clinical implications of long-term suppressive thyroxin therapy on bone are critical, largely 
because of the favourable prognosis of DTC. However, the potential deleterious effects 
of TSH suppressive therapy on the skeleton remain controversial. Our aim was to review 
the literature on the effects of TSH-suppressive therapy on bone metabolism focussing on 
reported changes in BMD measurements. There are many differences in the outcome of 
studies addressing this issue so that we have systematically categorized studies according 
to predefined criteria in an attempt to reach a more uniform conclusion.
The majority of studies do not report an effect of TSH suppressive therapy on BMD in men 
and premenopausal women. A significant effect of TSH-suppressive thyroxin replacement on 
BMD is reported in a substantial number of studies conducted in postmenopausal women. 
This suggests that there may indeed be a relevant effect of TSH-suppressive therapy on 
bone mass in postmenopausal women, whereas these effects are not clear in men and in 
premenopausal women. This conclusion is in agreement with that of other reviews and meta-
analyses addressing this issue (14;15;55-57). Another important aspect of TSH suppressive 
therapy in young patients is that it may affect bone development and the peak bone mass as 
investigated together with the contribution of hypoparathyroidism by Schneider et al. (58). 
Table 4. Postmenopausal women Longitudinal studies
Author Patients
(N)
Duration 
(Years) 
L-thyroxin Dose
(µg/day) 
TSH
(mU/L) 
Controls Outcome
(BMD (z-scores) unless 
otherwise indicated)
Jodar (45) 39
13
5.8 ± 2.9 160 ± 38 0.50 ± 1.28 Yes FN change (%/year):
-1.50 ± 3.18 vs. 
-0.24 ± 1.32 (p<0.05)
Muller (48) 10 11.2 ± 0.9 200 ± 7 0.09 ± 0.01 Yes NS
Kung (51) 46 2 2 < 0.03 No LS1 -5% vs. baseline
FN2 -6.7%
T3 -4.7%
WT4 -8.8%
Fujiyama (52) 24 11.6 ± 7.36
14.8 ± 9.43
152.1 ± 22.51
95.83 ± 50.94
n=12: < 0.1  
n=12: > 0.1
No NS
All values expressed as mean±SD unless indicated otherwise.  1 LS=Lumbar Spine, 2 FN=Femoral Neck, 3 
T=Trochanter, 4 WT=Ward’s triangle
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Estrogen deprivation is the most common cause of osteoporosis. The removal of the 
physiological block by gonodal steroid hormones allows the release of inflammatory cytokines 
which in turn enhance the production of M-CSF and RANKL. RANKL is identified as an 
essential cytokine for the formation and activation of osteoclasts (23;24;59). This effect could 
be enhanced by the subclinical hyperthyroid state resulting from TSH suppressive therapy. 
Hofbauer et al (59) found that TSH inhibits RANKL mRNA levels by 60 % and upregulates 
OPG mRNA levels threefold. OPG inhibits osteoclastogenesis by binding to RANKL (27;59-
61), thus preventing RANK-RANKL interactions. In the subclinical hyperthyroid state, TSH 
levels are suppressed resulting in an absence of this block.
The discrepancy in outcome between studies in postmenopausal women might be explained 
by a difference in duration of thyroxin therapy or additional risk factors. However, no 
differences in duration of thyroxin therapy or additional risk factors such as smoking, calcium 
intake, alcohol abuse, and physical activity were observed. A third explanation could be a 
difference in methodological approaches. However, all authors used BMD measurements 
to examine the effect of TSH-suppressive therapy on bone mass. Another explanation 
could be the instability of the TSH concentration in the years of TSH-suppressive therapy as 
suggested in the study of Pujol et al. (62). Other possible factors could be differences in study 
population with regard to additional determinants of BMD such as dietary factors, physical 
exercise, endogenous factors and genetic susceptibility, which become relevant only once 
the powerful contribution of estrogens has disappeared in postmenopausal women (63). For 
instance, Kung et al mentioned that the patients taking part in the study had a low dietary 
calcium (51)
Regardless of these considerations it is clear that postmenopausal women with DTC 
treated with TSH-suppressive therapy are most at risk for bone loss. It has also been shown 
that bone protecting agents such as bisphosphonates are effective in preventing bone 
loss in patients with DTC on TSH-suppressive therapy (35) The availability of therapeutic 
interventions that beneficially influence skeletal morbidity in patients with a low bone mass 
and consequently risk of fractures dictates that patients at high risk should be screened 
using BMD measurements. We have identified postmenopausal women with DTC receiving 
TSH suppressive therapy as a high risk group for bone loss. Based on our analysis of available 
data we strongly advise screening this group of patients at start of TSH suppressive therapy 
and at regular intervals to allow timely intervention with bone protective agents.
Table 6. Men Longitudinal studies
Author Patients
(N) 
Duration 
(Years) 
L-thyroxin Dose
(µg/day) 
TSH
(mU/L) 
Controls Outcome
(BMD (z-scores) unless 
otherwise indicated)
Karner (54) 9 8.1 ± 6.0 200 ± 50 0.06 ± 0.09 No S 
BMD DR 0.748 ± 0.086 vs. 
0.732 ± 0.083, p<0.05
All values expressed as mean±SD unless indicated otherwise. TSH, thyrotropin; DR, Distal Radius
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Abstract
Objective: It has been proposed that thyrotropin (TSH) has thyroid hormone independent 
effects on bone mineral density (BMD) and bone metabolism. This concept is still 
controversial and has not been studied in human subjects in detail. We addressed this 
question by studying relationships between serum TSH concentration and indicators of 
bone turnover, after controlling for T3, FT4 and non-thyroid factors relevant to BMD and 
bone metabolism. We also studied the contribution of the TSHR-Asp727Glu polymorphism 
to these relationships.
Design: We performed a cross-sectional study with 148 patients, who had been 
thyroidectomized for differentiated thyroid carcinoma.
Methods: We measured BMD of the Femoral Neck and Lumbar Spine. FT4, T3, TSH, Bone 
Specific Alkaline Phosphatase, procollagen type 1 aminoterminal propeptide levels, C-
crosslinking Terminal Telopeptide of Type I collagen and Urinary N-Telopeptide of Collagen 
Cross-links were measured. Genotypes of the TSHR-Asp727Glu polymorphism were 
determined by Taqman assay.
Results: We found a significant, inverse correlation between serum TSH levels and indicators 
of bone turnover that was independent of serum FT4 and T3 levels as well as other parameters 
influencing bone metabolism. We found that carriers of the TSHR-Asp727Glu polymorphism 
had an 8.1% higher femoral neck BMD, which was however no longer significant after 
adjusting for body mass index. 
Conclusion: We conclude that in this group of patients, serum TSH was related to indicators 
of bone remodeling independently of thyroid hormone levels. This may point to a functional 
role of the TSHR in bone in humans. Further research into this mechanism needs to be 
performed.
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Introduction
The effects of thyroid hormone on bone metabolism are well established, ranging from 
decreased skeletal development in childhood hypothyroidism to an increased risk 
for osteoporosis in hyperthyroidism (1,2,3). The pathophysiology of osteoporosis in 
hyperthyroidism is multifactorial (4,5), including shortening of the bone remodeling cycle 
(6) and acceleration of bone turnover (7). Thyroid hormone indirectly promotes osteoclast 
formation and activation by inducing the expression of cytokines, prostaglandins and 
the receptor activator of nuclear factor κ-B ligand (RANKL) (8,9,10). Apart from overt 
hyperthyroidism, subclinical hyperthyroidism also appears to be associated with decreased 
bone mineral density as reviewed by Heemstra et al. (11,12,3).
An important development has been the discovery of the thyrotropin (TSH) receptor (TSHR) 
in bone (13,14,15). It has been reported that TSHR knockout and haploinsufficient mice with 
normal thyroid hormone levels have decreased bone mass suggesting that TSH might directly 
influence bone remodeling (14,5,16). This is intriguing, because effects on bone metabolism 
that were previously ascribed to high thyroid hormone levels could also be attributed to 
suppressed TSH levels (17,5,16). Furthermore, in animal studies, low doses of TSH increased 
bone volume and improved microarchitecture in ovariectomized rats (18), without increasing 
serum thyroid hormone levels. However, the concept has been challenged by investigations 
concluding that bone loss in thyrotoxicosis is mediated predominantly by thyroid hormone 
receptor (TR) α (19). The functional role of a TSHR in bone has been studied in humans 
to a limited extent. The relationship between low TSH levels and decreased bone mineral 
density (BMD) has been documented in humans (20,21) but this could still be attributed 
to elevated thyroid hormone levels. In a study in patients in follow-up for differentiated 
thyroid carcinoma (DTC), a supraphysiological dose of recombinant human TSH had thyroid 
hormone independent effects on bone-metabolism parameters (22). We therefore decided 
to study the independent relation between serum TSH levels and indicators of bone turnover 
in thyroidectomized patients for differentiated thyroid carcinoma receiving thyroid hormone 
substitution. The advantage of this group is that these subjects have more uniform FT4 levels. 
As it was recently reported that the TSHR-Asp727Glu polymorphism was associated with 
2.3% higher BMD in elderly carriers (23), we also decided to study this relationship and BMD 
in these patients. Although the functional consequences of the polymorphism are debated 
(24), the lower plasma TSH levels in patients carrying the polymorphism could point toward 
a higher sensitivity of the variant compared to the wild-type TSHR. (25,26). We hypothesized 
that a group of thyroidectomized patients receiving thyroid hormone substitution would be 
optimal to study the relationship between the TSHR-Asp727Glu polymorphism and bone as 
these subjects are not expected to show compensatory lower serum TSH levels if they carry 
the TSHR-Asp727Glu polymorphism (26,25). 
Patients and Methods
Patients were recruited from the outpatient clinic of the Department of Endocrinology of 
Leiden University Medical Center. Patients were included in the study who had a diagnosis 
of DTC, for which they had been treated by near-total thyroidectomy, followed by routine 
postoperative I-131 radioiodine ablation therapy, in all but 4 cases. All patients were cured as 
defined by the absence of I-131 accumulation at diagnostic scintigraphy, serum thyroglobulin 
concentrations below 2 µg/L after TSH stimulation, the absence of Tg antibodies, a normal 
neck ultrasound and no other indication for disease (27). Patients with tumour relapse were 
only included if they were subsequently cured. 
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None of the patients used any drug or had a disease known to influence bone metabolism, 
including estrogen-replacement therapy. Patients taking calcium or vitamine D supplements 
were also excluded. The Leiden University Medical Center ethics committees approved the 
study, and written informed consent was obtained from all subjects.
Study design
After an overnight fast, patients had a full clinical examination, including, height (meters [m]) 
and weight (kilograms [kg]). Blood was collected and measured for TSH, FT4, triiodothyronine 
(T3), calcium, parathyroid hormone (PTH), 25-hydroxy-vitamin D (25(OH)vitD), bone specific 
alkaline phosphatase (BAP), C-crosslinking terminal telopeptide of type I collagen (CTx) 
and procollagen type 1 aminoterminal propeptide (P1NP). Second morning void urine 
was measured for excretion of N-telopeptide of collagen cross-links (NTx). We choose not 
to measure Cathepsin K or TRAP levels for various reasons, including age- and gender 
differences (28,29). Furthermore, CTx seems to reflect bone resorption better than TRAP, 
especially during hyperthyroidism (29). Plasma, serum and urine samples were handled 
immediately and stored at –80o C in Sarstedt tubes. BMD (expressed in grams per square 
centimetre) was measured at the femoral neck and the lumbar spine (vertebrae L2-L4) by 
dual energy x-ray absorptiometry (NHAMES adjusted, Hologic 4500, Hologic Inc., Bedford, 
MA, USA). Osteopenia was defined as a T-score between –1 and –2.5 according to the WHO 
criteria. Osteoporosis was defined as a T-score below –2.5 according to the World Health 
Organization (WHO) criteria or the presence of fractures at an X-ray of the thoracic and lumbar 
vertebral column. As fractures of the lumbar vertebrae can affect BMD measurements by 
increasing X-ray resorption and therefore lead to inappropriate BMD values. We therefore 
excluded patients with fractures of the lumbar vertebrae from the BMD analyses. The 
following data were recorded: smoking habits, alcohol use, physical activity, calcium intake, 
medication (including self-prescription drugs) or vitamin or mineral supplements and 
daily calcium intake and for females: date of first menstruation (menarche), date of last 
menstruation, cycle regularity and estrogen substitution. 
Serum biochemistry
Serum FT4 and TSH were measured using a chemoluminescence immunoassay with a 
Modular Analytics E-170 system (intraassay CV of 1.6-2.2 % and 1.3-5.0 % respectively 
(Roche, Almere, The Netherlands). Serum T3 was measured with a fluorescence polarization 
immunoassay, CV 2.5-9.0 %, on an ImX system (Abbott, Abbott Park, IL, USA). Thyroglobulin 
was measured by Dynotest TG-s (Brahms Diagnostica GmbH, Berlin, Germany). Plasma 
PTH was measured using an immunoradiometric assay (Nichols Diagnostic Institutes, 
Wijchen, The Netherlands), Calcium by colorimetry and 25(OH)vitD by RIA (Incstar/DiaSorin, 
Stillwater, MN, USA). Serum BAP was measured by RIA (Hybritech Europe, Liege, Belgium), 
CTx and P1NP by chemoluminescence immunoassay with the Modular Analytics E-170 
system (Roche Diagnostics, Almere, The Netherlands). NTx was measured by ELISA (Ostex 
International Inc., Seattle, WA, USA). NTx was expressed as the ratio of urine creatinine 
excretion (NTx/creatinine) to correct for differences in creatinine excretion. 
Genotyping
DNA was isolated from peripheral leucocytes by the salting out procedure (30). Genotypes 
were determined using  5 ng genomic DNA by a 5’ fluoregenic Taqman assay and reactions 
were performed in 384-wells format on ABI9700 2x384well PCR machines with endpoint 
reading on the ABI 7900HT TaqMan® machine (Applied Biosystems, Nieuwerkerk aan 
den Ijssel, The Netherlands). Primer and probe sequences were optimized using the single 
nucleotide polymorphism assay-by-design service of Applied Biosystems. 
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Statistical Analysis
Values are presented as mean ± standard deviation (SD), mean ± SEM, median (range) or 
as numbers or proportions of patients. Non-normally distributed data (TSH and PTH) were 
directly log transformed. Factors contributing to BMD and indicators of bone turnover were 
first identified using univariate regression analysis. During univariate regression analysis, 
corrected for age, gender and estrogen status (estrogen deplete/replete), the relationship 
between BMD and the following parameters were analyzed: BMI, smoking, alcohol use, 
physical activity, duration of follow-up after initial therapy for DTC, total dose of radioiodine 
received, serum levels of calcium (corrected for an albumin concentration of 42 g/L), 
25(OH)vitD, lnPTH, FT4, T3, lnTSH and daily dose of thyroxin. The independent contributions 
of the TSHR-Asp727Glu polymorphism and serum TSH levels to BMD and indicators of bone 
turnover were studied by entering FT4, T3, age, gender, estrogen status and all significant 
covariates at univariate analysis in a multivariate model. Deviation from Hardy-Weinberg 
Equilibrium was analysed using a X2-test. All calculations were performed using SPSS 12.0 
for windows (SPSS, Inc., Chicago, IL). Differences were considered statistically significant at 
P<0.05
Results
Patient characteristics
Of a potential 330 patients with cured DTC, 105 were excluded for various reasons (Figure 
1). Sixty-nine patients did not want or were not able to participate in the study for reasons of 
time or geographical distance. A total of 156 patients were thus included in the study. Eight 
patients were left out from analyses because of incomplete data. The basal characteristics 
of the 148 patients included in the study are shown in Table 1. Thirteen patients had post-
surgical hypoparathyroidism for which they were adequately supplemented with active vitamin 
D metabolites and calcium as required. All patients were receiving L-thyroxin treatment at a 
mean dose of 182 ± 51 µg/day. The 25th, 50th and 75th percentiles of serum FT4 levels were 
19.5, 22.1 and 24.9 pmol/L. A total of 4.3% of patients met the criteria of osteoporosis and 
34% of the patients met the criteria for osteopenia (Table 2). 
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330 patients were treated for DTC
105 patients were excluded:
• N=26 <18 years or >75 years
• N=22 medication influencing bone metabolism
• N=15 not fulfilling criteria for cure
• N=9 diseases influencing bone metabolism
• N=5 hyperparathyroidism due to vitamin D deficiency
• N=4 moved abroad
• N=4 pregnant
• N=20 other reasons
225 patients were invited to take part in the study
69 patients did not wish to participate + 8 patients were 
excluded because of missing data
148 patients taking part in the study
Figure 1 Flowchart of the Study
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Serum TSH levels, BMD and indicators of bone turnover
All thyroid related parameters as well as covariates that contributed significantly to BMD and 
indicators of bone turnover are shown in Table 3. No significant association was observed 
between serum TSH levels, serum thyroid hormone levels and BMD. However, using univariate 
analyses, the natural logarithm of serum TSH levels (and the unconverted values) appeared 
to be significantly inversely correlated to CTx, P1NP, BAP and NTx (Figure 2). The significance 
was sustained after correction for FT4, T3, gender, age, estrogen status and other significant 
determinants of bone metabolism using multivariate analysis. The relationship of serum TSH 
levels with indicators of bone turnover was independent from circulating thyroid hormone 
levels. Using multivariate analyses no significant or relevant relationship was found between 
FT4 or T3 and BMD or indicators of bone turnover. 
The TSHR Asp727Glu polymorphism, BMD and indicators of bone turnover 
Genotype frequencies of the TSHR-Asp727Glu polymorphism (Asp/Asp = 131 (88.5%), Asp/
Glu = 17 (11.5%) and Glu/Glu = 0 (0.0%)) did not deviate from Hardy Weinberg equilibrium 
proportions. The Glu727 allele had a frequency of 6.1 %, which is similar to previous studies 
in Caucasians (26). Patient groups were comparable with respect to age, gender, duration 
of follow-up, BMI and thyroid hormone parameters. Using univariate analysis, the TSHR-
Asp727Glu polymorphism appeared to be a significant determinant of BMD. After correction 
for age, gender and estrogen status, carriers of the TSHR-Glu727 allele had an 8.1% higher 
femoral neck BMD (p=0.023). When BMI was added as a covariate in the analysis of the 
relationship of the TSHR Asp727Glu polymorphism with femoral neck BMD, the significance 
level decreased to p=0.102, the standardized β decreasing from 0.172 to 0.127 (Table 3). 
There was no significant difference in BMD at the lumbar spine between groups. 
Total (n=148)
Age (years) 49.4 ± 12.7
Males   27 (18.2%)
Females, premenopausal / postmenopausal 76 (51.4%)/ 45 (30.4%)
Histology  
- Papillary Thyroid Carcinoma   122 (82.4%)
- Follicular Thyroid Carcinoma 26 (17.6%)
pTNM Stage
- T1-3 N0 M0 / T1-3 N1 M0 / T4 or M1 90 (60.8%)/ 39 (26.4%)/ 19 (12.8%)
Relapse  18 (12.2%)
Follow-up Duration (years) 9.3 (1.2 –43.0)
FT4 (pmol/L) 22.3 ± 4.1
T3 (nmol/L) 1.47 ± 0.34
TSH (mU/L) 0.045 (0.003 – 6.830)
Thyroxin dose / weight (ug/kg) 2.15 ± 0.99
Age menarche women(years) 13.3 ± 1.4
Smoking 18 (12.2 %)
Regular physical activity 77 (52.0%)
BMI (kg/m2) 25.83 ± 4.50
Table 1. Characteristics of Patients 
Data are presented as mean ± SD, median (range) or number of patients (percentage). 
FT4: Free Thyroxin, T3= Triiodothyronine, TSH= Thyrotropin, BMI: Body Mass Index
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No significant differences were observed in indicators of bone turnover between groups (Table 
2). The above mentioned relationship between TSH and parameters of bone metabolism 
was not influenced by the TSHR polymorphism.
Discussion
The purpose of the present study was to identify the relationship between TSH levels, BMD 
and indicators of bone turnover in 148 thyroidectomized patients. In support for a potential 
direct effect of TSH on bone, we observed an inverse relationship between serum TSH 
levels and indicators of bone formation (BAP and P1NP) and bone resorption (CTx and NTx), 
independent of serum thyroid hormone levels. These results are consistent with a suppressive 
effect of TSH on bone remodeling and are in keeping with the reported effects of TSH on 
bone metabolism in animal studies (14). It may well be that the lower range of TSH levels in 
our patient group, and the more uniform FT4 concentrations (25th and 75th percentiles being 
19.5 and 24.9 pmol/L) have allowed to identify this relationship. We noticed no relationship 
between serum TSH levels and BMD, while we found an inverse relationship between serum 
TSH levels and indicators of bone turnover. 
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Figure 2 Relationship between lnTSH and indicators of bone turnover
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Thyroid related Variables Covariables
Dependent Variable Standardized 
Beta
p Co-variable Standardized 
Beta
P
BMD-Femoral Neck FT4 0.063 0.413 BMI # 0.298 <0.001
T3 -0.039 0.621
lnTSH 0.020 0.793
TSHR727Glu 0.172 (0.127)& 0.023 (0.102)&
BMD-Lumbar 
Spine
FT4 0.038 0.635 BMI # 0.160 0.045
T3 -0.014 0.867
lnTSH -0.026 0.740
TSHR727Glu -0.028 0.725
BAP FT4 0.148 0.103 BMI 0.177 0.050
T3 0.251 (0.117)& 0.005 (0.165)& Ca # 0.351 <0.001
lnTSH # -0.303 (-0.273)& 0.001 (0.002)& lnPTH 0.208 0.021
TSHR727Glu -0.061 0.509
P1NP FT4 0.140 0.112 Ca 0.237 0.006
T3 0.132 0.131
lnTSH # -0.282 (-0.268)& 0.001 (0.002)&
TSHR727Glu 0.008 0.926
CTx FT4 0.157 0.078
T3 0.168 (0.062)& 0.058 (0.481)&
lnTSH # -0.302 (-0.276)& 0.001 (0.003)&
TSHR727Glu 0.110 0.220
NTx/Creatinine FT4 0.234 (0.122)& 0.010 (0.200)& lnPTH 0.197 0.030
T3 0.108 0.240
lnTSH # -0.286 (-0.238)& 0.002 (0.018)&
TSHR727Glu 0.021 0.820
Table 3. Association between serum TSH levels, BMD and indicators of bone turnover
Univariate regression analysis, all corrected for gender, age and estrogen status. Due to a non-normal distribu-
tion, TSH and PTH were transformed by the natural logarithm.
& Values obtained with a multivariate regression model in which covariables that were significant using univariate 
analysis were included.  # Variable with sustained significant association at multivariate analysis.
FT4: Free Thyroxin, T3= Triiodothyronine, TSH= Thyrotropin , BMD: Bone Mineral Density; BAP: Bone Specific 
Alkaline Phosphatase; P1NP: Procollagen type 1 Aminoterminal Propeptide; CTx: C-crosslinking Terminal Tel-
opeptide of Type I collagen; NTx/Creatinine: Ratio of Urinary N-Telopeptide of Collagen Cross-links and Creatinine 
Concentration.
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This could be due to the fact that the TSH levels Were measured at one occasion. BMD 
is acquired by a lifelong process, whereas indicators of bone turnover reflect short term 
biochemical effects. Kim et al. and Morris et al. found a relationship between not only below 
normal TSH and BMD, but also between low-normal TSH and BMD (21,31). An explanation for 
this difference could be that Kim et al. and Morris et al. excluded patients with thyroid disease 
whereas we studied DTC patients. It may be objected that TSH measured at one occasion 
may not reflect the overall suppression of TSH over time. To address this shortcoming, we 
collected all TSH measurements after initial therapy of the patients who participated in the 
study, with the exception of stimulated TSH levels. We calculated for each patient the slope 
of TSH levels, to verify changes over time. An average of 15 TSH measurements per patient 
were obtained and we calculated a slope of TSH values of -0.0001 (range -0.004-0) mU/L/
year, thus indicating stable TSH levels over time.   
We also hypothesized that the TSHR-Asp727Glu polymorphism, which is associated with 
serum TSH, but not FT4, may influence BMD and bone metabolism in humans. Although we 
found that carriers of the TSHR-Asp727Glu polymorphism had a higher BMD as compared 
with 131 non-carriers, the relationship in our study was no longer significant after correction 
for BMI. This may imply that the effect of the polymorphism is explained by BMI, which 
is also in agreement with the study of van der Deure et al (23). An explanation for the 
difference in outcome of our study and the study of van der Deure et al. could be that the 
number of patients in our study was too small to detect a significant correlation between the 
polymorphism and BMD. We did not find an association of serum TSH levels with lumbar 
spine BMD. This might be due to the fact that the BMD measurements of the lumbar spine 
are influenced by osteoarthritis and therefore cannot be accurately assessed (32). 
The mechanisms of TSH effects on bone metabolism have not been fully elucidated. In a 
provocative study, Abe et al. suggested that TSH inhibits osteoclast formation and survival 
by attenuating JNK/c-jun and NFκB signaling in response to RANK-L and inhibits osteoblast 
differentiation and type 1 collagen expression as well by downregulating Wnt and VEGF 
signalling (14). The same group found that TSH directly inhibits Tumour Necrosis Factor-
α (TNF-α) production and that TNF-α is the critical cytokine mediating the downstream 
antiresorptive effects of TSH on the skeleton (33). Other authors suggested that serum 
TSH activates the type 2 deiodinase in osteoblasts, thereby linking TSH and increased local 
thyroid hormone availability (15). Our data are in agreement with the notion of a direct 
effect of TSH on bone, as we found a significantly inverse relationship between serum TSH 
levels and indicators of bone formation and degradation, which is consistent with an overall 
suppressive effect on bone turnover. However, 2 recent papers by Bassett et al. added to the 
controversy on the net contribution of TSH to BMD and bone metabolism (19,34).  Bassett 
et al. studied mice with complete or haploinsufficiency of TR-α and -β. They found skeletal 
hypothyroidism and osteosclerosis accompanied by reduced osteoclastic bone resorption in 
adult mice lacking TR-α, whereas young mice had delayed endochondral ossification, in the 
presence of normal circulating thyroid hormone and TSH concentrations. Adult mice lacking 
the TR-β, leading to elevated TSH and thyroid hormone levels, had skeletal hyperthyroidism, 
with evidence of increased bone resorption. The authors concluded that TR-α regulates both 
skeletal development and adult bone maintenance, with euthyroid status during development 
being essential to establish normal adult bone structure and mineralization. In the study of 
van der Deure et al. (23) a stronger effect of FT4 than TSH on BMD was observed, which 
supports the importance of thyroid hormone effects on bone. In our study, which involved a 
different patient group in many respects, we did not find a relationship between serum levels 
of FT4, TSH and BMD, which may well be due to the fact that serum thyroid hormone and 
TSH levels have changed after the thyroidectomy. Indeed, despite the low serum TSH levels 
in most patients, overall BMD was within the normal age-corrected range, which is in line 
with a recent report in DTC patients (35). 
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It is obvious that the net contribution of TSH in bone development and bone metabolism 
has not been established yet. We belief that our study may add important human data to 
the determination of the role of TSH in bone metabolism, since we were able to study the 
independent relation between serum TSH and bone in thyroidectomized patients.
In summary, we found an independent inverse relationship between serum TSH levels and 
biochemical indicators of bone turnover, which may point to a functional role of the TSHR 
in bone in humans. This study documents a direct effect of TSH, independent of thyroid 
hormone levels on BMD and indicators of bone turnover in humans. Further research into 
the mechanisms of TSH in bone metabolism needs to be performed.
0
5
 
R
el
at
io
ns
hi
p 
be
tw
ee
n 
TS
H
 a
nd
 b
on
e 
in
 h
um
an
s
88
References
1.   Franklyn JA, Betteridge J, Daykin J et al. Long-term thyroxine treatment and bone mineral density. Lancet 
1992; 340(8810):9-13.
2.   Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Ann Intern Med 1999; 
130(9):750-758.
3.   Heemstra KA, Hamdy NA, Romijn JA, Smit JW. The effects of thyrotropin-suppressive therapy on bone 
metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 2006; 16(6):583-591.
4.  Murphy E, Williams GR. The thyroid and the skeleton. Clin Endocrinol (Oxf) 2004; 61(3):285-298.
5.   Galliford TM, Murphy E, Williams AJ, Bassett JH, Williams GR. Effects of thyroid status on bone metabolism: 
a primary role for thyroid stimulating hormone or thyroid hormone? Minerva Endocrinol   
2005; 30(4):237-246.
6.   Eriksen EF, Mosekilde L, Melsen F. Trabecular bone remodeling and bone balance in hyperthyroidism. 
Bone 1985; 6(6):421-428.
7.   Mosekilde L, Melsen F, Bagger JP, Myhre-Jensen O, Schwartz SN. Bone changes in hyperthyroidism: 
interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. 
Acta Endocrinol (Copenh) 1977; 85(3):515-525.
8.   Basset P, Okada A, Chenard MP et al. Matrix metalloproteinases as stromal effectors of human carcinoma 
progression: therapeutic implications. Matrix Biol 1997; 15(8-9):535-541.
9.   Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K. Thyroid hormone stimulates 
osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. J Cell Physiol 2004; 
201(1):17-25.
10.   Miura M, Tanaka K, Komatsu Y et al. A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) 
in osteoclast formation. Biochem Biophys Res Commun 2002; 291(4):987-994.
11.   Salerno M, Lettiero T, Esposito-del Puente A et al. Effect of long-term L-thyroxine treatment on bone 
mineral density in young adults with congenital hypothyroidism. Eur J Endocrinol 2004; 151(6):689-
694.
12.   Lee WY, Oh KW, Rhee EJ et al. Relationship between subclinical thyroid dysfunction and femoral neck 
bone mineral density in women. Arch Med Res 2006; 37(4):511-516.
13.   Inoue M, Tawata M, Yokomori N, Endo T, Onaya T. Expression of thyrotropin receptor on clonal osteoblast-
like rat osteosarcoma cells. Thyroid 1998; 8(11):1059-1064.
14.   Abe E, Marians RC, Yu W et al. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115(2):151-
162.
15.   Morimura T, Tsunekawa K, Kasahara T et al. Expression of type 2 iodothyronine deiodinase in human 
osteoblast is stimulated by thyrotropin. Endocrinology 2005; 146(4):2077-2084.
16.  Sun L, Davies TF, Blair HC, Abe E, Zaidi M. TSH and bone loss. Ann N Y Acad Sci 2006; 1068:309-318.
17.  Davies T, Marians R, Latif R. The TSH receptor reveals itself. J Clin Invest 2002; 110(2):161-164.
18.   Sampath TK, Simic P, Sendak R et al. Thyroid-stimulating hormone restores bone volume, 
microarchitecture, and strength in aged ovariectomized rats. J Bone Miner Res 2007; 22(6):849-859.
19.   Bassett JH, O’Shea PJ, Sriskantharajah S et al. Thyroid hormone excess rather than thyrotropin deficiency 
induces osteoporosis in hyperthyroidism. Mol Endocrinol 2007; 21(5):1095-1107.
20.   Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-
stimulating hormone. Ann Intern Med 2001; 134(7):561-568.
21.   Kim DJ, Khang YH, Koh JM, Shong YK, Kim GS. Low normal TSH levels are associated with low bone 
mineral density in healthy postmenopausal women. Clin Endocrinol (Oxf) 2006; 64(1):86-90.
22.   Mazziotti G, Sorvillo F, Piscopo M et al. Recombinant human TSH modulates in vivo C-telopeptides of 
type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal 
women monitored for differentiated thyroid carcinoma. J Bone Miner Res 2005; 20(3):480-486.
23.   van der Deure WM, Uitterlinden AG, Hofman A et al. Effects of serum TSH and FT4 levels and the TSHR-
Asp727Glu polymorphism on bone: the Rotterdam Study. Clin Endocrinol (Oxf).  accepted for publication. 
2007.
24.   Haraguchi K, Saito T, Kaneshige M, Endo T, Onaya T. Desensitization and internalization of a thyrotrophin 
receptor lacking the cytoplasmic carboxy-terminal region. J Mol Endocrinol 1994; 13(3):283-288.
25.   Peeters RP, van TH, Klootwijk W et al. Polymorphisms in thyroid hormone pathway genes are associated 
89
with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab 2003; 88(6):2880-
2888.
26.   Hansen PS, van der Deure WM, Peeters RP et al. The impact of a TSH receptor gene polymorphism on 
thyroid-related phenotypes in a healthy Danish twin population. Clin Endocrinol (Oxf) 2007; 66(6):827-
832.
27.   Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and 
differentiated thyroid cancer. Thyroid 2006; 16(2):109-142.
28.   Kerschan-Schindl K, Hawa G, Kudlacek S, Woloszczuk W, Pietschmann P. Serum levels of cathepsin K 
decrease with age in both women and men. Exp Gerontol 2005; 40(6):532-535.
29.   Minisola S, Dionisi S, Pacitti MT et al. Gender differences in serum markers of bone resorption in healthy 
subjects and patients with disorders affecting bone. Osteoporos Int 2002; 13(2):171-175.
30.   Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated 
cells. Nucleic Acids Res 1988; 16(3):1215.
31.   Morris MS. The association between serum thyroid-stimulating hormone in its reference range and bone 
status in postmenopausal American women. Bone 2007; 40(4):1128-1134.
32.   Burger H, van Daele PL, Algra D et al. The association between age and bone mineral density in men and 
women aged 55 years and over: the Rotterdam Study. Bone Miner 1994; 25(1):1-13.
33.   Hase H, Ando T, Eldeiry L et al. TNFalpha mediates the skeletal effects of thyroid-stimulating hormone. 
Proc Natl Acad Sci U S A 2006; 103(34):12849-12854.
34.   Bassett JH, Nordstrom K, Boyde A et al. Thyroid status during skeletal development determines adult 
bone structure and mineralization. Mol Endocrinol 2007; 21(8):1893-1904.
35.   Reverter JL, Holgado S, Alonso N, Salinas I, Granada ML, Sanmarti A. Lack of deleterious effect on bone 
mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocr 
Relat Cancer 2005; 12(4):973-981.
0
5
 
R
el
at
io
ns
hi
p 
be
tw
ee
n 
TS
H
 a
nd
 b
on
e 
in
 h
um
an
s

06
Thyroid hormone rather than TSH 
decreases bone turnover during 
hypothyroidism in athyroid patients 
with differentiated thyroid carcinoma
Karen A. Heemstra, Hendrieke C. Hoftijzer, Neveen A. Hamdy, Marcel P. Stokkel, 
Johannes A. Romijn, Johannes A. Smit, Eleonora P. Corssmit
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Abstract
Context: Primary hypothyroidism affects bone metabolism. It is not clear whether this has to 
be attributed to decreased serum thyroid hormone levels per se or to increased TSH levels. 
Objective: To document the effects of primary hypothyroidism on bone metabolism and to 
discriminate between effects mediated by decreased thyroid hormone levels versus those 
mediated by increased TSH levels. 
Design: Prospective study
Setting: University Hospital
Patients: We studied the effects of recombinant human TSH (rhTSH) in 11 athyroid DTC 
patients on thyroxine substitution. In addition, we included 11 age-, gender- and BMI-matched 
athyroid patients previously treated for differentiated thyroid carcinoma (DTC), who were 
studied after 4 weeks of thyroxine withdrawal and during thyroxine replacement therapy. 
Main outcome measures: We measured plasma levels of PTH, 25-OH-vitamin D, procollagen 
type 1 aminoterminal propeptide levels (P1NP), C-cross-linking terminal telopeptide of type 
I collagen (Ctx), receptor activator for nuclear factor κ B ligand (RANKL) and osteoprotegerin 
(OPG).
Results: No differences were observed on parameters of bone turnover after rhTSH 
administration. During thyroxine withdrawal, levels of C-cross-linking terminal telopeptide of 
type I collagen were significantly lower, whereas levels of osteoprotegerin were significantly 
higher compared to thyroxine replacement therapy. 
Conclusion: Hypothyroidism results in decreased bone turnover. As rhTSH did not impact on 
bone turnover, it seems that low thyroid hormone levels instead of the increased TSH levels 
are responsible for the changes in bone turnover during hypothyroidism in DTC patients. 
93
Introduction
The effects of thyroid hormone on bone are established and the conventional view is that 
hyperthyroidism results in bone loss (1). However, the consequences of hypothyroidism on 
bone metabolism remain unclear (Table 1). Some studies document low bone turnover as 
evidenced by decreased markers of bone resorption and formation (2-5), whereas others 
report normal bone turnover (6-8). Most studies, however, included patients with Hashimoto 
thyroiditis, in whom the duration of hypothyroidism is not known (3-5;7). Moreover, it is not 
clear, given the recent suggestion that THS may be a negative regulator of bone remodelling 
by directly affecting bone independently of thyroid hormone levels (9-11), if the effects of 
hypothyroidism must be attributed to increased TSH levels or decreased thyroid hormone 
levels. It has been reported that TSHR knockout and haploinsufficient mice with normal 
thyroid hormone levels have decreased bone mass, suggesting that TSH might directly 
influence bone remodeling (10;12;13). However, other studies question the role of TSH in 
bone metabolism (14;15).
Three studies in humans have investigated the effect of recombinant human TSH (rhTSH) on 
bone metabolism, but their results were inconclusive by showing either no impact on bone 
turnover (16), increased markers of bone formation (17;18) or decreased markers of bone 
resorption (18). In hypothyroidism the relative importance of decreased thyroid hormone 
levels or increased TSH levels on bone remains thus to be established. 
The present study was designed in an attempt at discriminating between potential effects 
mediated by decreased thyroid hormone levels from those mediated by increased TSH levels 
in a human model in which the reciprocal relationship between thyroid hormones and TSH 
was interrupted. To this effect, we studied parameters of bone metabolism after parenteral 
administration of recombinant human TSH (rhTSH) resulting in exogenously increased TSH 
levels while preserving normal thyroid hormone levels by uninterrupted thyroid hormone 
substitution in athyroid differentiated thyroid carcinoma (DTC) patients. We studied the 
same parameters in age-, gender- and BMI matched athyroid DTC patients during short-
term thyroxine withdrawal, resulting in decreased thyroid hormone levels and endogenously 
increased TSH levels and after reestablishment of thyroid hormone substitution. 
Material and methods
Subjects
Patients were recruited from the outpatient clinic of the Department of Endocrinology & 
Metabolic Diseases of Leiden University Medical Centre, which is a tertiary referral centre for 
differentiated thyroid carcinoma (DTC). Patients included in the study had a diagnosis of DTC 
for which they had been treated by near-total thyroidectomy, followed by routine postoperative 
I-131 radioiodine ablation therapy. Only patients cured of DTC were included, documented 
by the absence of measurable serum thyroglobulin (Tg) levels during TSH stimulation as 
well as by negative total-body scintigraphy. Patients with DTC planned for a TSH-stimulated 
diagnostic protocol were asked to participate in the study. Patients with diabetes mellitus, 
body mass index (BMI) >35 kg/m2 or other endocrine diseases were excluded. Patients who 
used any drugs known to influence bone turnover, such as bisphosphonates, corticosteroids 
or thiazide diuretics, were also excluded. 
The local Ethics Committees of the Leiden University Medical Centre approved the study, 
and written informed consent was obtained from all subjects.
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Two groups matched for age, gender and BMI were studied. The first group consisted of 
11 athyroid DTC patients who were receiving uninterrupted thyroxine replacement therapy 
and were undertaking a TSH stimulation test in the course of monitoring disease state 
by receiving injections of rhTSH. This resulted in exogenously increased TSH levels with 
unchanged normal FT4 levels (rhTSH group). The second group also consisted of 11 athyroid 
DTC patients with short-term thyroxine withdrawal resulting in decreased FT4 levels and 
endogenously increased TSH levels (thyroxine withdrawal group).
Study Design
Patients in the rhTSH group continued to receive thyroxine substitution and were evaluated 
prior to receiving recombinant human TSH (Thyrogen, 0.9 mg) which was injected 
intramuscularly once daily for two consecutive days and patients were also evaluated 1 and 
3 days after the last injection of rhTSH. 
Patients in the thyroxine withdrawal group were evaluated four weeks after withdrawal of 
thyroxine substitution and again 8 weeks after restarting thyroxine replacement therapy. 
All patients were assessed at 8.00 hr after a 12 hour fast. Height (meters [m]) and weight 
(kilograms [kg]) were measured and BMI (weight [kg]/lenght2 [m]) was calculated. Plasma 
samples were obtained for measurement of FT4, TSH, T3, PTH, 25-OH-vitamin D, procollagen 
type 1 aminoterminal propeptide levels (P1NP), C-cross-linking terminal telopeptide of type 
I collagen (Ctx), receptor activator for nuclear factor κ B ligand (RANKL) and osteoprotegerin 
(OPG). Plasma samples were handled immediately and stored at –20o C in Sarstedt tubes.
Biochemical parameters
All plasma and serum samples were measured in one batch. Serum free thyroxine (FT4) 
and TSH were measured using an electrochemiluminescent immunoassay with a Modular 
Analytics E-170 system with an intra-assay CV of 1.6-2.2 % and 1.3-5.0 % respectively 
(Roche Diagnostics, Almere, The Netherlands). Serum T3 was measured using a fluorescent 
polarisation immunoassay on an AxSYM system (Abbott, Abbott Park, IL, USA CV 2.5-9.0 %). 
Plasma Parathyroid Hormone (PTH) was measured by an immunoradiometric assay (Nichols 
Diagnostic Institutes, Wijchen, The Netherlands), calcium and alkaline phosphatase activity 
by colorimetry on a fully automated Modular P800 system (Roche, Almere, The Netherlands) 
and 25(OH) vitamin D by RIA (Incstar/DiaSorin, Stillwater, MN, USA). CTx and P1NP were 
measured by electrochemiluminescent immunoassays using a Modular Analytics E-170 
system (Roche Diagnostics, Almere, The Netherlands). RANKL was measured using the 
ampli sRANKL human kit (Biomedica, Vienna, Austria), an enzyme linked immunoassay 
with a detection limit of 0.02 pmol/l (intra-assay CV 8-9%, interassay CV 3-6%). All samples 
were measured in triplo in single batches for the levels of RANKL and osteoprotegerin. 
Osteoprotegerin was measured by ELISA (Meso Scale Discovery, Gaithersburg, Maryland, 
USA) with a detection limit of 5.9 pg/ml. In our hands, the range was 206 to 404 pg/ml; CVs 
were 0.6-16.2%, with an average of 4.6%. 
Statistical Analyses
SPSS 12.0 for windows was used for statistical analyses (SPSS. Inc., Chicago, IL, USA). 
Values are expressed as mean ± SE. Data within subjects were analysed with the paired 
samples t-test or the ANOVA for repeated measures. Data between subjects were measured 
with the Mann-Whitney test. Differences were considered statistically significant at P<0.05. 
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Eleven patients (4 male and 7 female patients) were included in the rhTSH-group. Mean 
thyroxine dose at time of the evaluation was 200 ± 12 µg/day. TSH levels were significantly 
increased without any changes in FT4 levels 1 and 3 days after rhTSH was administered 
(Table 4).
There were no differences in the levels of calcium, PTH, 25-OH-vitamin D, alkaline 
phosphatase activity, P1NP, Ctx, OPG, RANKL and in the RANKL/OPG ratio between baseline 
and time points after rhTSH administration.
Eleven patients (4 male and 7 female patients) were included in the thyroxine-withdrawal-
group. Mean thyroxine dose prior to withdrawal was 197 ± 13 µg/day. Four weeks after 
thyroxine withdrawal, TSH levels were significantly increased at 142.4 ± 10.4 mU/L (normal 
laboratory reference range 0.3-4.8 mU/L) and FT4 levels were significantly decreased at 1.4 
± 0.2 pmol/L (normal laboratory reference range 10-24 pmol/L). Eight weeks after restarting 
thyroxine replacement therapy, six patients had TSH levels within the normal laboratory 
reference range and five patients had suppressed TSH levels. 
There were no significant differences in levels of calcium, PTH, 25-OH-vitamin D, alkaline 
phosphatase activity, P1NP, RANKL and the RANKL/OPG ratio between thyroxine withdrawal 
status and 8 weeks after reintroduction of thyroxine replacement therapy (Table 3). Serum 
concentrations of Ctx were significantly lower and OPG levels significantly higher during 
hypothyroidism compared to 8 weeks after reintroduction of thyroxine replacement therapy. 
There was no significant difference between endogenously and exogenously increased 
TSH levels respectively obtained 4 weeks after thyroxine withdrawal and 1 day after rhTSH-
administration. As expected, FT4 levels were significantly decreased during thyroxine 
withdrawal compared to the normal levels attained by thyroxine substitution therapy 1 and 
3 days after rhTSH administration.
The differences in Ctx levels and OPG levels were significantly different between the 
thyroxine withdrawal group and rhTSH group. Calcium levels were significantly lower during 
hypothyroidism compared to rhTSH administration. There were no significant differences 
observed in any other parameters measured between the groups. 
Results
Patient demographic characteristics are shown in Table 2. Patients in the rhTSH-group and 
thyroxine withdrawal-group were well matched and there were no differences in age, gender, 
BMI, thyroxine dose or duration of follow-up between groups.
Thyroxine withdrawal-study
(n=11)
rhTSH stimulation study
(n = 11) 
P-value
Age (years) 45.5 ± 3.0 47.0 ± 2.8 0.65
Sex (m/f) 4 : 7 4:7 0.67
BMI (kg/m2) 28.1 ± 1.3 29.7 ± 2.6 0.75
Thyroxine dose (µg/day) 197 ± 13 200 ± 12 0.70
Duration of TSH suppressing 
treatment (years, (range))
5.0 ± 2.1 (0.6-24.3) 6.7 ± 2.4 (1.2 -25.3) 0.33
Table 2. Patient characteristics 
Data are expressed as mean ± SE (range) or number of patients
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Discussion
In this study, we have attempted to dissect the effects of increased TSH levels from those 
of decreased thyroid hormone levels on bone by studying athyroid DTC patients in which the 
relationship between thyroid hormone levels and TSH is disrupted. Our findings suggest that 
acute increases in TSH in the presence of stable thyroid hormone levels obtained by rhTSH 
administration do not significantly affect skeletal metabolism. The data from our model 
suggest that hypothyroidism results in decreased bone turnover rather by decreased plasma 
thyroid hormone concentrations than by increased TSH concentrations, because rhTSH 
did not impact on bone turnover in DTC patients. To our knowledge, this is the first study 
comparing rhTSH-injection versus thyroxine withdrawal in age-, gender- and BMI matched 
DTC patients. 
It has been proposed that TSH may modulate bone remodelling independently of thyroid 
hormones through binding to the TSH receptor on osteoblasts and osteoclasts. (10). However, 
other studies question these findings. Bassett et al. reported that Pax -/-  mice and hyt/hyt 
mice, two mouse models of congenital hypothyroidism in which the feedback between TSH 
and thyroid hormones was intact or disrupted, both displayed delayed ossification, reduced 
cortical bone, trabecular bone remodeling defects and reduced bone mineralization, 
indicating that the effects of congenital hypothyroidism on bone are independent of TSH (15). 
Moreover, Bassett et al. showed that osteoblasts and osteoclasts express TSH-receptors, 
but TSH did not affect a cAMP response or the differentiation or function (15). We used the 
model of thyroidectomised DTC patients in whom a rhTSH simulation test was performed in 
an attempt to discriminate the effects of TSH from those of FT4 on bone metabolism. These 
patients have no endogenous thyroid hormone production and are therefore an excellent 
model to study the effects of TSH without interfering effects of changes in thyroid hormone 
concentrations. However, rhTSH did not affect bone turnover. This is in keeping with a study 
using the same model (16), but ad odds with two others studies (17;18). Mazzioti et al. 
found significantly increased levels of bone specific alkaline phosphatase with decreased 
levels of cross-linking terminal telopeptide of type I collagen in postmenopausal women 
after rhTSH administration (18). They found no changes in premenopausal women. Martini 
et al. found significantly increased levels of P1NP and RANKL after rhTSH administration 
(17). These differences were only significant in postmenopausal women for P1NP levels 
and in postmenopausal women and men for RANKL levels after stratification for gender 
and menopausal state. We studied only 2 postmenopausal women. This might explain the 
differences in outcome. We found no differences in OPG levels, which is consistent with 
previous studies (16-18) and in agreement with the finding that TSH regulates bone turnover 
by different mechanisms than OPG (10;19). Osteoprotegerin, a member of the TNF receptor 
superfamily, inhibits osteoclastogenesis by interrupting the cell-to-cell interaction (20;21). 
In the thyroxin withdrawal group, levels of C-cross linking terminal telopeptide of type 
1 collagen were lower during hypothyroidism compared to 8 weeks after reinstitution of 
thyroxine replacement therapy. This is consistent with most reports on hypothyroidism 
(2;5;22), although Sabancu et al. reported no differences in markers of bone turnover during 
hypothyroidism in a heterogeneous patient population including patients with Hashimoto 
thyroiditis (7). A disadvantage of the inclusion of patients with Hashimoto thyroiditis may be 
that the duration and extent of hypothyroidism are not known. OPG levels were significant 
higher during hypothyroidism compared to thyroxine replacement therapy. This is consistent 
with previous studies (2-4) and strengthens our finding that thyroxine withdrawal decreases 
bone turnover. 
In summary, bone turnover is decreased during hypothyroidism due to thyroxine withdrawal 
in DTC patients. As rhTSH did not impact on bone turnover, we conclude that the low thyroid 
hormone levels instead of the increased TSH levels are responsible for the decreased bone 
resorption during hypothyroidism in DTC patients. 
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The Type 2 Deiodinase Thr92Ala 
Polymorphism is Associated with 
Increased Bone Turnover and Decreased 
Femoral Neck Bone Mineral Density
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Abstract
Background: The role of type 2 deiodinase (D2) in the human skeleton remains unclear. The 
D2 polymorphism Thr92Ala has been associated with lower enzymatic activity, which could 
result in lower local T3 availability in bone.
Aims: We hypothesized that the D2 Thr92Ala polymorphism may influence bone mineral 
density (BMD) and bone turnover. 
Patients:  We studied 154 patients (29 men, 125 women: 79 estrogen replete, 46 estrogen 
deficient) with cured differentiated thyroid carcinoma. 
Methods:  BMD and bone turnover markers (bone specific alkaline phosphatase (BAP), C-
crosslinking terminal telopeptide of type I collagen (CTx), procollagen type 1 aminoterminal 
propeptide (P1NP) and N-telopeptide of collagen cross-links (NTx) were measured. Effects 
of the D2 Thr92Ala polymorphism on BMD and bone turnover markers were assessed by a 
linear regression model, with age, gender, estrogen state, BMI, serum calcium, 25-hydroxy 
vitamin D, PTH, TSH and free T4 as covariables.
Results:  60 patients were wildtype (Thr/Thr), 66 heterozygous  (Thr/Ala) and 28 homozygous 
(Ala/Ala) for the D2 polymorphism. There were no significant differences in any covariables 
between the 3 genotypes. Corrected BMD of the femoral neck was 6% lower in homozygotes 
than in wild-type subjects (p=0.028). Serum P1NP, CTx and urinary NTx/creat were 27%, 
32% and 54% higher in homozygotes than in wildtype patients (p<0.05). 
Conclusion:  In patients with cured DTC, the D2 Thr92Ala polymorphism is associated with 
a decreased femoral neck BMD and higher bone turnover, independently of serum thyroid 
hormone levels, which points to a potential functional role for D2 in bone. 
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Introduction
The involvement of thyroid hormone in bone metabolism has been well documented 
clinically, ranging from decreased skeletal development in childhood hypothyroidism (1-4), 
accelerated growth in childhood hyperthyroidism (5) to an increased risk for osteoporosis in 
overt and subclinical hyperthyroidism (6-14). 
Although clinical observations suggest a clear involvement of thyroid hormone in bone 
metabolism, the molecular mechanisms by which thyroid hormone acts on bone is have 
so far only been partially uncovered. T3 promotes osteoblastic proliferation, differentiation 
and apoptosis and, by induction of IL-6, prostaglandins and RANKL, probably also promotes 
osteoclast formation and activation. This suggests that osteoblasts are the primary target 
cells for T3 in the regulation of bone remodeling (1,2,15-18). A functional role of thyrotropin 
(TSH) on skeletal development and metabolism has been proposed on the basis of data 
obtained in animal studies (19-25) and in humans (26-28). This was however disputed by 
data obtained in thyroid hormone receptor (TR) deficient mice, which indicated that bone 
remodeling was predominantly mediated by T3 via TRalpha (29,30). It has also recently 
been reported that in humans there is a significant association between BMD and serum 
thyroid hormone concentrations than TSH (31). 
Most actions of thyroid hormone are mediated by the active form of thyroid hormone, T3. 
Circulating and local T3 concentrations are mainly regulated by the iodothyronine deiodinases 
D1, D2 and D3 (32). D2 is essential for the local production of T3 through deiodination 
of T4. Although earlier studies on the role and functional expression of  iodothyronine 
deiodinase enzymes in the skeleton have been equivocal (18,21,33-36),  a recent study 
reported normal growth in mice with deficiencies in D1 and D2 indicating that D2 may not 
be critical in skeletal development (37). This notion was supported in a recent study which 
demonstrated that D2 activity is restricted to mature osteoblasts, suggesting a possible role 
for D2 in mature osteoblast function (38). Devising a study addressing the potential role of 
deiodinases, including D2 on skeletal metabolism is difficult in humans, but the study of the 
effects of functional D2 polymorphisms on BMD and bone turnover in humans may shed 
light on this role.
Several polymorphisms in D2 have been described (39-41). The single-nucleotide 
polymorphism D2 Thr92Ala polymorphism has been associated with BMI and insulin 
resistance in subjects with obesity and type 2 diabetes mellitus (39.40), although this was 
not confirmed in the Framingham offspring study (42). In the study of Canani et al (39), the 
maximal velocity of D2 was decreased by 3–10-fold in thyroid and skeletal muscle of carriers 
of the Thr92Ala polymorphism.  This effect was observed in the absence of differences in 
D2 mRNA level or in the biochemical protein properties of the 92Ala allele. It was, therefore, 
suggested that either a functionally relevant single nucleotide polymorphism occurs in linkage 
disequilibrium the Thr92Ala polymorphism or the 92Ala allele affects protein translation or 
stability.
The objective of our study was to try and elucidate a potential role for D2 in skeletal metabolism 
and BMD by evaluating the relationship between the D2 Thr92Ala polymorphism, BMD and 
bone turnover markers in cured thyroidectomized differentiated thyroid carcinoma patients 
receiving thyroid hormone substitution. This human model has the advantage having strictly 
regulated serum thyroid hormone levels which are kept in a relatively narrow range.
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Patients and Methods
Patients included in the study were all under control of the outpatient clinic of the 
Department of Endocrinology of the Leiden University Medical Center. All patients had a 
diagnosis of DTC, for which they had been treated by near-total thyroidectomy, followed by 
standard postoperative I-131 radioiodine ablation therapy. All patients were cured as defined 
by the absence of I-131 accumulation at diagnostic scintigraphy, serum thyroglobulin (Tg) 
concentrations below 2 µg/L after TSH stimulation, the absence of Tg antibodies, a normal 
neck ultrasound and no other indication for disease (43). Patients with tumour relapse were 
only included if they were subsequently cured. None of the patients used any drug or had a 
disease known to influence bone metabolism. The Leiden University Medical Center Local 
Ethics Committees approved the study, and written informed consent was obtained from all 
subjects.
Study design
On the day of the study, patients had a full clinical examination, including, height (meters [m]) 
and weight (kilograms [kg]). Blood was collected after an overnight fast, and measured for 
TSH, FT4, triiodothyronine (T3), calcium, parathyroid hormone (PTH), 25-hydroxy-vitamin D 
(25(OH)vitD), bone specific alkaline phosphatase (BAP), C-crosslinking terminal telopeptide 
of type I collagen (CTx) and procollagen type 1 aminoterminal propeptide (P1NP). Second 
morning void urine was measured for excretion of N-telopeptide of collagen cross-links 
(NTx). Plasma, serum and urine samples were handled immediately and stored at –80o C 
in Sarstedt tubes. BMD (expressed in grams per square centimeter) was measured at the 
femoral neck and the lumbar spine (vertebrae L2-L4) by dual energy x-ray absorptiometry 
(NHANES III adjusted, Hologic 4500, Hologic Inc., Bedford, MA, USA). Following WHO criteria, 
osteopenia was defined as a T-score between –1 and –2.5 and osteoporosis as a T-score 
below –2.5. The following data were additionally recorded: smoking habits, alcohol use, 
physical activity, calcium intake, medication (including self-prescription drugs) or vitamin or 
mineral supplements and daily calcium intake and for females: date of first menstruation 
(menarche), date of last menstruation, cycle regularity and estrogen substitution if 
applicable. 
Biochemical parameters
Serum free T4 (FT4) and TSH were measured using a chemoluminescence immunoassay 
with a Modular Analytics E-170 system (intraassay CV of 1.6-2.2 % and 1.3-5.0 % respectively 
(Roche, Almere, The Netherlands). Serum T3 was measured with a fluorescence polarization 
immunoassay, CV 2.5-9.0 %, on an ImX system (Abbott, Abbott Park, IL, USA). Thyroglobulin 
was measured by Dynotest TG-s (Brahms Diagnostica GmbH, Germany). Plasma PTH was 
measured using an immunoradiometric assay (Nichols Diagnostic Institutes, Wijchen, 
The Netherlands). Calcium was measured by colorimetry and 25(OH)vitD by RIA (Incstar/
DiaSorin, Stillwater, MN, USA). Serum BAP was measured by RIA (Hybritech Europe, Liege, 
Belgium). Serum CTx and P1NP were measured by chemoluminescence immunoassay using 
the Modular Analytics E-170 system (Roche Diagnostics, Almere, The Netherlands). NTx was 
measured by ELISA (Ostex International Inc., Seattle, WA, USA). NTx was expressed as the 
ratio between NTx and urine creatinine excretion (NTx/creatinine) to correct for differences 
in creatinine excretion. Insulin sensitivity was estimated by homeostasis model assessment 
[HOMA _ fasting insulin (milliunits per milliliter) _ fasting glucose (millimoles per liter)/22.5.
Genetic analyses
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DNA was isolated from peripheral leucocytes by the salting out procedure. Genotypes were 
determined using  5 ng genomic DNA by a 5’ fluoregenic Taqman assay and reactions were 
performed in 384-wells format on ABI9700 2x384well PCR machines with endpoint reading 
on the ABI 7900HT TaqMan® machine (Applied Biosystems, Nieuwerkerk aan den Ijssel, 
The Netherlands). Primer and probe sequences were optimized using the single nucleotide 
polymorphism assay-by-design service of Applied Biosystems. 
Statistical Analyses
Values are presented as mean ± standard error (SE), median (range) or as numbers or 
proportions of patients. Non-normally distributed data (TSH and PTH) were log transformed 
before analyses. Comparisons between groups were analyzed by Anova or Chi-square tests. 
The relation between the 3 D2 Thr92Ala genotypes (Thr/Thr (wild-type); Thr/Ala (heterozygote) 
and Ala/Ala (homozygote)), BMD and markers of bone turnover was studied by a stepwise 
univariate regression analysis. After correction for age, gender and estrogen status (estrogen 
deplete or replete), the following co-variables were entered: BMI, serum levels of calcium 
(corrected for an albumin concentration of 42 g/L), 25(OH)vitD, lnPTH, FT4, T3 and lnTSH. 
Because it has been documented that the D2 Thr92Ala polymorphism is associated with 
insulin resistance (39), we also compared insulin sensitivity (HOMA) in the 3 genotypes. 
Deviation from Hardy-Weinberg Equilibrium was analysed using a X2-test. All calculations 
were performed using SPSS 12.0 for windows (SPSS, Inc., Chicago, IL). Differences were 
considered statistically significant at P<0.05
Results
Patient characteristics
Of a potential of 330 patients with cured DTC, 105 were excluded for various reasons 
(Figure 1). Sixty-nine patients were not willing or able to participate in the study for different 
reasons. 
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330 patients were treated for DTC
105 patients were excluded:
• N=26 <18 years or >75 years
• N=22 medication influencing bone metabolism
• N=15 not fulfilling criteria for cure
• N=9 diseases influencing bone metabolism
• N=5 hyperparathyroidism due to vitamin D deficiency
• N=4 moved abroad
• N=4 pregnant
• N=20 other reasons
225 patients were invited to take part in the study
69 patients did not wish to participate + 2 patients were 
excluded because of missing data
154 patients taking part in the study
Figure 1 Flowchart of the Study
108
A total of 156 patients were thus included in the study. Two patients were left out from 
analyses because of incomplete data. Thirteen patients had post-surgical hypoparathyroidism 
for which they were adequately supplemented with active vitamin D metabolites and calcium 
as required. Additional analyses were performed leaving out these patients (see below and 
Tables 2 and 3). In addition, serum PTH levels were included as covariable in the analyses 
(see below), to correct for potentially confounding effects of hypoparathyroidism. The basal 
characteristics of the 154 patients included in the study are shown in Table 1. All patients 
were receiving L-thyroxine treatment at a mean dose of 183 ± 4 µg/day. 
The D2 Thr92Ala polymorphism, BMD and biochemical parameters of skeletal metabolism 
The characteristics of the 3 genotype subgroups are given in Table 2. Genotype frequencies 
of the D2 Thr92Ala polymorphism (Thr/Thr = 60 (39 %), Thr//Ala = 66 (43 %) and Ala/
Ala =  28 (18 %)) did not deviate from Hardy Weinberg equilibrium proportions. The Ala92 
allele had a frequency of 45%, which is similar to previous studies in Caucasians (42,44). 
The characteristics of the 3 genotype subgroups are given in Table 2. The 3 groups were 
comparable with respect to age, gender, estrogen state (including ages at menarche and 
menopause) and BMI. Physical activity and smoking habits did not differ either. Biochemical 
covariables for bone metabolism (serum calcium, 25OHvitD and PTH) were not different as 
were serum free T4 and T3 levels, serum T3/T4 ratio and TSH levels.  Because it has been 
documented that the D2 Thr92Ala polymorphism is associated with insulin resistance (39), 
we also compared insulin sensitivity by HOMA in the 3 genotypes, which again did not differ 
(p=0.361). We also calculated whether HOMA was a significant determinant of BMD and of 
biochemical parameters of skeletal metabolism (corrected for age, gender, estrogen state 
and BMI). Univariate analyses revealed that p values for HOMA as an independent variable 
were respectively 0.912 for femoral neck BMD,  0.583 for lumbar vertebral BMD, 0.826 for 
Total (n=154)
Age (years) 49.2 ± 1.0
Males 
Females: Estrogen Replete / Deplete 
29 (18.8 %)
79 (51.3 %) / 46 (29.9 %)
Age at diagnosis 36.6 ± 1.1
Histology
• Papillary Thyroid Carcinoma (PTC) 107 (69 %)
• Follicular Thyroid Carcinoma 25 (16 %)
• Follicular variant PTC 21 (14 %)
• Hurthle cell Thyroid Carcinoma 1 (1 %)
Total Activity Radioiodine 8067  ±  699 MBq
Lymph Node Surgery 14 (9 %)
pTNM Stage
• T1-3 N0 M0 90 (63 %)
• T1-3 N1 M0 30 (21%)
• T4 or M1 n=143 23 (16 %)
Relapse DTC 20 (13 %)
Table 1. Characteristics of Patients 
(all were cured after relapse)
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NTX / creatinine, 0.575 for BAP, 0.798 for P1NP and 0.906 for CTx. HOMA was therefore not 
a determinant of BMD or bone turnover markers.
The relation between the 3 D2 Thr92Ala genotypes, BMD and biochemical parameters 
of skeletal metabolism were studied by a stepwise univariate regression analysis. After 
correction for age, gender, estrogen status and BMI, the following co-variables were 
subsequently entered: serum levels of calcium,  25(OH)vitD, lnPTH, FT4 and lnTSH (Table 
3). 
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Thr / Thr (60) Thr / Ala (66) Ala / Ala (28) P
Men (n) 13 11 5 0.861 Chi-square
Women (n) 
Estrogen Replete  / Deplete 
32 / 15 33 / 22 14 / 9 
Age (years) 47.2 ± 1.6 51.2 ± 1.7 48.3 ± 1.9 0.148 A
Height (m) 1.72 ±0.01 1.70 ± 0.01 1.71 ± 0.02 0.307 A
BMI (kg/m2) 25.6 ± 0.6 26.2 ± 0.4 25.8 ± 1.1 0.773 A
Sports (hrs/week) 3.1 ± 1.1 5.0 ± 1.6 4.5 ± 2.3 0.654 A
Smoking (n) 12 (9%) 7 (5%) 5 (1%) 0.092 Chi-square
Menarche (age) 13.4 ± 0.2 13.1 ± 0.2 13.6 ± 0.3 0.399 A
Menopause (age) 48.2 ± 1.5 47.7 ± 1.1 50.1 ± 1.5 0.484 A
Follow-up duration (years) 13.1 ± 1.2 10.5 ± 1.0 11.3 ± 1.5 0.241 A
Hypoparathyroidism (n) 5 (3%) 6 (4%) 2 (1%) 0.952 Chi-square, #
Vertebral fractures (n) 1 (1%) 2 (1%) 1 (1%) 0.832 Chi-square
HOMA (mmol*22.5/L) 1.75 ± 0.20 2.16 ± 0.21 1.86 ± 0.32 0.361 A
Calcium (mmol/L) 2.39 ± 0.02 2.38 ± 0.01 2.39 ± 0.02 0.943 A
25 OH vitD (nmol/L) 64.5 ± 3.9 60.4 ± 2.9 69.9 ± 4.8 0.277 A
PTH (pmol/L) 4.88 ± 0.36 5.27 ± 0.43 6.19 ± 0.83 0.250 A
TSH (mU/L) 0.051 (0.003-
4.620) 
0.031 (0.003-
4.910) 
0.051 (0.003-6.830) 0.753 A
Dose thyroxine (ug/kg) 2.09 ± 1.04 2.23 ± 0.87 2.19 ± 1.03 0.398 A
Free T4 (pmol/L) 22.7 ± 0.1 22.4 ± 0.1 21.6 ± 0.2 0.562 A
T3 (nmol/L) 1.49 ± 0.04 1.47 ± 0.05 1.40 ± 0.07 0.624 A
T3/T4 ratio * 10 6.6 ± 0.2 6.7 ± 0.2 6.6 ± 0.4 0.903 A
BMD femoral neck (g cm2) 0.90 ± 0.02 # & 0.84 ± 0.01 0.85 ± 0.03 0.028 (0.015) 1
BMD lumbar spine 1.08 ± 0.03 1.04 ± 0.02 1.07 ± 0.04 0.741 (0.094) 1
NTX / Creatinine * 1/1000 44.0 ± 4.1 # 56.5 ± 5.8 67.7 ± 10.6 0.008 (0.002) 1
BAP (ng/mL) 12.5 ± 0.5 13.5 ± 0.6 13.9 ± 0.7 0.063 (0.085) 1
P1NP (ng/mL) 40.0 ± 2.6 # 42.9 ± 3.4 50.9 ± 5.5 0.028 (0.032) 1
CTx (mg/mL) 0.28 ± 0.02 # 0.28 ± 0.02 # 0.37 ± 0.05 0.043 (0.036) 1
Table 2. Characteristics of Patients by the D2-Thr92Ala genotype 
Values are presented as mean ± standard error (SE), median (range) or as numbers or proportions of patients. 
PTH: Parathyroid hormone, BAP: Bone Specific Alkaline Phosphatase; P1NP: Procollagen type 1 Aminoterminal 
Propeptide; CTx: C-crosslinking Terminal Telopeptide of Type I collagen; NTx/Creatinin: Ratio of Urinary N-Telopep-
tide of Collagen Cross-links and Creatinin Concentration; A=One-way ANOVA; 1 general linear model, univariate 
with age, gender, estrogen state, BMI, Ca, lnPTH, 25-OHvitD, lnTSH and Free T4 as covariables; values between 
brackets: postoperative hypoparathyroidism left out  # p<0.05 vs. homozygotes; & p<0.05 vs. heterozygotes 
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We found a significant independent relationship between the Thr92Ala genotypes and femoral 
neck BMD (p=0.022) with a 6% lower BMD in homozygotes than in wild-type patients. We 
also found independent relationships between the D2 Thr92Ala genotypes and biochemical 
parameters of skeletal metabolism: P1NP (p=0.028), CTx (p=0.043) and NTX / creatinine 
(p=0.008), which were higher in homozygotes than in wild-type patients. Data for analyses 
leaving out patients with post-surgical hypoparathyroidism did not influence these results 
(Tables 2 and 3). The largest difference was observed for NTX / creatinine, being 54% higher 
in homozygotes than in wild-types. 
Discussion
The main objective of the present study was to investigate a potential role for the deiodinase 
D2 in bone metabolism in humans by studying the relationship between the D2 Thr92Ala 
polymorphism, BMD and bone turnover. The D2 Thr92Ala polymorphism is associated with 
a lower D2 Vmax and may therefore lead to decreased local availability of T3 (39), which 
may in turn affect skeletal metabolism. We studied this relationship in a human model of 
thyroidectomized patients cured from differentiated thyroid carcinoma receiving thyroid 
hormone substitution. The advantage of this model is that study subjects have more uniform 
FT4 levels, which fell between the 25th and 75th percentiles for FT4 (19.5 and 24.9 pmol/L) 
in our group of patients. 
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Figure 2. Relationships between D2Thr92ALA Genotypes and Indicators of Bone Turnover. a. Femoral neck BMD, 
b. Ratio of Urinary N-Telopeptide of Collagen Cross-links and Creatinine Concentration c. Procollagen type 1 
aminoterminal propeptide (P1NP) levels, d. C-crosslinking Terminal Telopeptide of Type I collagen. For levels of 
significance, see text and Table 2.
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In support for the involvement of D2 in bone metabolism was the observation of a 6% 
decrease in femoral neck BMD and increased levels of P1NP (32%), CTx (27%) and NTX/
creatinine (54%) in the Ala/Ala subgroup as compared with wildtype. These effects were 
independent of factors known to influence BMD and bone metabolism such as age, gender, 
BMI, estrogen state, PTH and vitamin D. These effects were also independent of circulating 
levels of T3 and TSH and were thus indicative of an independent role of D2 in bone 
metabolism. We did not find an association of the D2 polymorphism with lumbar spine BMD, 
possibly due to a differential effect of the polymorphism on predominantly trabecular bone 
at the lumbar spine versus predominantly cortical bone at the femoral neck. Our data did not 
confirm earlier observations of an association of the D2 Thr92Ala polymorphism with insulin 
sensitivity (39.40). This discrepancy may be explained by differences in the populations 
studied, with a low prevalence of obesity or insulin resistance in our subjects. Our data are 
however in keeping with the Framingham offspring study, which found no relation between 
the D2 Thr92Ala polymorphism and insulin resistance (42). We did not observe differences in 
height, indicating no difference in skeletal development between the 3 genotype subgroups. 
This is in line with recent observations in the C3H/HeJ D2−/− compound mutant mice with 
D1 deficiency and deletion of D2, that were shown to maintain normal growth (37). 
This notion is supported by a recent study, suggesting that D2 may not play a physiological 
role in growth plate chondrocytes (38). 
The observed effects of the D2 Thr92Ala polymorphism on femoral neck BMD are in line with 
the importance of local availability of T3 for bone formation. D2 activity has been found on 
mature osteoblasts (45) which are the primary target cells for T3 regulatory effects on bone 
formation (1,2,16-18). 
The effects of the D2 Thr92Ala polymorphism on bone turnover markers are not easy to 
explain. It is conventionally accepted that higher rather than lower circulating thyroid hormone 
levels result in higher bone turnover and decreased bone mass. However, the model we used 
is unique in the sense that circulating T3 levels were similar between the 3 D2 genotypes, 
allowing to specifically study the consequences of the polymorphism for local T3 availability 
in the bone microenvironment.  Williams et al (38) showed no D2 activity in osteoclasts. The 
effects of the polymorphism on the markers of bone degradation (NTX/creatinine and CTx) 
may therefore not be explained by direct effects on osteoclasts but are more likely to result 
from changes in the interaction between osteoblasts and osteoclasts, possibly by alterations 
in the RANK/RANKL/OPG signaling pathway which can be possibly modulated by local T3 
availability in the bone microenvironment. In the context of conflicting data on a functional 
role for TSH in skeletal development, our data, which were corrected for serum TSH levels, 
outline the importance of local T3 for bone metabolism (19-25,27,28). Two recent papers 
by Bassett et al. (29,30) who studied mice with complete or haploinsufficiency of TR alpha 
and beta, concluded that TR alpha regulates both skeletal development and adult bone 
maintenance.
Whereas a limitation of our study may be its relatively small size and its cross sectional 
design, one of its clear strengths is that all subjects were phenotyped for factors other 
than thyroid status known to modulate bone metabolism. This design enabled us to use 
regression models, including relevant covariables, the feasible of which is difficult in large 
cohort studies. A potential further limitation of our study is that thyroid hormone parameters 
measured at one point of time may not reflect the overall thyroid status over time. To address 
this issue, we calculated the slope of all TSH measurements routinely obtained after initial 
therapy in every patient participating in the study to verify the stability over time. An average 
of 15 TSH measurements were obtained per patient and the slope of TSH values was -
113
0.0001 (range -0.004-0) mU/L/year, thus indicating stable TSH levels over time.   
In summary our data suggest, that a decrease in local availability of T3 potentially due to a 
D2 polymorphism may result in increased bone turnover and decreased bone mass at the 
predominantly cortical femoral neck. We believe our study provides additional information 
on the role of D2 in bone metabolism and the functional consequences of the D2 Thr92Ala 
polymorphism, supporting a role for D2 in mature bone cells (38). 
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Abstract
Objective: The impact of prolonged subclinical hyperthyroidism on glucose and lipid 
metabolism is unclear. Therefore, we evaluated glucose and lipid metabolism in patients 
with differentiated thyroid carcinoma (DTC) on TSH suppressive thyroxin therapy as a model 
for subclinical hyperthyroidism and investigated whether restoration to euthyroidism affects 
metabolism. 
Design: We performed a prospective, single-blinded, placebo-controlled, randomised trial of 
6 months duration with 2 parallel groups. 
Patients: Twenty-five subjects with a history of differentiated thyroid carcinoma with >10 
years TSH-suppressive therapy with L-thyroxin completed the study. L-thyroxin dose was 
replaced by study medication containing L-thyroxin or L-thyroxin plus placebo. Medication 
was titrated to establish continuation of TSH suppression (low-TSH group, 13 patients) and 
euthyroidism (euthyroidism group, 12 patients). 
Measurements: We evaluated glucose metabolism by glucose tolerance test and HOMA (IR) 
and lipid metabolism by lipid profile. In addition, we measured plasma concentrations of 
glucoregulatory hormones. 
Results: At baseline, glucose tolerance, HOMA (IR), lipid profile and plasma concentrations of 
glucoregulatory hormones were within the normal range. No significant differences between 
the low TSH and euthyroidism group were observed. After 6 months, neither glucose- nor 
lipid metabolism in the low TSH group were different from baseline values. 
Conclusion: In summary, glucose- and lipid metabolism in patients with DTC and long-term 
subclinical hyperthyroidism in general are not affected. Restoration of euthyroidism in 
general does not affect glucose and lipid metabolism.
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Introduction
In overt hyperthyroidism, impaired glucose tolerance and increased insulin resistance have 
long been observed as a frequent complication (1-7)(Table 1), predominantly at the level 
of the liver (1). The underlying mechanisms have not been completely elucidated, but have 
been ascribed to a combination of multiple factors, like decreased pancreatic secretion of 
insulin (8,9), decreased suppression of glucagon by glucose (10) and increased adrenergic 
activity (11)(Table 1). Regarding lipid metabolism, overt hyperthyroidism is associated with 
decreased plasma concentrations of total and/or LDL cholesterol (3,12-16), that normalize 
after correction of hyperthyroidism (17-19) (Table 2). 
Subclinical hyperthyroidism is a state, in which the patient has a suppressed thyrotrophin 
(TSH) level (below 0.4 mU/l), although the free T4 level is within the normal range. This 
condition affects several organ systems, including bone (20-23) and the cardiovascular system 
(24-28). Only scarce data are available on the consequences of subclinical hyperthyroidism 
for glucose- and lipid metabolism. Glucose metabolism in subclinical hyperthyroidism has 
been studied only by Yavuz et al., who observed a decreased insulin sensitivity index by 
oral glucose tolerance test in patients with exogenous subclinical hyperthyroidism compared 
to values after restoration of euthyroidism and compared to controls (29) (Table 1). Most 
studies report no differences in lipid profile in subclinical hyperthyroidism (29-30), with the 
exception of 2 studies, that report decreased total and LDL cholesterol levels (32,33). In 
the study of Franklyn et al., total cholesterol concentrations were decreased only in patients 
older than 55 years and LDL cholesterol levels were decreased only in patients older than 
65 years (32). Most of the above described studies contained patients with endogenous 
(subclinical) hyperthyroidism. A disadvantage of those studies can be that the duration and 
degree of (subclinical) hyperthyroidism are not known. Exogenous subclinical hyperthyroidism 
is a good model to study the effects of subclinical hyperthyroidism on metabolism, because 
the duration and degree of subclinical hyperthyroidism are known.
In the present study, we therefore conducted a randomised, controlled trial in patients 
with differentiated thyroid carcinoma to compare the effects of restoration of exogenous 
subclinical hyperthyroidism to euthyroidism on glucose- and lipid metabolism. 
 
Material and methods
Subjects
Consecutive patients were recruited from the outpatient clinic of the Department of 
Endocrinology of Leiden University Medical Centre. This department is a tertiary referral 
centre for differentiated thyroid carcinoma. Patients were included who had been diagnosed 
with DTC, who had received initial therapy consisting of total-thyroidectomy and radioiodine 
ablation therapy. Additional therapies were allowed, as long as they resulted in cure of DTC. 
Cure was documented by the absence of measurable serum thyroglobulin (Tg) during TSH 
stimulation as well as by a negative total-body scintigraphy with 4 mCi 131-I. The patients 
had to be on TSH suppressive therapy, defined as TSH levels below the lower reference value 
for TSH (0.4 mU/l), for at least 10 years. The adequacy of the TSH suppressive therapy had 
to be documented by yearly TSH measurements. 
Patients who had diabetes mellitus according to the WHO criteria (34) or a BMI >30 were 
excluded. Patients who used any drugs known to influence the metabolic parameters we 
studied were also excluded. The local ethics committees approved the study, and written 
informed consent was obtained from all subjects.
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Study design
The study was a prospective, single-blinded randomised controlled trial with 2 parallel groups 
with a duration of 6 months. After inclusion, patients were randomised in a single-blinded 
way to continue TSH suppressive therapy (low TSH group, target TSH level < 0.4 mU/L) or 
to restore euthyroidism by decreasing the L-thyroxin dose (euthyroidism group, target TSH 
levels within the normal reference range (0.40-4.8 mU/L)). 
After randomisation, standard thyroxin therapy of all patients was replaced in part by study 
medication according to an algorithm. Study drugs consisted of either 25 µg thyroxin or 
placebo tablets with similar appearance. Serum TSH levels were checked every 6 weeks 
in every patient, and study medication was adjusted if necessary to obtain the target TSH 
levels. Before and after 6 months, a physical examination was performed and fasting blood 
samples were drawn for hormonal and metabolic parameters. 
Experimental protocol
Subjects were admitted to the clinical research unit, where they handed in the urine 
collected over the previous 48 hours. Patients were asked to follow a diet free of potential 
catecholamine stimulating food or medication (excluding coffee, alcohol, bananas, nuts and 
acetaminophen) from two days before urine collection. All subjects fasted from the preceding 
evening (18.00 hr) until the end of the study. On the study day, at 08.00 hr, height (meters 
[m]) and weight (kilograms [kg]) were measured. Body composition was measured by DEXA 
(Hologic 4500, Hologic Inc., Bedford, MA, USA). Patients were subsequently requested 
to lie down on a bed in a semi recumbent position. A catheter was inserted in a dorsal 
hand vein to collect plasma samples for measurement of glucose, insulin, cortisol, growth 
hormone, leptin, free fatty acids (FFA), total cholesterol, HDL-cholesterol, LDL-cholesterol 
and triglycerides. To investigate insulin sensitivity an Oral Glucose Tolerance Test (OGTT) was 
performed. After an overnight fast patients were given 75 gram of glucose. At 0, 30, 60, 90 
and 120 minutes serum glucose and insulin was measured. Plasma and serum samples 
were handled immediately and stored at –20o C in Sarstedt tubes.
Blood Chemistry 
All plasma and serum samples were measured in one batch. Serum free thyroxin (FT4) 
and TSH were measured with an electrochemoluminescentic immunoassay with a Modular 
Analytics E-170 system with an intraassay CV of 1.6-2.2 % and 1.3-5.0 % respectively 
(Roche, Almere, The Netherlands). Serum free triiodothyronine (FT3) was measured with 
a fluorescentic polarisatic immunoassay, CV 2.5-9.0 %, on an ImX system (Abbott, Abbott 
Park, IL, USA). Serum insulin was measured by IRMA (Medgenix, Fleurus, Belgium) with a CV 
of 4.8-8.5 %, leptin by RIA (Linco Research, St. Charles, MO, USA) with an intraasaay CV of 
3.0-5.1 %, growth hormone by IFMA on a Delfia system (Wallac OY, Turku, Finland), cortisol 
by TDX (Abbott) with an intraassay CV of 3.5-6.5 %, ACTH by IRMA (Nichols Institute, san Juan 
Capistrano, CA, USA) and FFA by spectrofotometry by a validated kit (Boehringer, Mannheim, 
Germany). Glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were 
measured with a fully automated Modular P800 system (Roche).
Twenty-four hour excretion of urinary catecholamines (epinephrine, norepinephrine) was 
measured by HPLC with electrochemical detection.
Calculations
Insulin resistance was assessed by HOMA score (HOMA-IR) with the formulas as described 
by Matthews et al. (35). Insulin Sensitivity Index (ISI) was calculated as described by Matsudo 
and DeFronzo (36). 
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Statistical Analysis
Values are presented as mean ± standard deviation (SD). Data between groups were 
analysed using an unpaired T-test. Data within groups were analysed using a paired T-test. 
All calculations were performed using SPSS 12.0 for windows (SPSS. Inc., Chicago, IL, USA). 
Differences were considered statistically significant at P<0.05.
Results
Patient characteristics
Thirty-two patients were recruited initially (Figure 1). Before randomisation 2 patients left 
the study; one patient because of comorbidity and the other patient without a clear reason. 
The other 30 patients were randomised in two groups of 15 patients. Two patients in the 
euthyroidism group left during the study, one because of pregnancy, the other because of 
mood disorders. In the subclinical hyperthyroidism group one patient left the study, because 
diabetes mellitus was diagnosed on the basis of a fasting glucose > 7 mmol/l. At the 
end of the study 2 patients, one in each group, were excluded because of incompliance. 
Consequently, 25 patients were included in the calculations, 8 men and 17 women (Table 
3). Thirteen patients (9 women and 4 men, mean age 48.18 ± 8.60 years) were treated 
with thyroid hormone to suppress TSH level below 0.4 mU/l. Mean dose of thyroid hormone 
before randomisation was 179 ± 31 μg per day. Twelve patients (8 women and 4 men, 
mean age 50.81 ± 9.99 years) were treated to restore euthyroidism. Mean dose of thyroid 
hormone treatment before randomisation was 185 ± 39 μg. 
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Low TSH (n=13) Euthyroidism (n=12) p-value
Age (yr) 48.18 ± 8.60 50.81 ± 9.99 0.487
Sex (m/f) 4 : 9 4 : 8 0.891
Weight (kg) 68.07 ± 19.84 74.8± 9.9 0.302
Length (m) 1.70 ± 0.08 1.73 ± 0.07 0.458
BMI (kg/m2) 23.46 ± 6.74 24.98 ± 2.20 0.463
DEXA LBM (kg) 49.8 ± 8.5 48.8 ± 13.0 0.809
DEXA total fat (kg) 21.9 ± 6.4 21.1 ± 3.0 0.693
Tumor Stage 0.328
T2 N0 M0 9 5
T2 N1 M0 3 3
T3 N0 M0 1 2
T3 N1 M0 0 2
Histology Tumor 0.564
Papillary 10 10
Papillary-follicular variant 2 1
Follicular 0 1
Follicular Hurthle 1 0
Dose I-131 3174 ± 1817# 2418 ± 602 0.183
Duration of TSH suppressing treatment (years, (range)) 13 ± 2 13 ± 2 0.724
Table 3. Patient Characteristics at baseline
# 1 patient received 6900 MBq I-131 for persisting thyroid remnants
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Thyroid hormone levels
Thyroid hormone levels are summarized in Table 4. All patients had suppressed TSH levels 
at baseline. TSH, free T4 (FT4) and free T3 (FT3) concentrations were not different between 
the 2 groups at baseline. At 6 months no differences were observed in TSH, FT4 and FT3 
concentrations and thyroxin dose in the subclinical hyperthyroid group compared to baseline. 
In the euthyroidism group, TSH, FT4 and FT3 concentrations were significant different at 6 
months compared to baseline. Serum TSH concentrations were significantly lower (0.07 ± 
0.10 vs. 4.35 ± 3.63 μmol/ml, p=0.002) and serum free T4 (22.97 ± 4.23 vs. 18.29 ± 4.76 
nmol/l, p=0.012) and FT3 (3.59 ± 0.65 vs. 2.63 ± 0.60 pmol/l, p=0.001) concentrations 
were significantly higher in the low-TSH group compared with the euthyroidism group. 
Anthropometric data
At baseline, BMI, DEXA total fat and DEXA Lean Body Mass were not different between the 
subclinical hyperthyroidism group and the euthyroidism group (Table 3). In addition, these 
parameters were not different within each groups at 6 months compared to baseline, or 
between groups at 6 months.
Glucose metabolism
At baseline, 2 of 13 patients in the subclinical hyperthyroidism group had impaired glucose 
tolerance on the basis of the OGTT according to the WHO criteria (34). In the euthyroidism 
group, 2 of 12 patients had impaired glucose tolerance. There were no differences between 
both groups. At 6 months, 1 of 13 patients in the subclinical hyperthyroidism group had 
impaired glucose tolerance. In the euthyroidism group, 1 of 12 patients had impaired 
glucose tolerance and 1 patient had type 2 diabetes mellitus based on the OGTT. There were 
no differences between groups or compared to baseline in both groups. 
32 patients were recruited
2 patients left the study 
before randomization
30 patients were randomized,
15 in the euthyroid group and
15 in the low TSH group
Figure 1 Study Flow Chart 
5 patients left the study:
3 in the euthyroid group
• 1 incompliance
• 1 pregnancy
• 1 mood disorderse
2 in the low-TSH group
• 1 incompliance
• 1 Diabetes Mellitus
End of study 
12 patients in the euthyroid group and
13 patients in the low TSH group 
completed the study
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Baseline plasma insulin concentrations, HOMA-IR and ISI were not different between 
the subclinical hyperthyroidism and euthyroidism group (Table 5). At 6 months, plasma 
insulin concentrations, HOMA-IR and ISI were not different compared to baseline values 
in both experimental groups and not different between groups. In our study, basal glucose 
concentrations and HOMA-IR were within the normal range of a Dutch study including 277 
healthy controls with normal glucose tolerance with a median BMI of 25.6 kg/m2 (37).
Lipid metabolism
At baseline, concentrations of total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides 
and FFA were not different between the subclinical hyperthyroidism group and the 
euthyroidism group (Table 5). After 6 months, no differences were seen in these parameters 
in both groups compared to baseline values. In addition, there were no differences between 
the two groups in any of these parameters at 6 months. 
Hormone concentrations
At baseline and after 6 months plasma concentrations of cortisol, ACTH, growth hormone, 
leptin and 24 hour urinary excretion of catecholamines were not different between both 
groups. At 6 months those values were not different within each groups. 
Discussion 
The present study was performed to investigate the effects of restoration of euthyroidism 
after long-term subclinical hyperthyroidism on glucose- and lipid metabolism. The study was 
a prospective, placebo-controlled randomised study and as such the first using this design. 
The findings indicate, that restoration to euthyroidism in patients with long-term subclinical 
hyperthyroidism had no appreciable influence on several parameters of glucose- and lipid 
metabolism. 
In our study, according to reference values using WHO criteria, 4 of 26 patients (15.4%) had 
impaired glucose tolerance at baseline. These percentages are in accordance with previous 
studies in The Netherlands and USA. Mooy et al. (38) found a prevalence of impaired glucose 
tolerance of 10.3% in the Dutch population, Harris et al. (39) a prevalence of 15.6% in 
the USA population. Two patients had a familiarity for type 2 diabetes mellitus. However, 
these patients did not have impaired glucose tolerance at baseline or at 6 months. The 
findings of our study on glucose metabolism are in conflict with the study of Yavuz et al. (29), 
which reports a decreased insulin sensitivity index after 6 months of exogenous subclinical 
hyperthyroidism compared to matched controls. Basal glucose values are not reported in 
that study. Most studies, performed in overt hyperthyroidism (1-7) found insulin resistance, 
whereas one study found no difference in glucose tolerance (40). An explanation for these 
differences in outcome of subclinical hyperthyroidism on glucose metabolism could be the 
duration of subclinical hyperthyroidism. We studied a population, that was treated for over 
10 years with TSH suppressive therapy which might result in adaptation, whereas Yavuz 
et al. studied 20 patients with multinodular goitre who were treated for 6 months (29). 
Alternatively, it might imply that the “dose” (the extent of subclinical hyperthyroidism) in 
our study was not relevant to result in a “response” (glucose intolerance), However, this is 
unlikely, because TSH values in our study were comparable to values in the study of Yavuz 
et al. (29). 
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Alternatively, it might indicate the absence of a direct relationship between plasma levels 
of hormones and tissue specific hormone effect parameters (41). It might be argued that 
the number of patients included in our study was too low, resulting in underpowering of 
the study. A posthoc power analysis, however, for some important items of the different 
questionnaires, showed a sufficient power, e.g. range 70-97 %. Therefore, it seems unlikely 
that underpowering of our study plays a major role in the negative findings. 
Restoration of subclinical hyperthyroidism to euthyroidism did not affect lipid profile. This is 
in accordance with previous studies (29-31). Only one study in 27 patients with endogenous 
subclinical hyperthyroidism (33) and one study in 59 patients with exogenous subclinical 
hyperthyroidism (32) found a decrease in total- and/or LDL cholesterol. In the latter study, 
also a decrease in LDL-cholesterol was observed. 
In overt hyperthyroidism, total cholesterol was mostly decreased (3,12-16). Only one study 
(42) found a total cholesterol level within the normal range. Triglycerides are either decreased 
(17,18,43), within the normal range (42), or increased (44,12). Free fatty acids were within 
the normal range (45) or increased (46). 
In our study, basal glucoregulatory hormones were all within the normal range and were not 
different after restoration of subclinical hyperthyroidism. In contrast to our findings, Hsieh et 
al. (47) noticed a significant increase in serum leptin in patients with exogenous subclinical 
hyperthyroidism. This change was more profound in females. 
Successful restoration of subclinical hyperthyroidism to euthyroidism, as indicated 
by normalization of TSH concentration and a decrease in FT3/FT4 concentration by 
approximately 40% and 30%, respectively, did not result in any changes in parameters of 
glucose metabolism or lipid profile, which is comparable with baseline observations that 
glucose- and lipid metabolism are not affected to a considerable extent in subclinical 
hyperthyroidism. In addition, minimally if any changes were observed in any other of the 
studied metabolic parameters. We cannot exclude that a period of 6 months of restoration 
of euthyroidism is too short to detect differences in metabolic parameters. 
In summary, we investigated the effects of subclinical hyperthyroidism in patients treated 
for differentiated thyroid carcinoma on several metabolic parameters. A prospective, single-
blinded, randomised controlled trial was performed to investigate whether restoration 
of euthyroidism has effects on these metabolic parameters. We observed no relevant 
differences in glucose- and lipid metabolism during long-term subclinical hyperthyroidism 
and after restoration of subclinical hyperthyroidism to euthyroidism. 
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Abstract
Context: Knowledge on the relationship between the autonomic nervous system and 
subclinical hyperthyroidism is mainly based upon cross-sectional studies in heterogeneous 
patient populations and the effect of restoration to euthyroidism in subclinical hyperthyroidism 
has not been studied. 
Objective: We investigated the long-term effects of exogenous subclinical hyperthyroidism 
on the autonomic nerves system and the potential effects of restoration of euthyroidism.  
Design: Prospective single blinded, placebo-controlled, randomized trial. 
Setting: University Hospital.
Patients: 25 patients who were on >10 years of TSH suppressive therapy after 
thyroidectomy.
Intervention: Patients were studied at baseline and subsequently randomized to a 6-months 
thyroid hormone substitution regimen to obtain either euthyroidism or maintenance of the 
subclinical hyperthyroid state.
Main outcome measures: Urinary excretion of catecholamines and heart rate variability were 
measured. Baseline data of the subclinical hyperthyroidism patients were compared to data 
obtained in patients with hyperthyroidism and controls.
Results: Urinary excretion of NE and VMA was higher in the subclinical hyperthyroidism 
patients compared to controls and lower compared to patients with overt hyperthyroidism. 
Heart rate variability was lower in patients with hyperthyroidism, intermediate in subclinical 
hyperthyroidism patients and highest in the healthy controls. No differences were observed 
after restoration of euthyroidism.
Conclusions: Long term exogenous subclinical hyperthyroidism has effects on the autonomic 
nerves system measured by heart rate variability and urinary catecholamine excretion. No 
differences were observed after restoration to euthyroidism. This may indicate occurrence 
of irreversible changes or adaptation during long-term exposure to excess thyroid hormone 
that are not remedied by 6 months of euthyroidism.
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Introduction
Overt hyperthyroidism has profound effects on the heart, including tachycardia and/
or arrhythmias, increased systolic pressure, increased systolic function, left ventricular 
hypertrophy and diastolic dysfunction (1,2,3). These effects are thought to be the result 
of direct effects of thyroid hormone on the cardiovascular system and the interaction of 
thyroid hormones with the sympathetic nervous system (2,4). This interaction has been 
shown to result from a sympathovagal imbalance, characterized by increased sympathetic 
activity in the presence of diminished vagal tone, which coincides with increased urinary 
excretion of catecholamines (5,6,7). Hence, the current consensus is that manifestations of 
altered autonomic nervous system function play a role in the pathophysiology and clinical 
presentation of thyrotoxicosis. 
For subclinical hyperthyroidism, defined as low serum thyroid stimulating hormone (TSH) 
concentrations despite normal free thyroxin (FT4) and tri-iodothyronine (T3) concentrations, 
cardiovascular effects may also occur, but these are less well known and seemingly less 
severe. The most consistent findings include increased heart rate, supraventricular 
arrhythmias and abnormalities of LV morphology and function (8,2,9,10). Altered autonomic 
nervous system function in subclinical hyperthyroidism is also less well defined. Petretta et. 
al. (9), Goichot et. al. (11) and Portella et. al. (12), using measures of heart rate variability 
, found evidence that in patients with endogenous subclinical hyperthyroidism a reduction 
of cardiac parasympathetic control is present and this is supported by findings on heart 
rate turbulence by Osman et al (13). However, in the study of Goichot (11) there were no 
differences in the heart rate variability measure (the ratio of low frequency power over high 
frequency power: LF/HF) that is commonly used to characterize the balance between vagal 
and sympathetic influences in these patients. In addition, it seems that the most prominent 
differences between patients with (subclinical) hyperthyroidism and controls were present 
during a challenge of the autonomic nervous system. Apart from this, the interpretation of 
these findings is difficult as studies on the role of the possibly altered autonomic nervous 
system abnormalities and the cardiovascular consequences of subclinical hyperthyroidism 
are complicated by several factors. First, subclinical hyperthyroidism is a heterogeneous 
clinical syndrome with many possible etiologies with as sole common denominator the 
(biochemical) definition of low TSH and normal T3/T4 concentrations. Second, the duration 
and course of the underlying disease is often not known and therefore it cannot be excluded 
that the underlying disease itself, treatment with thyreostatic medication and use of β-
blockers may have influenced cardiovascular parameters independent of serum thyroxin 
levels. 
These considerations suggest that the most appropriate population to study the consequences 
of subclinical hyperthyroidism are patients treated for differentiated thyroid carcinoma (DTC) 
in whom, after thyroidectomy, continuous suppression of TSH occurs with individualized 
doses of levothyroxine (L-thyroxin). In these patients, subclinical hyperthyroidism is solely the 
result of exogenous L-thyroxin. We therefore performed a prospective, randomized, placebo-
controlled study to assess autonomic nervous function in patients with DTC with longer than 
10 years exogenous subclinical hyperthyroidism and to investigate whether restoration to 
euthyroidism affects autonomic nervous function. Autonomic nervous function was assessed 
using urinary catecholamine excretion, heart rate variability measurements during rest and 
by measuring the response in heart rate to a standardized mental stress test.
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Subjects and methods
The ethics committee of Leiden University Medical Center (LUMC) approved the study 
protocol, and written informed consent was obtained from all subjects. The study was 
performed in compliance with the principles of the Declaration of Helsinki.
 
Subjects
Patients treated for DTC were recruited from the outpatient clinic of the Department of 
Endocrinology of the LUMC, a tertiary referral centre for DTC. Patients were included who had 
been diagnosed with DTC, and had received initial therapy consisting of total-thyroidectomy 
and radioiodine ablative therapy. Cure was documented by the absence of measurable serum 
thyroglobulin (Tg) during TSH stimulation as well as by a negative total-body scintigraphy with 
4 mCi I-131. Patients had been on TSH suppressive therapy, defined as TSH levels below 
the lower reference values for normal serum levels of TSH (0.4 mU/L), for at least 10 years. 
The adequacy of this therapy was documented by yearly TSH measurements. Patients were 
excluded when they used medication affecting the sympathetic nervous system or when they 
were currently treated for or had experienced major cardiovascular events as uncontrolled 
hypertension or a myocardial infarction.                     
The study was a prospective, single-blinded randomized study of 6 months duration with 2 
parallel groups. After inclusion, patients were randomized in a single-blinded fashion (patients 
were blinded) to a maintenance group or an intervention group. Only the treating physician 
prescribing the study medication was aware of the randomization. The other research staff 
involved in study-related activities was also blinded to treatment. In the maintenance group 
the existing TSH-suppressive therapy was continued (target TSH level <0.4 mU/L). In the 
intervention group it was attempted to reach a restoration of euthyroidism by decreasing 
the L-thyroxin dose target TSH levels within the normal reference range (0.4-4.8 mU/L)). This 
was achieved by replacing in all patients the standard L-thyroxin therapy in part by study 
medication according to an algorithm. Study medication consisted of either L-thyroxin 25 µg 
or identically looking placebo tablets. Serum TSH levels were checked every 6 weeks in every 
patient, and study medication was adjusted if necessary to obtain the target TSH levels. 
Patients were compared to data obtained in patients with overt hyperthyroidism and healthy 
controls using similar methodology (5). 
Before and after 6 months, identical assessments were performed. After an overnight fast, 
subjects were admitted to the clinical research unit, where the urine collected over the 
previous 48 hrs was handed in. After a medical history and physical examination, blood 
samples to assess thyroid hormone status were taken. At least 30 minutes after blood 
sampling, continuous ECG and blood pressure measurements were made while the subject 
was in supine position for at least 15 minutes. During this period the patients were acquainted 
with the test procedures that were about to follow. The measurements consisted of a 1-lead 
electrocardiogram (ECG) registration (recording 600 subsequent beats). The subjects were 
instructed to relax, to breathe regularly, not to speak and to stay awake. ECG signals were 
sampled at a rate of 500 Hz and the arterial pulse wave at a rate of 300 Hz. The signals were 
digitized using a customized laboratory interface (model 1401, Cambridge Electronic Design, 
Cambridge, UK), and analyzed with software supplied with the interface. Each registration 
was screened for artefacts and subsequently analyzed for heart rate variability parameters in 
the time domain: mean RR-interval (RR-int), the coefficient of variation (CV) of the successive 
RR-intervals (reflecting total variability), and the standard deviation of differences between 
adjacent R-R intervals (SDSD) reflecting “beat-to-beat” and, therefore, vagally mediated 
variability) as previously described (5) and according to the applicable guidelines (14). 
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The registrations were also analyzed for heart rate variability parameters in the frequency 
domain according to the same guidelines (14). Upon completion of the recording at rest, 
another 5-min recording was started during which the subjects were subjected to a mental 
stress test (15). During this test the subjects had to perform a standardized arithmetic test 
about which they had been instructed before. The registration made during this test was 
used to determine the percentage increase in heart rate from baseline.
Assays 
Thyroid hormones, thyroid-stimulating hormone (TSH), and urinary creatinine and 
catecholamines concentrations were determined using standardized routine methodology 
at the clinical chemistry laboratories of the LUMC.
FT4 was measured on an IMx (Abbott, Abbott Park, IL; intra-assay variability: 2.5-7.6%, 
interassay variability: 5.6-12.4%) at different levels). Total T4 was determined on the TDx 
(Abbott; interassay CVs: 2.4-5.9%). Free tri-iodothyronine (FT3) was measured by RIABEAD 
(Abbott; interassay CVs of 2.0-4.4%). Serum TSH was determined with a Modular Analytics 
E-170 system (Roche Diagnostic Systems, Basle, Switzerland), interassay variability:0.88-
10.66%). Reference values for FT4, FT3 and TSH are respectively 10-24 pmol/L, 2.5-5.4 pmol/
L and 0.4-4.8 mU/L. Urinary norepinephrine (NE), dopamine (DOPA) and vanillylmandelic 
acid (VMA) were determined by routine HPLC methodology. 
Statistical analysis
Data are expressed as mean ± standard deviation (SD). For assessment of the treatment 
effect between groups, the variables were log-transformed to meet the requirements for 
analysis of variance. Subsequently the transformed data were analyzed using analysis of 
covariance (ANCOVA, SAS Proc MIXED) with the baseline value as co-variate. Treatment least 
square means were back-transformed resulting in geometric mean treatment estimates 
corrected for differences in the baseline values. Contrasts and 95% confidence intervals 
(95% CI) between treatments were back-transformed resulting in geometric mean ratios, 
which were subsequently translated into percentage increase of the therapy treatment 
relative to the maintenance treatment.
The data obtained at baseline in the subclinical hyperthyroidism patient cohort were compared 
with data obtained in patients with overt hyperthyroidism and healthy controls using ANOVA 
and unpaired Student’s t-test assuming unequal variances. The latter data were obtained 
using similar methodology and were reported earlier by our group (5). These data were also 
used to perform a post-hoc power analysis (using power=80% and alpha=5%) to calculate 
the required sample size per group for detecting relevant changes in the study parameters. 
Relevant changes were defined as the change required for normalizing the values obtained 
in the subclinical hyperthyroidism patients to the values observed in healthy controls. 
All analyses were performed using SAS software (V9.1.2, SAS Institute, Inc., Cary, NC, USA).
Results
Patient characteristics 
Thirty-three patients who fulfilled all inclusion criteria were included in the study. Four 
patients left the study before randomization: 1 patient because of abdominal surgery, 2 
patients withdrew consent because of the perceived burden of the study and 1 patient did 
not present at the randomization visit. 
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During the study 3 patients from the intervention group were withdrawn: 1 patient (at 12 
weeks) because of fatigue, headache and diarrhea, a second patient left (at 6 weeks) 
because of pregnancy and the third patient was excluded because of apparent incompliance: 
despite lowering the thyroxin dose, serum FT4 levels increased throughout the study. Two 
patients in the maintenance group (persistent low TSH) were also excluded for apparent 
incompliance; TSH levels rose despite being in the TSH suppression group. Thus 25 
subclinical hyperthyroidism patients completed the study, 12 patients in the intervention 
group and 13 patients in the maintenance group. A summary of the subject characteristics 
is given in table 1.
L-thyroxin dose and thyroid hormones
The mean ± SD L-thyroxin dose in the maintenance group was 164 ± 34 µg/day before 
randomisation and remained virtually unchanged at 173 ± 28 µg/day at the second 
assessment. In the intervention group, the L-thyroxin dose was reduced from 185 ± 39 µg/
day to 129 ± 37 µg/day in order to restore euthyroidism. The thyroid hormone levels are 
summarized in table 2. Thyroid hormone concentrations were not different between the 
groups at baseline. Particularly, the range of TSH concentrations was 0.003 - 0.339 mU/L in 
the maintenance group and 0.003 - 0.302 mU/L in the intervention group. At the end of the 
study, TSH concentrations were higher in the intervention group (range: 0.218 - 6.09 mU/L), 
while these remained virtually unchanged in the maintenance group (0.005- 0.210 mU/L). 
Eight patients in the intervention group became euthyroid 2 months after thyroxin dosage 
reduction, one patient 3 months after thyroxin dosage reduction and 2 patients 4 months 
after thyroxin dosage reduction. In these latter patients, FT4 levels decreased significantly 
every month, whereas TSH levels stayed behind. FT3 concentrations decreased by 42% 
(95% CI: 19-69%) and FT4 concentrations by 29% (95% CI: 12-48%) in the intervention 
group compared to the maintenance group. One patient in the intervention group had a 
persistently low TSH (<0.4 mU/L) for the duration of the study. After 6 months, this patient 
had a TSH of 0.218 mU/L, however, her baseline TSH was 0.0025 mU/L. Since her FT4 
decreased from 21 tot 14 pmol/L, we considered the intervention in this patient successful, 
although her TSH at 6 months was still below 0.4 mU/L. Two patients in the intervention 
group had a TSH>4.8 mU/L (5.80 and 6.09 mU/L) at the end of the study. FT4 levels were 
18.8 and 26.7 mmol/L.
Urinary catecholamine excretion
The urinary excretion of NE, DOPA and VMA (normalized for creatinine) is summarized in 
table 2. In order to illustrate the effects of longitudinal follow-up and the intervention, the 
urinary excretion of VMA for both groups is depicted in figure 1. This shows that in general the 
urinary excretion is remarkably stable during a 6-month follow-up period without treatment. 
Restoration to euthyroidism did not result in significant reductions in catecholamine 
excretion.
Maintenance group
(persistent TSH suppres-
sion) (n=13)
Intervention group
(restoration euthyroidism)
(n=12)
Control group
(n=15) 
Hyperthyroidism 
group
(n=15)
Gender (F : M) 9 : 4 8 : 4 14:1 14:1
Age (yr) 49 ± 7.2 (36-64) 51 ± 10.5 (36-67) 40 ± 10.3 (21 - 56) 39 ± 9.7 (21-56)
Weight (kg) 77 ± 11.5 (60-103) 74 ± 9.8 (58-91) 68 ± 13.9 (47-97) 65 ± 11.9 (44-83)
Table 1. Characteristics of the study population 
Data are presented as mean ± SD (range). 
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Autonomic nervous system function tests
The RR-interval in the intervention group increased from a mean value of 899 ± 135 
milliseconds (ms) to 956 ± 135 ms (p =0.04). In the patients in whom thyroid suppression 
was continued, the RR-interval before the study was 849 ± 29 ms and this was not changed 
at the end of the study (869 ± 25 ms). Between the groups the change in RR-interval was not 
significantly different (6.7%; 95%CI: -0.5, 14.4%; p= 0.07). Both the time domain parameter 
reflecting the overall variability (CV) and the parameter reflecting the vagal influence on 
heart rate (SDSD) remained unchanged both within and between the treatment groups. The 
difference between the groups in CV and SDSD at the end of the treatment period were 3.6 
(95% CI: -18.9, 32.3%) and 9.8% (95%CI: -25.0, 60.8%) respectively. The measurements of 
the SDSD for both groups are also depicted in figure 1. The data in the frequency domain 
were also not different between the groups (data not shown). All data are summarized in 
table 3. The difference in the increase in heart rate observed during the mental stress test 
was 9.0% (95%CI: -37.4; 32.3%) between the groups. 
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Maintenance group
(persistent TSH 
suppression)
Intervention group
(restoration 
euthyroidism)
Between group
comparison
before after before after p-value
TSH (mU/L) 0.08 ± 0.10 0.05 ± 0.02 0.10 ± 0.11 2.97 ± 2.30 p <0.001
FT3 (pmol/L) 3.4 ± 0.6 3.6 ± 0.6 3.6 ± 0.4 2.6 ± 0.6 p <0.001
FT4 (pmol/L) 22.8 ± 4.3 23.6 ± 1.0 22.6 ± 3.9 18.5 ± 4.1 p <0.001
Norepinephrine* 21.0 ± 6.5 23.6 ± 7.6 26.1 ± 7.4 24.7± 6.6 p =0.40
Dopamine* 0.17 ± 0.07 0.13 ± 0.04 0.15 ± 0.07 0.10 ± 0.04 p =0.40
VMA* 1.76 ± 0.35 1.72 ± 0.42 1.97 ± 0.48 2.03 ± 0.48 p =0.83
Table 2. Summary of thyroid hormone status and urinary catecholamine excretion normalized for creatinine excretion
Data are presented as Mean ± SD. In the last column the p-value for the difference between the groups is given 
(using ANCOVA with baseline as co-variate).
TSH: thyroid stimulating hormone; FT3: free tri-iodothyronine; FT4: free thyroxin (FT4); VMA: vanillylmandelic acid. 
* expressed as mmol/mmol creatinine
Figure 1 Scatter plots showing the urinary vanillylmandelic acid excretion (VMA; left) and the SDSD measure-
ments (right) illustrating that, except for the occasional outlier, both parameters were remarkable stable for the 
patients whether treated or not.
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Comparison between patient groups and power calculation
First, it is of note that the groups were comparable (ranges in age and weight show great 
overlap) albeit there were minor differences, particularly in weight which is obviously not 
surprising as patient with overt hyperthyroidism tend to lose weight (table 1). There was a 
difference between the groups regarding gender distribution with a female predominance 
in the comparison groups. However, there are no indications that gender is an important 
determinant of autonomic nervous system function (16). 
There was a slight difference in age between the groups, and it has been shown that increasing 
age is related to a decline in heart rate variability-related parameters (17). However, the 
difference in age between the groups was small and even overlapping, making it unlikely that 
this may have caused important differences in the heart rate variability presented here.
Table 4 summarizes the results obtained at baseline in the current study and the data 
obtained in patients with overt hyperthyroidism and healthy controls.
The ANOVA analysis showed that the urinary excretion of NE (p=0.03) and of VMA (p=0.003) 
differed between the groups. The analysis shows that urinary excretion of the catecholamines 
was lower in the healthy controls compared to patients with subclinical hyperthyroidism; the 
mean (95% CI) difference was 3.80 mmol/mmol creatinine
(-0.46/+8.061; p=0.053) for NE excretion and 0.434 mmol/mmol creatinine (+0.194/+0.675; 
p<0.001) for VMA excretion. Comparing the patients with subclinical hyperthyroidism with 
patients with overt hyperthyroidism showed a difference for the NE excretion of 4.00 mmol/
mmol creatinine (-1.83/+9.83; p=0.217) and a difference in VMA excretion of -0.139 mmol/
mmol creatinine (-0.4/+0.1223; p=0.275). 
Analysis of variance showed significant differences between the groups for the measures 
of heart rate variability; the p-value was <0.001 for the RR-interval, a p-value of 0.0018 
was observed for the coefficient of variation and for the differences in SDSD the p-value 
was <0.001. Patients with hyperthyroidism had on average a lower RR-interval of 280 
ms (+201/+359; p<0.0001) than the patients with subclinical hyperthyroidism. This was 
accompanied with lower measures of heart rate variability; the coefficient of variation was 
1.50% (+0.30/+2.70; p= 0.0088) lower, and the SDSD was 22.14 ms lower (+8.95/+35.33; 
p=0.0002). Comparing the patients with subclinical hyperthyroidism to the healthy controls 
showed that the RR-interval was 33 ms lower (-48/+114; p= 0.402). The coefficient of 
variation in heart rate was 1.88% (-0.04/+3.72; p= 0.08) lower and the SDSD was 12.92 
Maintenance group
(persistent TSH sup-
pression) 
Intervention group
(restoration euthyroidism) 
Between group
comparison
before after before after p-value
RR-int (ms) 849 ± 29 869 ± 25 899 ± 135 956 ± 135* 0.068
CV RR-int (%) 4.7 ± 1.6 4.7  ± 1.7 4.6 ± 2.4 4.4 ± 1.4 0.765
SDSD (ms) 35.8 ± 3.5 42.5 ± 5.6 26.3± 12.5 35.5 ± 24.2 0.614
HR response (%) 23 ± 3 23 ± 3 28 ± 17 24 ± 16 0.606
Table 3. Heart rate variability parameters in the time domain.
Data is expressed as mean ± SD The last column shows the p-value for the difference between the groups (using 
ANCOVA with baseline as co-variate).
RR-int: RR-interval; CV RR-int: coefficient of variation in RR-interval; SDSD: standard deviation of differences 
between adjacent R-R intervals; HR response: increase in heart rate during a mental stress test.
*p=0.04 for difference between before and after treatment 
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ms (-4.13/+29.98; p=0.142) lower. The findings are summarized in figure 2 which shows 
that the patients with subclinical hyperthyroidism have intermediate urinary excretion of NE 
excretion compared to patients with thyrotoxicosis and controls. Also, the measures for overall 
heart rate variability and the parameter reflecting the vagally mediated component of heart 
rate variability (SDSD) are between the values of the patients with frank hyperthyroidism and 
control subjects. 
Table 4 also shows the effect size and the size of the population that would have been 
required if restoration to euthyroidism in the subclinical hyperthyroidism patients would 
have resulted in complete normalization of the effects parameters. 
Discussion
This study was performed to investigate the long-term effects of exogenous subclinical 
hyperthyroidism on the autonomic nervous system and the potential effects of restoration 
of euthyroidism. The autonomic nervous system was characterized by assessment of the 
urinary catecholamine excretion and by heart rate variability parameters. Our study is the 
first prospective, placebo-controlled randomized study in which the effects of restoration 
of euthyroidism on the autonomic nervous system in patients with long-term exogenous 
subclinical hyperthyroidism were studied. The main finding of the study was that restoration 
to euthyroidism in patients with long-term subclinical hyperthyroidism due to TSH suppression 
had no appreciable influence on the autonomic nervous system. Urinary catecholamine 
excretion, the heart rate variability parameters in the time domain and the response to a 
mental stress test remained virtually unchanged between the patients who remained on 
TSH suppression and those in whom biochemical euthyroidism was restored.
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Urinary catecholamine excretion Heart rate variability
NE (mmol/mmol 
creatinine)*
VMA#
(mmol/mmol 
creatinine)
RR-interval&
(ms)
CV RR-int‡
(%)
SDSD†
(ms)
Subclinical hyperthyroidism 
patients
(n=25)
23.4 ±  7.3 1.85 ± 0.42 903 ± 135 4.46 ± 1.67 30 ± 13
Hyperthyroid patients
(n=15)
27.5 ± 11.1 1.70 ± 0.37 621 ± 102 2.86 ± 0.80 9 ± 3
Healthy controls
(n=15)
19.0 ± 4.3 1.40 ± 0.26 936 ± 114 6.66 ± 3.76 45 ± 28
Effect size for normalization 
of parameter
- 19.3% - 24.3% 16.7% 43.0% 47.4%
Population required
(n per group)
17 7 6 11 22
Table 4.   Urinary catecholamine excretion (normalized for creatinine) and heart rate variability parameters.
Data is expressed as mean ± SD. The bottom part of the table indicates the effect size needed for each for 
complete normalization for patients with subclinical hyperthyroidism and the size of the population that would be 
required to detect this normalization.
VMA: vanillylmandelic acid; CV RR-int: coefficient of variation of the RR-intervals (measure of overall heart rate 
variability); SDSD: standard deviation of the differences in subsequent RR-intervals (measure of beat-to-beat 
heart rate variability). 
* ANOVA p=0.03, # ANOVA p=0.003, & ANOVA p<0.001, ‡  ANOVA p=0.0018, † ANOVA p<0.001
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If the current data are compared with data obtained using similar methodology reported 
earlier by our group (5), values for activation of the autonomic nervous system in the 
current patient group with subclinical hyperthyroidism seem to be in between the group 
of patients with thyrotoxicosis and healthy controls. There were some differences between 
the groups particularly with regard to age and gender distribution. However, these are not 
confounding factors. It has been shown that the autonomic nervous system and its activity 
are not substantially influenced by gender (16). Admittedly, there are reports indicating that 
increasing age is associated with a decrease in heart rate variability (17,18) due to an age-
related decline in parasympathetic regulation (19). These reports however show that this 
decline occurs over the age range of 20 to 80 years and that the change in heart rate 
variability occurring in the age range of the population that we studies is very small (17).
We could show that urinary NE excretion in the patients with subclinical hyperthyroidism 
was indeed lower compared to patients with overt hyperthyroidism and higher compared 
to the healthy controls. This seems at odds with data reported by Mercuro et al. (20) who 
showed that plasma NE concentrations were significantly lower in patients with exogenous 
subclinical hyperthyroidism than in controls. However, these data are based on plasma 
NE concentrations in a single sample of venous forearm blood, while it is known that 
catecholamine levels are more appropriately determined in arterial(ized) blood, inasmuch 
as extraction from venous circulation occurs across various organs (21,22), while the urinary 
excretion of catecholamines and their metabolites is considered to better reflect their average 
plasma concentrations and whole body turnover in plasma (22,23). We also showed that the 
heart rate, its total variability (coefficient of variation) and the vagally mediated influence on 
heart rate variability (SDSD) of the patients were between the values found for patients with 
thyrotoxicosis and healthy controls. 
Interestingly, however, restoration to the euthyroid state in subclinical hyperthyroidism 
patients did not result in relevant changes in most autonomic nervous system parameters. 
Apparently, restoring a biochemical euthyroid state in patients who have been subclinical 
hyperthyroid for >10 years is not reflected in a state of the autonomic nervous system state 
that is identical to the situation in healthy euthyroid subjects. 
Figure 2. Graph (mean ± SD) for urinary norepinephrine excretion (in mmol per mmol creatinine), urinary VMA 
excretion (in mmol per mmol creatinine), overall heart rate variability (CV of RR-intervals in %) and the vagal com-
ponent of heart rate variability (SDSD in ms) for patients with overt hyperthyroidism, subclinical hyperthyroidism 
and control subjects. The values for urinary VMA excretion were multiplied 10 times for legibility reasons. The 
values for CV were multiplied 5 times for legibility reasons.
Hyperthyroid Subclinical Hyperthyroid Control
NE excretion
VMA excretion
CV Of RR-int (overall HRV)
SDSD (vagal component HRV)
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It is important to note that in the present study, the intervention of restoring euthyroidism in 
the patients was successful. TSH concentrations normalized and FT3/FT4 concentrations 
decreased by approximately 40% and 30% respectively and became in the normal ranges 
utilized by the laboratories of our hospital. Obviously, it is of crucial importance that the 
study was sufficiently powered to detect relevant differences. As it was impossible to 
perform a priori power analysis because of lack of data, a population size was chosen which 
at least would allow exploratory analyses. Subsequently the data that were obtained were 
used to perform a post-hoc power analysis. This analysis showed that the present study was 
sufficiently powered to detect differences that would have changed most of the parameters in 
the Subclinical hyperthyroidism patients to the normal values for these parameters. In order 
to demonstrate normalization of the urinary NE and VMA excretion two groups of 17 or 7 
patients respectively would have been needed. Also for the heart rate variability parameters, 
it seems that the study was sufficiently powered as for normalization of the RR-interval two 
groups of 7 patients were required and for the normalization of the overall heart variability (CV) 
two groups of 6 patients would have sufficed. Admittedly, more patients, (namely 22 patients 
per group) would have been necessary to also demonstrate normalization of the parameter 
that is commonly used to characterize the beat-to-beat variability. Nevertheless, we would 
like to argue that the current study was sufficiently powered for most of the parameters. We 
feel that our approach in which the restoration to euthyroidism in a homogenous group of 
patients with exogenous subclinical hyperthyroidism was studied, in a seemingly sufficiently 
powered randomized experiment is the most appropriate approach to study the effects of 
subclinical hyperthyroidism on the autonomic nervous system. 
Notwithstanding this, the interpretation of these findings is not straightforward. It could be 
that irreversible changes or adaptation occurs during long term exposure to excess thyroid 
hormone. If the latter would be true, this would imply that restoration of the autonomic 
nervous system set-point takes a longer time than half a year. This may explain the 
difference with studies with a shorter duration in overt hyperthyroidism (5,6) or subclinical 
hyperthyroidism (13). In addition, another probably crucial difference between our and other 
studies is that our study the population of patients with subclinical hyperthyroidism was 
homogenous regarding etiology and duration of the syndrome whereas in other studies 
more heterogeneous patient populations or populations with endogenous subclinical 
hyperthyroidism are studied. 
In conclusion, long-term exogenous subclinical hyperthyroidism affects the autonomic 
nerve system as measured by heart rate variability and urinary catecholamine excretion. 
No differences were observed 6 months after restoration of euthyroidism. This may indicate 
irreversible changes or adaptation during long-term exposure to excess thyroid hormone that 
are not remedied by 6 months of euthyroidism. To explore this further additional research 
is needed.
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Abstract
Context: Thyroid hormone impacts on the cardiovascular system. (Subclinical) Hyperthyroidism 
results in sympathovagal imbalance due to a decreased vagal tone. However, conflicting 
data have been reported on the effects of hypothyroidism on the activity of the autonomic 
nervous system (ANS). In hypothyroidism; both increased and decreased sympathetic activity 
and an increased vagal tone have been found. 
Objective: To study the effects of acute short term overt hypothyroidism and thyroxin 
replacement therapy on the ANS by measuring urinary excretion of catecholamines and 
heart rate variability (HRV).
Design: Prospective study
Setting: University hospital
Patients: We studied 11 patients, previously treated by thyroidectomy for differentiated 
thyroid carcinoma during hypothyroidism caused by cessation of thyroxin substitution for 4 
weeks and during thyroxin replacement therapy and 21 matched healthy controls.
Main outcome measures: The activity of the ANS was assessed by measuring urinary 
excretion of catecholamines and HRV in rest and during a challenge of the ANS by a mental 
stress test. 
Results: Urinary dopamine excretion was significantly lower during hypothyroidism. Although 
in the patients total variability was unchanged, HRV analysis showed a significantly lower 
LF/HF ratio, indicating sympathovagal imbalance with sympathetic withdrawal. The mental 
stress test in the patients resulted in a significant increase in heart rate of 16-18%. This 
response was not different between the hypothyroid state and during thyroxin replacement 
therapy suggesting that cardiovascular reflexes in these patients remain intact. 
Conclusion: Acute short-term overt hypothyroidism results in sympathovagal imbalance with 
sympathetic withdrawal with preservation of the cardiovascular reflexes to (mental) stress. 
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Introduction
Changes in thyroid hormone concentrations influence the cardiovascular system. Both 
overt and subclinical hyperthyroidism have been associated with cardiac arrhythmias, 
left ventricular hypertrophy, diastolic dysfunction and increased systolic function (1-5). In 
addition, (subclinical) hyperthyroidism results in sympathovagal imbalance with increased 
sympathetic activity and a decreased vagal tone (6-12). Osman et al. found decreased 
vagal modulation during overt hyperthyroidism which persisted when patients became 
in the subclinical hyperthyroid state (13). In contrast, in hypothyroidism bradycardia, 
decreased cardiac output, diastolic cardiac dysfunction, mild diastolic hypertension, and 
increased peripheral cardiovascular resistance are observed (2;14-16). Acute short-term 
hypothyroidism shows similar cardiovascular abnormalities as in chronic hypothyroidism 
including bradycardia, diastolic dysfunction, impaired systolic function during effort and 
increased systemic vascular resistance (17). Although hypothyroidism has also been 
associated with sympathovagal imbalance (18-20), current literature shows conflicting 
results with either increased sympathetic activity (18), decreased sympathetic modulation 
(19) or an increased vagal tone in hypothyroidism (20). These differences can be due to the 
heterogeneity of the study populations regarding the cause and duration of hypothyroidism.
Patients with differentiated thyroid carcinoma (DTC) being withdrawn from thyroxin for 
diagnostic purposes represent an excellent group to study the effects of acute short-term 
hypothyroidism on the autonomic nervous system. Only one study has documented the 
consequences of hypothyroidism on the autonomic nervous system in this situation. (21) In 
that study, however, no healthy controls were studied. In addition, the response to a challenge 
of the autonomic nervous system, which seems to reveal the most prominent differences 
in the autonomic nervous system during (subclinical) hyperthyroidism (9;11;22), was not 
studied in these hypothyroid patients. We therefore conducted a study on the autonomic 
nervous system in DTC patients during acute short-term hypothyroidism and subsequently 
during treatment with thyroxin, and compared these to healthy age-, gender- and BMI-
matched controls. We studied urinary catecholamine excretion and heart rate variability 
measurements at rest and during a mental stress test (23).
Materials and methods
Subjects
Patients were recruited from the outpatient clinic of the Department of Endocrinology of 
Leiden University Medical Centre, which is a tertiary referral centre for differentiated thyroid 
carcinoma. Patients were included who had been diagnosed with DTC and had received 
initial therapy consisting of total-thyroidectomy and radio iodine ablation therapy. Additional 
therapies were allowed, as long as they resulted in cure. Cure was documented by the 
absence of measurable serum thyroglobulin (Tg) during TSH stimulation as well as by a 
negative total-body scintigraphy with 4 mCi 131-I. 
Patients who had cardiovascular diseases, diabetes mellitus, other endocrine diseases or 
had a BMI >35 kg/mm2 were excluded. Patients who used any drug known to influence the 
heart rate variability were also excluded. The local ethics committees approved the study 
and written informed consent was obtained from all subjects.
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Study design
Eleven consecutive patients with DTC undergoing TSH stimulated I-131 scan were asked to 
participate in the study. Four weeks after thyroxin withdrawal and 8 weeks after restarting 
thyroxin replacement, patients were admitted to the clinical research unit. For each patient, 
two healthy age-, gender- and BMI-matched controls were included. Subjects handed in the 
urine collected over the previous 48 hours. Subjects were asked to follow a diet free of 
potential catecholamine stimulating food or medication (excluding coffee, alcohol, bananas, 
nuts and paracetamol) from two days before and during urine collection. All subjects fasted 
from the preceding evening (18.00 hr) until the end of the study. On the study day, at 08.00 
hr, height (meters [m]), weight (kilograms [kg]) and BMI (weight [kg]/height2 [m]) were 
measured. Plasma samples were collected for measurement of FT4, TSH and FT3. Plasma 
samples were handled immediately and stored at –20o C in Sarstedt tubes. 
Heart rate variability
At least 30 minutes after blood sampling, a continuous ECG registration was made while the 
subject was in supine position for at least 15 min. The measurements consisted of a 1-lead 
electrocardiogram (ECG) registration (recording 600 subsequent beats). The subjects were 
instructed to relax, to breathe regularly, not to speak and to stay awake. The ECG signal 
was sampled at a rate of 500 Hz, digitized using a customized laboratory interface (model 
1401, Cambridge Electronic Design, Cambridge, UK), and analyzed with software supplied 
with the interface. Each registration was screened for artefacts and subsequently analyzed 
for HRV parameters in the time domain: mean RR-interval (RR-int), the coefficient of variation 
(CV) of the successive RR-intervals (reflecting total variability), and the standard deviation 
of differences between adjacent R-R intervals (SDSD) reflecting “beat-to-beat” variability) as 
previously described (6) and according to the applicable guidelines (24). The registrations 
were also analyzed with HRV Analysis Software 1.1 for windows developed by The Biomedical 
Signal Analysis Group, Department of Applied Physics, University of Kuopio, Finland. The 
software is distributed free of charge upon request (http://venda.uku.fi/research/biosignal), 
and conforms with the same guidelines (27). The power spectra were analyzed for the Low 
Frequency (LF) and high frequency (HF) components and are expressed as normalized units. 
Upon completion of the recording at rest, another 5-min recording was started during which 
the patients were subjected to a mental stress test (23). During this test the subjects had 
to perform a standardized arithmetic test with which they had been familiarized before. The 
registration made during this test was used to determine the percentage increase in heart 
rate from baseline. This test was not performed in the healthy controls as the increase in 
heart rate reported in the literature in healthy subjects is always between 15 and 25% (25-
28) and this is also the case in our experience (data on file at CHDR).
Assays
All plasma and serum samples were measured in one batch. Serum free thyroxin (FT4) 
and TSH were measured with an electrochemoluminescentic immunoassay with a Modular 
Analytics E-170 system with an intraassay CV of 1.6-2.2 % and 1.3-5.0 % respectively (Roche, 
Almere, The Netherlands). Serum free thyronine (FT3) was measured with a fluorescentic 
polarisatic immunoassay, CV 2.5-9.0 %, on an ImX system (Abbott, Abbott Park, IL, USA). 
Reference values for FT4, FT3 and TSH are respectively 10-24 pmol/L, 3.9-6.7 pmol/L 
and 0.4-4.8 mU/L. Urinary excretion of norepineprhine, epinephrine and dopamine were 
determined by routine HPLC methodology. 
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Statistical Analyses
Values are expressed as mean ± SD. Data between subjects were analyzed with the 
paired samples t-test. Data between DTC patients and control group was analyzed with the 
independent t-test. Differences were considered statistically significant at P<0.05. SPSS 
12.0 for windows was used for statistical analyses (SPSS. Inc., Chicago, IL, USA). 
Results
Patient characteristics
Eleven patients were included (4 male, 7 female). Mean age was 45.5 ± 10.0 years and 
BMI was 28.1 ± 4.2 kg/m2. All patients had been treated by total thyroidectomy followed by 
radioiodine ablation. Median (range) duration after initial therapy was 1.3 (0.6-24.3) years. 
Before thyroxin withdrawal the majority of patients was receiving TSH suppressive therapy 
(n=8). Three patients were receiving thyroxin replacement therapy, because their duration 
after initial therapy was more then 15 years. None of the patients had recurrent disease. 
Thyroid hormone levels are presented in table 1. All patients were overtly hypothyroid 
during the first study day, 4 weeks after withdrawal of thyroxin replacement therapy. Eight 
weeks after restarting thyroxin replacement therapy, six patients had thyroid parameters 
within the reference range, whereas 5 patients had a TSH below the reference range with 
normal plasma T3 and T4 levels. Mean thyroxin dose was 197 ± 42 mg/day. Diastolic blood 
pressures were significantly higher during the hypothyroidism state (84 ± 0 vs. 79 ± 6 mm 
Hg, p=0.0049), whereas systolic blood pressures were not significantly different.
Urinary catecholamine excretion
Urinary catecholamine excretion (normalized for creatinine excretion) is summarized in Table 
1. Urinary excretion of dopamine was significantly lower during hypothyroidism compared to 
thyroxin replacement (97 ± 33 vs. 132 ± 048 µmol/mmol creatinine, p=0.016). Urinary 
epinephrine and norepinephrine excretion rates were not significantly different. 
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Overt hypothyroidism Thyroxin replacement P-value
TSH (Mu/L) 142.4 ± 34.4  0.8 ± 1.0 <0.001
FT4 (pmol/L) 1.4 ± 0.7 24.8 ± 4.06 <0.001
FT3 (pmol/L) 0.1 ± 0.2 4.8 ± 0.8 <0.001
BMI (kg/m2) 28.08 ± 4.19 27.41 ± 4.42 0.004
BP systolic (mm Hg) 121 ± 6 123 ± 11 0.460
BP diastolic (mmHg) 84 ± 9 79 ± 6 0.049
Norepineprhine (µmol/mmol 
creatinine) 
25.1 ± 10.0 23.6 ± 11.4 0.690
Epinephrine (µmol/mmol 
creatinine) 
1.6 ± 1.2 2.8 ± 2.2 0.064
Dopamine(µmol/mmol cre-
atinine) 
97 ± 33 132 ± 48 0.016
Table 1. Thyroid hormone levels and urinary catcholamine excretion in 24 h urine collections
Paired samples t-test. Data are expressed as mean ± SD
BMI= body mass index, BP=blood pressure
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Heart rate variability
Parameters of heart rate variability are presented in Table 2. The RR-interval was significantly 
prolonged during hypothyroidism compared to during thyroxin replacement (1074 ± 123 
vs. 948 ± 156 ms, p=0.03). Total variability (represented by the CV) and SDSD were not 
significantly different between hypothyroidism and thyroxin replacement. Frequency domain 
analysis showed that LF tended to be lower during hypothyroidism (54.7 ± 22.7 vs. 67.4 ± 
14.5 nu, p=0.050) during hypothyroidism compared to thyroxin replacement. The LF/HF 
power ratio was significantly lower during hypothyroidism compared to thyroxin replacement 
therapy (p=0.042).
Mental stress test
The mental stress test produced a significant increase in heart rate of 16 ± 11% in the 
hypothyroid state and 18 ± 14.0% during thyroxin treatment. The response did not differ 
between the two conditions (p= 0.377) and has the same order of magnitude as previously 
reported for healthy subjects (25-28).
Overt hypothyroidism (n=11) Thyroxin replacement (n=11)  P-value
RR-interval (ms) 1074 ± 123 948 ± 156 0.003
CV (%) 4.3 ± 2.3 4.4 ± 1.8 0.767
SDSD (ms) 40.1 ± 33.7 32.3 ± 19.7 0.159
LF (nu%) 54.7  ± 22.7 67.4  ± 14.5 0.050#
HF (nu%) 45.6 ± 22.7 32.6 ± 14.5 0.081#
LF/HF 2.20 ± 1.80 2.56 ± 1.33 0.041#
Table 2. Parameters of heart rate variability during hypothyroidism and thyroxin replacement therapy
Data are expressed as mean ± SD
CV: coefficient of variation; SDSD: standard deviation of the successive differences in RR-intervals; LF: power in 
low frequency band; HF power in high frequency band; LF/HF: ratio of power in low frequency band over power in 
high frequency band
# p-value for log-transformed variables
Thyroxin replacement (n=11) Control group (n=21) P-value
RR-interval (ms) 948 ± 156 863 ± 124 0.118
CV (%) 4.4 ± 1.8 3.5 ± 1.5 0.121
SDSD (ms) 32.3 ± 19.7 27.4 ± 18.6 0.517
LF (nu%) 67.4 ± 14.5 54.0 ± 22.0 0.037#
HF (nu%) 32.6 ± 14.5 46.0 ± 22.0 0.141#
LF/HF 2.56 ± 1.33 1.83 ± 1.69 0.112#
Table 3. Parameters of heart rate variability between patients and controls
Data are expressed as mean ± SD
CV: coefficient of variation; SDSD: standard deviation of the successive differences in RR-intervals; LF: power in 
low frequency band; HF power in high frequency band; LF/HF: ratio of power in low frequency band over power in 
high frequency band
# p-value for log-transformed variables
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Comparison between controls and patients
Comparisons were made between patients on thyroxin substitution and healthy controls. The 
control group consisted of 8 men and 14 women. One male subject was excluded because 
the ECG recording had too many artefacts to be analyzed properly. Mean age was 45.5 ± 8.7 
years and mean BMI was 28.3 ± 4.3 kg/m2, which was not different compared to controls. 
There were no differences in the RR-interval or CV between patients and controls (Table 3). 
The LF component was significantly higher in patients compared to controls, whereas there 
were no differences in LF component or the LF/HF ratio between patients and controls.
Discussion
We investigated the impact of acute short-term hypothyroidism and restoration to subclinical 
hyperthyroidism on the autonomic nervous system in thyreoidectomized patients with DTC by 
measuring urinary catecholamine excretion and heart rate variability at rest and in response 
to a mental stress test.
Heart rate was significantly lower during hypothyroidism compared to thyroxin replacement 
therapy and controls. As expected, the RR-interval was significantly prolonged during 
hypothyroidism in the patients. The LF/HF power ratio, representing sympathovagal balance 
with lower levels suggesting sympathetic withdrawal (24), was significant lower during 
hypothyroidism compared to thyroxin replacement therapy, indicating sympathovagal 
imbalance with sympathetic withdrawal. The LF component tended to be lower during 
hypothyroidism compared to thyroxin replacement therapy. Although the LF component is 
associated with both sympathetic and vagal activity (24), other studies report that the LF 
component, especially when expressed in normalized units, reflects sympathetic activity 
(8;24;29). Our findings are consistent with some studies (19-21;30), but at odds with two 
other studies which reported a decreased LF/HF power ratio with an increased LF component 
and a decreased HF component in hypothyroid patients (18;19). We hypothesize that the 
discrepancies between the different studies may be explained by differences in duration, 
cause and severity of hypothyroidism as in these studies patients with hypothyroidism 
caused by Hashimoto thyreoiditis were investigated, whereas we studied thyreoidectomized 
patient with DTC with a controlled duration and degree of hypothyroidism. Our patients did 
not have any endogenous thyroid hormone production and therefore represent a unique 
model population to study controlled hypothyroidism.
In our study, the LF component was significant higher in patients compared to controls, 
whereas there were no differences in the HF component and the LF/HF power ratio between 
the patients compared to healthy controls. Other studies reported sympathovagal imbalance 
with increased sympathetic activity and a decreased vagal tone during (subclinical) 
hyperthyroidism characterized by an increased LF component (expressed in normalized 
units) and a decreased HF component resulting in an increased LF/HF power ratio (6-
13),13. Possible explanations for the fact that the HRV spectrum had characteristics of 
hyperthyroidism despite normal mean TSH levels could be that the patients in the present 
study were treated for a long period (5.0 ± 7.1 years) with TSH suppressive thyroxin 
replacement therapy preceding the present study and it is plausible that irreversible changes 
or adaptation of the autonomic nervous were present. This would concur with other recent 
findings of our group which showed that long-term subclinical hyperthyroidism affects the 
autonomic nervous system and that these changes persist even after a 6 months-period of 
restoration to euthyroidism (31). 
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It has been suggested that the VLF component reflects influences on heart rate variability 
mediated by thermoregulatory and angiotension-mediated mechanisms (32). We noticed a 
substantial difference between patients and controls. In controls, the absolute VLF power 
(92 ± 115 ms2) was much lower than in the patients (208 ± 152 ms2 when hypothyroid and 
321 ± 369 ms2 when on thyroxin replacement therapy). It may well be that this difference 
in the contribution of the VLF frequency band influenced our findings on the LF and HF 
component. We suggest that investigations in the VLF component should receive more 
attention in patients with thyroid disorders. 
To our knowledge, this is the first report showing that the cardiovascular adaptation mediated 
by the autonomic nervous system during mental stress is preserved in thyreoidectomized 
patients irrespective of a hypothyroid state or when on thyroxin replacement. Apparently, 
short term thyroid hormone withdrawal is not crucial in the (short-term) reflex-mediated 
cardiovascular regulation as indicated by the mental stress test. 
Urinary excretion of dopamine was significantly lower during hypothyroidism. This is consistent 
with the results reported by Guasti et al (21). There were no differences in urinary excretion 
rates of norepinephrine and epinephrine.
In conclusion, acute short-term hypothyroidism in thyreoidectomized DTC patients results in a 
sympathovagal imbalance with sympathetic withdrawal. This, however, does not compromise 
the ability of the cardiovascular system to react normally to a (short-term) challenge of the 
autonomic nervous system. 
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Abstract
Objective: This study was performed to evaluate the impact of cured differentiated thyroid 
carcinoma (DTC) on quality of life.  Previous studies on quality of life in patients with DTC 
were hampered by small patient numbers, limited of quality of life parameters or were 
uncontrolled. 
Design: Cross-sectional case-control study.
Method: We assessed quality of life in 153 cured DTC patients with a median duration of cure 
of 6.34 years (range 0.3-41.8) and studied the contribution of disease specific, biochemical 
and social variables, focusing on the degree of TSH suppression. Four validated health-
related questionnaires were used (Short Form-36, Multidimensional Fatigue Index-20, 
Hospital Anxiety and Depression Scale and Somatoform Disorder Questionnaire), including 
multiple aspects of physical, psychological and social functioning. Patients were compared 
with 113 controls selected by patients themselves (control group-I), and with 336 pooled 
age- and gender-matched controls from other Leiden quality of life studies (control group-
II). 
Results:  Patients had significantly decreased quality of life in 11 of 16 subscales when 
compared with control group-I. Comparison with control group-II, decreased scores in 13 of 
16 items were observed. An important independent predictor for quality of life was duration 
of cure. Quality of life parameters were not influenced by serum TSH levels, both measured 
at the time of quality of life assessment and measured over time since initial therapy.
Conclusions: Patients cured for DTC have impaired quality of life, independently of TSH level. 
Quality of life parameters were inversely affected by duration of cure and consequently may 
be restored after prolonged follow-up. 
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Introduction
Well-differentiated thyroid carcinoma (DTC) is associated with an excellent medical prognosis, 
with 10-year survival rates reaching 90-95% (1). Following initial therapy, usually consisting 
of total thyroidectomy and radioiodine thyroid remnant ablation therapy, most patients used 
to be treated with high doses of L-thyroxin in order to suppress TSH levels (1). On one hand, 
the excellent prognosis and the moderate invasiveness of the initial therapy may implicate 
that quality of life in cured DTC patients may be relatively normal. On the other hand, TSH 
suppressive thyroxin replacement therapy may lead to a decreased quality of life (2,3,4). 
Only a few studies have evaluated quality of life in cured DTC patients (5,6,7,8,9). These 
studies are limited by small patient numbers (6,7), limited number of quality of life 
questionnaires (5,9) or the absence of a healthy control group (5,6,8). 
Studies that focused on the relation between the level of TSH suppression and quality of life 
in DTC patients are inconclusive because of small patient numbers, selection of patients 
with symptoms of hyperthyroidism or selection of patients with a long duration of cure (2,10). 
Therefore, the aim of the present study was to assess quality of life in a large cohort of cured 
DTC patients and to investigate the determinants of quality of life, including serum TSH 
levels. We used four validated, health-related questionnaires and included controls matched 
for age, gender and socioeconomic status. 
Patients and methods
Cured DTC patients, 18-70 years old, were recruited from the outpatient clinic of the 
Department of Endocrinology of the Leiden University Medical Center. Other medical 
conditions or drugs that could influence quality of life were not permitted.
Initial therapy consisted of near-total thyroidectomy, followed by postoperative radioiodide 
ablation therapy with I-131. Cure after initial therapy was defined as the absence of I-131 
accumulation at diagnostic 185 MBq scintigraphy, serum Tg concentrations below 2 µg/L 
after TSH stimulation in absence of Tg antibodies and no other evidence of disease (11). 
Patients with tumor relapse were only included if they were subsequently cured.
Initially, 157 DTC patients who met these criteria were asked to participate. Four validated 
questionnaires were sent to their homes together with a list of general questions about level 
of education, country of origin and marital state. Four patients specifically wished not to 
participate. Each patient was also asked to provide a control person of comparable sex, age 
and socio-economic status (friend, neighbour, relative) (control group-I). We received 153 
completed questionnaires from patients and 113 questionnaires from controls. To exclude 
bias in the selection of control group-I, we also compared the patients with a larger cohort 
of age, gender and socioeconomic status matched healthy controls (n=336) obtained from 
other quality of life studies performed in our centre (12,13,14,15) (indicated as control 
group-II).
The study protocol was approved by the medical ethics committee of the Leiden University 
Medical Centre and written consent was obtained from all patients.
Study parameters
Primary study parameters were the outcomes of the four health related questionnaires and 
the contribution of patient characteristics (age, gender, educational level, marital status), 
disease specific characteristics (initial TNM stage, recurrent disease, duration of cure), 
treatment (extent of surgery, radioiodine therapy and additional treatments) and biochemical 
parameters (serum free T4, T3 and TSH levels) to quality of life. 
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The influence of TSH on quality of life was investigated both by evaluation of serum TSH 
levels at time of the survey (expressed as continuous variable or stratified as ‘profoundly 
suppressed’ (<0.1 mU/l), ‘moderately suppressed’ (<0.4 mU/l) and ‘unsuppressed’ (>0.4 
mU/l) and by summary TSH parameters over time since initial therapy for each patient. 
Summary TSH parameters over time were the mean, 25th, 50th and 75th percentiles and the 
percentage of profoundly suppressed, suppressed and unsuppressed TSH values from all 
available unstimulated TSH measurements since initial therapy.
Quality of life questionnaires
Short-form-36 (SF-36)
The SF-36 questionnaire comprises 36 items and records general well-being during the 
previous 30 days (16), subdivided in 8 health concepts. Scores are expressed on a 0–100 
scale, and higher scores are associated with a better quality of life.
Multidimensional Fatigue Index-20 (MFI-20)
The MFI-20 comprises 20 statements (5 dimensions) to assess fatigue, which are measured 
on a five-point scale (17). Scores vary from 0-20; higher scores indicate greater fatigue.
Hospital Anxiety and Depression Scale (HADS)
The HADS consists of 14 items pertaining to anxiety and depression. Scores for the anxiety 
and depression subscale range from 0 to 21, and values for the total score range from 0-42. 
Higher scores indicate more anxiety or depression (18). 
Somatoform disorders questionnaire (SDQ)
All somatoform disorders mentioned in classification DSM-III were comprised in this 
questionnaire (19). The total score varies from 0-51 for women and 0–55 for men. The total 
score expresses the extent of physical complaints that were present in the previous week.
Assays
Serum free thyroxin (FT4, normal range 10-24 pmol/L) and TSH levels (normal range 0.4-
4.5 mU/L) were measured by electrochemoluminescentic immunoassay using a Modular 
Analytics E-170 system (Roche, Almere, The Netherlands). 
Statistical analysis
SPSS for Windows, Version 12.0 (SPSS Inc., Chicago, IL. USA) was used to perform all analyses. 
Data are expressed as mean ± SD unless indicated otherwise. As dependent variables, we 
calculated delta scores between each patient and age and gender matched Leiden-controls 
by subtracting age and gender specific means of the controls from patient scores for all 
questionnaire subscales. Stepwise univariate linear regression analysis was used to identify 
independent variables for quality of life. Differences were considered statistically significant 
at p<0.05.
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Results
One hundred and fifty three patients (28 males, 125 females, age 49±13 years, 127 papillary- 
and 27 follicular carcinomas) were analyzed. Tumor stages were T1-3 M0 in 131, T4 in 18 
and M1 in 4 patients. Median duration of cure was 6.3 years (range 0.3-41.8). At the time 
of the survey, median TSH was 0.1 mU/L (range 0.005-6.8) and FT4 was 22.4±4 pmol/L. 
An average of 15 unstimulated TSH measurements per patient was obtained since initial 
therapy. Summary parameters of TSH over time per patient were: mean 0.4 mU/L (range 
0.1-3.4), median 0.05 mU/L (range <0.005 - 2.18); proportions of profoundly suppressed 
values: 58% (range 0 –100) and moderately suppressed values: 80% (range 0-100%). The 
slope of TSH values was -0.0001 mU/year (range -0.004-0.000 mU/year), indicating that 
the TSH levels were reasonably stable.  Mean dose of L-thyroxin was 183 ± 51 µg/day. 
Quality of life in DTC patients and controls
Quality of life scores in patients were significantly reduced in 11 of the 16 items assessed 
when compaired to control group-I. According to the SF-36 questionnaire, patients had 
significantly worse scores on social functioning and general health perception. All MFI-20 
subscales and HADS subscales were affected in DTC patients. The SDQ total score was also 
significantly worse than in control group-I. Comparison of the patients with control group-II 
(12,13,14,15) showed similar results: 13 of 16 quality of life parameters differed significantly 
between patients and controls (Table 1). 
Determinants of quality of life
Marital status, country of birth, initial TNM-stage, total activity of I-131, tumor recurrence, 
L-thyroxin dose, post-surgical hypoparathyroidism, and serum FT4-level did not affect any of 
the questionnaire items. 
TSH levels measured at the time of the assay (both continuous and stratified) and summary 
TSH values over time appeared not to be a significant independent predictor for quality 
of life. Post-hoc power calculation revealed sufficient power (all items > 0.9) to draw this 
conclusion.
A longer duration of cure was correlated with better scores on SF-36 social functioning 
(standardized β=0.21, p=0.030), role limitations due to physical problems (β=0.17, p=0.049), 
general health perception (β=0.32, p=0.001), MFI-20 general fatigue (β= -0.17, p=0.035), 
physical fatigue (β= -0.24, p=0.003) and mental fatigue scores (β=-0.17, p=0.038). We 
calculated the duration of cure needed for the quality of life scores to reach the normal 
range of all healthy subjects (Figure 1).  The 95% CI intervals of quality of life scores only 
included 0 (no difference between quality of life of patients and controls) after a relatively 
long duration of cure (approximately 12 to 28 years for SF-36 respectively MFI-20).
Discussion
The purpose of this study was to evaluate quality of life in a large cohort of cured DTC 
patients using multiple quality of life parameters and a matched healthy control group. 
We found that quality of life scores assessed by the majority of subscales are reduced in 
patients previously treated for DTC, compared to controls. Although our observations are 
in line with other studies on quality of life in DTC patients (5,9,6,7,8), our study includes 
a higher numbers of patients, uses more quality of life questionnaires and uses matched 
control groups. 
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Longer duration of cure was associated with better scores on different quality of life items. 
This finding is in line with studies by Dagan et al (7) and Crevenna et al (5), but this is the 
first study to quantify the predicted duration of affected quality of life in relation to duration 
of cure. After a long duration of cure, approximately 15 to 20 years (MFI-20 respectively SF-
36) the 95% confidence intervals of 6 of the 16 quality of life subscales included a normal 
score (Figure 1).
In our study, quality of life was not influenced by TSH levels at the time of the survey and 
by TSH levels over time since initial therapy, although it can be objected that generic 
questionnaires were used. Other studies on the effects of subclinical hyperthyroidism on 
well-being have yielded inconclusive results. Most of these studies have been performed in 
patients with endogenous subclinical hyperthyroidism (3) who cannot easily be compared 
with DTC patients or contained selected patients with DTC (2).  
Questionnaire Patients
(n=153) 
Control 
group I
(n=113) 
P
(patients vs. control 
group-I) 
Control group II
(n=336) 
P
(patients vs.
control group-II)
Age 49.10 48.08 0.522 49.99 0.496
M/F 28/125 19/94 0.754 67/269 0.672
SF-36
Physical functioning 83.70±21.02 88.27±16.78 0.052 87.77±17.14 0.040
Social functioning 81.09±24.90 87.39±20.01 0.037 88.06±19.28 0.007
Role limitations due to 
physical problems
75.35±40.04 81.42±34.36 0.194 83.38±32.43 0.035
Role limitations due to 
emotional problems
83.22±35.43 84.66±31.82 0.734 85.93±30.21 0.422
Bodily pain 82.74±21.70 84.78±18.93 0.426 85.17±19.24 0.216
General health percep-
tion
65.59±20.48 71.45±18.43 0.027 71.34±18.79 0.007
Change in health 52.15±18.37 55.18±18.19 0.185 54.77±18.64 0.105
MFI-20
General fatigue 11.03±4.72 8.11±3.35 <0.001 8.60±4.01 <0.001
Physical fatigue 9.95±4.93 6.65±2.64 <0.001 7.60±3.69 <0.001
Reduced activity 8.79±4.15 6.85±3.30 <0.001 7.18±3.57 <0.001
Reduced motivation 8.64±3.76 6.67±2.79 <0.001 7.26±3.53 <0.001
Mental fatigue 9.53±4.50 7.93±3.60 0.002 7.92±3.31 <0.001
HADS
Anxiety 5.69±3.95 4.14±3.15 <0.001 4.21±3.21 <0.001
Depression 3.61±3.08 2.37±2.52 <0.001 2.86±2.99 0.011
Total 9.30±6.30 6.51±4.92 <0.001 7.07±5.39 <0.001
SDQ
SDQ total 5.92±6.20 1.66±2.51 <0.001 1.65±2.50 <0.001
Table 1: Quality of life in patients treated for DTC compared with controls selected by patients themselves (Con-
trol Group I) and age and gender matched controls from other Leiden quality of life studies (Control Group II) 
(12,13,14,15). Data shown are mean ± SD. 
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Comparison of DTC survivors to survivors of other cancer types is complicated because of 
the many differences between the several cancer types. A large study (20) revealed that 
DTC survivors had similar quality of life as patients with breast cancer, worse than survivors 
of melanoma or colorectal cancer but better than hematological malignancies. Despite 
cure, excellent prognosis and moderate aggressive treatment, DTC patients have an evident 
decrease in quality of life that may only be restored after years of follow-up. The findings of 
our study have therefore implications for the approach of the cured DTC patients: attention 
for the psychological well-being of the patient and availability of professional support may be 
important aspects in follow-up. 
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Figure 1 Differences between age- and gender-matched controls and patients for the quality-of-life parameters 
plotted against duration of cure; linear regression line and 95% confidence interval are shown (standardized B 
and significance of linear regression analysis). The horizontal line represents the value for quality-of-life param-
eters where there is no difference between patients and the means of age- and gender-matched controls
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Abstract
Objective: The type 2 deiodinase (D2)-Thr92Ala polymorphism has been associated with 
decreased D2 activity in some in vitro experiments but not in others. So far no association 
between the D2-Thr92Ala polymorphism and serum thyroid hormone levels has been 
observed in humans, but in a recent study in athyroid patients, it was suggested that 
patients homozygous for the Ala92 allele needed higher thyroxine doses to achieve TSH 
suppression. 
We studied the association between the D2-Thr92Ala polymorphism with thyroid hormone 
levels and thyroxine dosage, in patients treated for differentiated thyroid carcinoma (DTC) 
and in a group of patients treated for Hashimoto thyroiditis. 
Design: Cross sectional study
Patients: We studied 154 patients with DTC treated with TSH suppressive thyroid hormone 
replacement therapy for longer than 3 years and 141 patients with Hashimoto thyroiditis 
treated for at least 6 months with thyroxine. 
Measurements: In all patients, serum levels of TSH, free thyroxine, triiodothyronine and 
reverse T3 were measured and genotypes of the D2-Thr92Ala polymorphism were determined 
by Taqman assay. Univariate regression analysis was performed to determine the relation 
between thyroxine dosages and the D2-Thr92Ala polymorphism corrected for age, gender, 
BMI and serum TSH levels.
Results:  Both in DTC patients and Hashimoto patients, no association was observed 
between serum thyroid hormone levels or thyroxine dosages in presence of the D2-Thr92Ala 
polymorphism. Categorization of DTC patients according to degree of TSH suppression did 
not change these results. 
Conclusion: The D2-Thr92Ala polymorphism is not associated with thyroid hormone levels or 
thyroxine dose in patients treated for DTC or Hashimoto thyroiditis.
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Background
Most actions of thyroid hormone are mediated by the active form of thyroid hormone, 
triiodothyronine (T3). Serum and local T3 concentrations are mainly regulated by the 
iodothyronine deiodinases D1, D2 and D3(1). D2 is essential for the local production of 
T3 through deiodination of T4. D2 is thus essential for the negative feedback regulation 
of thyroid hormone on thyrotropin (TSH) production in the pituitary. Several polymorphisms 
in D2 have been described (2-5). Controversy exists about the functional implications of 
the D2-Thr92Ala polymorphism, which has been associated with a decreased D2 activity 
in some in vitro experiments (2) but not in others (5). So far no associations were found 
between the D2-Thr92Ala polymorphism and serum thyroid hormone levels in studies in 
healthy subjects(4;6;7). 
Torlontano et al. reported in thyroidectomized differentiated thyroid carcinoma (DTC) patients 
that homozygous carriers of the D2-Ala92 allele needed higher dosages of thyroxine(8). This 
difference was most prominently observed in the group with near-suppressed TSH (TSH 
values between 0.1 and 0.5 mU/L). Limitations of this study were that actual values of 
serum TSH levels for wild-type and homozygous groups within the near-suppressed TSH 
group were not given. It is therefore unclear whether TSH levels in both groups were indeed 
identical, which would be a key finding to ascribe the slight differences in thyroxine dose 
indeed to the polymorphism. The fact that serum T4 and T3 levels did not differ between 
the wild-type group and D2-Thr92Ala homozygotes is also remarkable. Moreover, as TSH is 
a continuous variable, we believe that the optimal analytic strategy would be by regression 
analysis, rather than a categorized approach. We therefore performed this study to reconfirm 
the findings of Torlontano et al. 
For this reason, we studied the association between the D2-Thr92Ala polymorphism and 
thyroid hormone levels and thyroxine dosage in 154 patients treated for DTC and 141 
patients substituted with thyroxine for Hashimoto thyroiditis, using a linear regression model. 
In addition, we performed a categorized analysis to allow maximal comparability with the 
Torlontano study.
Patients and Methods
Patients
Patients treated for DTC were recruited from the outpatient clinic of the Department of 
Endocrinology of the Leiden University Medical Center. All patients had been treated by 
near-total thyroidectomy followed by radioiodine ablation. After initial treatment, thyroxine 
therapy was started in a dose intended to suppress TSH levels below 0.4 mU/l for 15 years. 
All patients were cured as defined by the absence of I-131 accumulation at diagnostic 
scintigraphy, serum thyroglobulin (Tg) concentrations below 2 μg/l after TSH stimulation in 
the absence of Tg antibodies, a normal neck ultrasound and no other indication for disease. 
Patients with tumor relapse were only included if they had been subsequently cured. The 
Local Ethics Committee of the Leiden University Medical Centre approved the study, and 
written informed consent was obtained from all subjects.
We also included 141 patients treated for at least 6 months with L-thyroxine for Hashimoto 
thyroiditis. Serum TSH levels were between 0.11 and 4.0 mU/L. These patients were 
described earlier by Appelhof et al (9). 
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Study design
After an overnight fast, patients had a physical examination, including, height (meters [m]) 
and weight (kilograms [kg]). Blood was collected for determination of TSH, free thyroxine 
(FT4), T3 and reverse T3 (rT3). Serum samples were handled immediately and stored at –80 
oC in Sarstedt tubes. DNA was collected for genotyping of the D2-Thr92Ala polymorphism. To 
be able to compare our study with the study of Torlontano et al. (8), patients were categorized 
in groups with a suppressed TSH (< 0.1 mU/L), near-suppressed TSH (0.1-0.5 mU/L) or non-
suppressed TSH (>0.5 mU/L).
Serum biochemistry
In the patients treated for DTC, serum FT4 and TSH were measured using a chemoluminescence 
immunoassay with a Modular Analytics E-170 system (intraassay CV of 1.6-2.2 % and 1.3-
5.0 % respectively (Roche, Almere, The Netherlands). Serum T3 was measured with a 
fluorescence polarization immunoassay, CV 2.5-9.0 %, on an ImX system (Abbott, Abbott 
Park, IL, USA). Reverse T3 was measured using a RIA as described previously (10).   
In the patients treated for Hashimoto thyroiditis, serum TSH and FT4 were measured by 
time-resolved fluoroimmunoassay and serum T4 and T3 by in-house RIA methods (6). 
Genotyping
DNA was isolated from peripheral leucocytes by the salting out procedure (11). Genotypes 
of the D2-Thr92Ala polymorphism (rs 225014) were determined using 5 ng genomic DNA 
in a 5’ fluoregenic Taqman assay and reactions were performed in 384-wells format on 
ABI9700 2x384well PCR machines with endpoint reading on the ABI 7900HT TaqMan® 
machine (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands). Primer and 
probe sequences were optimized using the single nucleotide polymorphism assay-by-design 
service of Applied Biosystems. 
Statistical Analysis
Values are presented as mean ± standard deviation (SD), median (range) or as numbers 
or proportions of patients. Deviation from Hardy-Weinberg Equilibrium was analysed 
using a X2-test. Dominant (Thr/Thr vs. Ala/X) and recessive (Thr/X vs. Ala/Ala) effects of 
the polymorphism were analyzed. The association between D2-Thr92Ala genotypes and 
thyroxine dosages or thyroid hormone levels were analyzed using multivariate regression 
analyses. This was corrected for age, gender, BMI and the natural logarithm of TSH levels. 
In addition, differences between the different D2 genotype groups were analyzed using 
unpaired t-test or ANCOVA. All calculations were performed using SPSS 12.0 for windows 
(SPSS, Inc., Chicago, IL). Differences were considered statistically significant at P<0.05.
Results
Patient characteristics
We studied 154 DTC patients. Mean duration of TSH suppressive therapy was 9.2 years 
(range 0.5-42.6 years). Median duration of cure was 8.9 years (range 1.0-41.8 years). The 
mean dose of thyroxine was 183 ± 51 µg/day. Mean thyroxine dose was 2.2 ± 1.0 µg/kg body 
weight. We also studied 141 patients with Hashimoto thyroiditis on thyroxine replacement 
therapy. Genotyping of the D2-Thr92Ala polymorphism failed in two subjects. The remaining 
139 patients were treated with thyroxine for a mean duration of 7.3 ± 5.8 years. Mean 
thyroxine dose was 125 ± 46 µg/day.
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Thyroid hormone parameters and D2-Thr92Ala
Allele frequencies of the D2-Thr92Ala polymorphism in the DTC patients and Hashimoto 
thyroiditis patients were 39.6% and 40.3%, respectively. The genotype distributions did not 
deviate from Hardy-Weinberg equilibrium. Thyroid hormone levels and thyroxine dose for 
patients with DTC and Hashimoto thyroiditis are presented in Table 1. No differences were 
observed in thyroid hormone levels and thyroxine dose, corrected for BMI and TSH levels 
between wild-type, heterozygous and homozygous carriers of the D2-Thr92Ala polymorphism. 
Analyses were comparable when thyroxine dose was corrected for BMI. No differences 
were observed in the correlation between lnTSH and thyroxine dose/kg or FT4 level for the 
different carriers of the D2-thr92ala polymorphism (figure 1 A-D).
No differences were observed either in thyroid hormone levels or thyroxine dose when 
patients were categorized according to the degree of TSH suppression in the cohort of DTC 
patients. 
Linear regression analysis showed no association between the D2-Thr92Ala polymorphism 
and thyroid hormone levels or thyroxine dose corrected for TSH levels and BMI (DTC: p=0.960, 
r=0.564, Hashimoto thyroiditis: p=0.274, r=0.302) 
12
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Figure 1.
a. Correlation between the natural logarithm of TSH and thyroxine dosage/kg for the different alleles of  
 D2-Thr92Ala polymorphism in 154 patients with differentiated thyroid carcinoma. 
 Lines: regression lines; bars: 95% confidence intervals of regression lines.
b. Correlation between the natural logarithm of TSH and FT4 for the different alleles of D2-Thr92Ala  
 polymorphism in 154 patients with differentiated thyroid carcinoma. Lines: regression lines; bars: 95%  
 confidence intervals of regression lines.
c.c. Correlation between the natural logarithm of TSH and thyroxine dosage/kg for the different alleles of  
 D2-Thr92Ala polymorphism in 139 patients treated for Hashimoto thyroiditis. 
d.d. Correlation between the natural logarithm of TSH and FT4 for the different alleles of D2-Thr92Ala poly 
 morphism in 139 patients treated for Hashimoto thyroiditis.
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Discussion
We studied the association between the D2-Thr92Ala polymorphism and thyroid hormone 
levels and thyroxine dose in 2 separate groups of patients, treated for DTC or Hashimoto 
thyroiditis. Frequencies of the alleles of D2-Thr92Ala are in agreement with previous studies 
varying between 30-38.8 % in patient with normal thyroid function or not taking thyroid 
replacement or thyreostatic medication (3;4;6;7). The D2-Thr92Ala polymorphism was 
not associated with thyroid hormone parameters or thyroxine dosages in the 2 separate 
group of patients included in our analyses. This is in accordance with previous studies 
(4-7). Torlontano et al. found that homozygous DTC carriers of the D2-Ala92 allele need 
higher thyroxine dosages (8). This association was observed in the near-suppressed TSH 
group, but not in the suppressed group. The study of Torlontano et al. has however several 
limitations. TSH levels in the near-suppressed group of the different alleles were not given, 
which would have been useful to investigate whether the differences in thyroxine dose are 
not caused by alterations in TSH levels. In our study, no differences were observed in TSH 
levels or thyroxine dose for the different alleles with and without categorization according to 
the degree of TSH suppression in the DTC patients or Hashimoto patients. In addition, we 
believe that the analysis strategy should be primarily based on regression analysis rather 
than TSH categories, because for alterations in TSH levels should be corrected. 
Remarkably, they did not find any differences in thyroid hormone levels suggesting that 
patients with D2-Ala92 alleles need a higher thyroxine dose to reach the same serum FT4 
level. By inference, the Ala allele would not affect T4 feedback but rather T4 resorption. 
Torlontano et al. explain the discrepancies of their findings with previous studies by two 
arguments. First, they state that in previous studies thyroid hormone levels were within 
the wide reference range, which makes is difficult to detect subtle differences in thyroid 
hormone levels for different carriers of the D2-Thr92Ala polymorphism. However, they found 
this difference only in the near-suppressed group, which is an ill-defined group with a wide 
plasma TSH range including patients with normal TSH levels. Second, Torlontano et al. 
argue that the difference between their finding and earlier studies may be explained by 
the absence of a thyroid gland in their patients. However, in our analysis with athyroid DTC 
and Hashimoto patients, we could not confirm this. A posthoc power analysis for thyroxine 
dose and thyroxine/kg showed a sufficient power of 100 %. Therefore, it seems unlikely that 
underpowering of our study plays a major role in the negative findings. 
In summary, we found no association between the D2-Thr92Ala polymorphism and thyroid 
hormone levels and thyroxine dose in 2 separate groups of patients treated for DTC or 
Hashimoto thyroiditis. 
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I. Introduction
Patients with differentiated thyroid carcinoma (DTC) have an excellent prognosis due to 
the biological behaviour of the tumor as well as the efficacy of initial therapy. Although the 
recent publications of Dutch, European and American guidelines and consensus papers 
have improved the implementation of uniform protocols for diagnosis, treatment and follow-
up, still many uncertainties are present. Some of these uncertainties are related to the fact 
that DTC is a low prevalent disease, which makes the conductance of randomized trials 
difficult. Other limitations are due to the fact that DTC is a unique malignant disease in 
which fascinating biological phenomena are present, including the pathophysiology of iodide 
transport and (controlled) alterations in thyroid hormone levels, which makes that general 
principles of clinical oncology cannot always be extrapolated to DTC. Another aspect is the 
decentralised approach of the treatment of the disease. Despite the low incidence, many 
centers treat patients with DTC.  
Many uncertainties still exist with respect to the optimal follow-up strategy of DTC. In the 
context of DTC, most research is dealing with specific aspects of DTC detection and treatment. 
In this thesis, we have studied the diagnostic and prognostic value of serum thyroglobulin 
measurements. However, the main part of this thesis we focused on the consequences 
of thyroidectomy and subsequent thyroxin substitution therapy on physiological endpoints 
and quality of life in patients with DTC. DTC patients are treated with high doses of thyroxin 
to suppress thyrotropin (TSH) levels, because TSH is a growth factor for thyrocytes and 
increased TSH levels are associated with growth of residual thyroid cancer cells. However, 
long-term TSH suppression, which in fact represents a state of exogenous (subclinical) 
hyperthyroidism, may impact on bone metabolism, glucose metabolism, the autonomic 
nervous system and quality of life (Figure 1). 
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Figure 1 Overview of effects of subclinical hyperthyroidism on bone metabolism, glucose metabolism, the auto-
nomic nervous system and quality of life.
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During follow-up, patients are sometimes withdrawn of thyroxin replacement therapy 
or alternatively are treated by recombinant human TSH to assess residual or recurrence 
disease by TSH stimulated thyroglobulin levels and I131 scans. During thyroxin withdrawal, 
patients become overt hypothyroid, which may affect the systems mentioned above as well 
(Figure 2). 
In addition to the clinical consequences of hyper- and hypothyroidism, patients with DTC are 
a unique substitution-model to investigate the effects of exogenous thyroid hormones, both 
deficiency and excess, on bone metabolism, glucose metabolism, the autonomic nervous 
system and quality of life. In this thesis the effects of exogenous subclinical hyperthyroidism 
and thyroxin withdrawal on bone metabolism, glucose metabolism, the autonomic nervous 
system and quality of life are discussed. In addition, we will discuss deiodinase 2 activity in 
skeletal muscle samples during hypothyroidism. Furthermore, we studied the contribution of 
the deiodinase 2 Thr92Ala-polymorphism on bone metabolism and thyroxin dosage. 
II. Diagnostic & prognostic value of Thyroglobuline
Serum thyroglobulin (Tg) level is the most important diagnostic marker in the follow-up of 
DTC. Because a European consensus paper recommended to define institutional Tg cut-off 
levels and the prognostic value of Tg has been hardly studied, we investigated the prognostic 
and diagnostic value of thyroglobulin (Tg) measurements on recurrence and death in a large 
cohort of DTC patients by using ROC curves (chapter 2). Our findings indicate an excellent 
diagnostic accuracy of serum Tg values during TSH stimulation 6 months after initial therapy 
(sensitivity 100%), with a higher Tg cut-off level (10•0 µg/l) than commonly reported. The 
specificity and positive predictive value decreased considerably when the more commonly 
Figure 2. Effects of hypothyroidism on bone metabolism, glucose metabolism, the autonomic nervous system and 
Muscle D2 activity.
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Used cut-off level of 2 µg/l was used. Advantages of our study are the homogeneity of the 
patient group for initial therapy, the fact that multiple Tg measurements were analyzed at 
fixed time-points during follow-up, and the use of ROC analyses. The higher cut-off level may 
be explained by the lower initial ablation rate in our institute as compared to others. A Tg level 
pre-ablation of < 27•5 µg/l may predict cure irrespective of prognostic indicators such as 
stage T4, follicular histology, metastases and higher age. TSH-stimulated Tg measurements 
6 months after initial therapy and at 2 and 5 years after initial therapy were independent 
predictors of thyroid carcinoma-related death. We found a less than 100 % specificity of Tg, 
which may be explained by the limitations of current imaging techniques to detect thyroid 
carcinoma. We therefore agree with the policy to administer high dose of RaI to patients with 
elevated Tg levels. We believe that Tg should be considered as a risk indicator and should 
therefore be included in the conventional panel of risk factors. A limitation of our study is 
that the analysis is based on retrospective data. The prognostic Tg cut-off values should 
therefore be interpreted with caution and prospective research should be performed.
Clinical implications
Our study shows that it is important in the follow-up of DTC to define institutional Tg cut-
off levels. A Tg level during TSH stimulation 6 months after initial therapy has an excellent 
diagnostic value. Tg levels are an independent prognostic indicator of disease free remission 
and death and using this strategy, allows the identification of high-risk patients in addition to 
conventionally used prognostic indicators.
Perspective
The methodological imperfections and the inter-institutional differences of the Tg 
measurements create the need for newer methods to detect tumor recurrence. In our opinion, 
harmonization of Tg measurements between institutes, at national and international level 
should be stimulated. RT-PCR to detect cells that produce other thyroid specific proteins, 
such as TPO could be novel methods to detect recurrent disease. However, more research 
into this field is needed to evaluate the role of these markers in the follow-up of DTC.
13
 
Su
m
m
ar
y 
an
d 
ge
ne
ra
l d
is
cu
ss
io
n
Figure 3. Polymorphism in proteins involved in thyroid hormone metabolism and their effects on bone metabolism 
and thyroxin dose.
Polymorphisms
In proteins involved 
in thyroid hormone 
metabolism
D2-Thr92Ala TSH-Asp727Glu
Bone Metabolism:
Increased levels of indica-
tors of bone turnover 
(P1NP, Ctx, Ntx)
Lower BMD femoral neck
(Chapter 7)
Thyroxin dose:
No effect on thyroxin dose 
(Chapter 12)
Bone Metabolism:
Higher BMD
Probably mediated by BMI
(Chapter 5)
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III. Deiodinase 2 activity in skeletal muscle during hypothyroidism
Recently it was reported that D2 is a major source of T3 production during euthyroidism and 
could therefore play an important role during hypothyroidism (1). The peripheral conversion 
of T4 to T3 is increased during hypothyroidism, which might be the result of increased D2 
activity. In rats, increased conversion of T4 to T3 by D2 was observed during hypothyroidism 
(2). Animal studies have shown significantly increased D2 activity in the cerebral cortex 
and pituitary during hypothyroidism. Because D2 activity has been reported in human 
skeletal muscles, we investigated D2 activity and expression of D2 and D3 mRNA in skeletal 
muscle samples during hypothyroidism and thyroxin replacement therapy in DTC patients 
(chapter 3). We found little D2 activity in skeletal muscle samples and no differences were 
observed in D2 activity during hypothyroidism or after thyroxin replacement therapy. To 
rule out interfering effects of lidocaine on D2 activity in the skeletal muscle samples, we 
analyzed the effects of increasing lidocaine concentrations on D2 activity expressed in D2-
COS1 cells. This experiment showed no differences in D2 activity with increasing lidocaine 
concentrations. Nevertheless, we cannot exclude a local effect of lidocaine resulting in 
downregulation of D2 activity. No differences were observed in the expression of D2 and D3 
mRNA during hypothyroidism compared to thyroxin replacement therapy. For that reason, 
elevated D2 activity in other tissues or elevated D1 activity must be responsible for the 
increased conversion of T4 to T3 in hypothyroid subjects.
In summary, D2 activity and expression in human skeletal muscle samples is not regulated 
by thyroid status. The low D2 activities in human skeletal muscle question the physiological 
relevance of D2 activity for extrathyroidal T3 production.
IV. Bone metabolism
The impact of subclinical hyperthyroidism on bone metabolism in DTC patients is important 
because DTC is associated with a good prognosis and patients are therefore long-term 
treated with TSH suppressive therapy. Studies investigating this subject are inconsistent 
because of limitations in study design, variations in patient groups, methodology, follow-up 
time and choice of outcome parameters. Although there are numerous studies, no attempts 
have been made to categorize the studies according to the parameters mentioned above. 
We therefore performed a systematic review including all studies investigating the effect of 
subclinical hyperthyroidism on bone metabolism in DTC patients focusing on the changes in 
bone mineral density (BMD) (chapter 4). 
Most studies in premenopausal women and men found no differences in BMD during TSH 
suppressive therapy, whereas several studies in postmenopausal women reported changes 
in BMD. This may suggest that there is a clinical effect of TSH suppressive therapy on BMD 
in postmenopausal women. Other studies in postmenopausal women have not reported 
differences in BMD. This may be the result of the instability of TSH levels over the years (3) or 
of differences in additional determinants of BMD such as dietary factors, physical exercise, 
endogenous factors or genetic susceptibility. These determinants become relevant after the 
contribution of estrogens has disappeared in postmenopausal women. Estrogen deprivation 
results in an increased release of cytokines and therefore an increased production of M-CSF 
and RANKL, which are essential cytokines for the formation and activation of osteoclasts. 
Subclinical hyperthyroidism could enhance this effect (4-6).
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It was found that TSH reduced RANKL mRNA levels and increased OPG mRNA levels resulting 
In a decreased osteoclast formation and survival (4;7). TSH is suppressed during subclinical 
hyperthyroidism which could result in a decreased inhibition of bone resorption.
We also studied the relationship between TSH and indicators of bone turnover in 148 
thyroidectomized DTC patients (chapter 5). The advantage of DTC patients is that they have 
more uniform thyroid hormone levels. We found a significant inverse relationship between 
serum TSH levels and indicators of bone formation (bone specific alkaline phosphatase 
(BAP) and procollagen type 1 aminoterminal propeptide (P1NP)) and indicators of bone 
resorption (C-cross-linking terminal telopeptide of type 1 collagen (CTx) and N-telopeptide 
of collagen cross-links (NTx)), independently of serum thyroid hormone levels. There was 
no relationship between TSH levels and BMD. This could be explained by the fact that BMD 
is acquired by a lifelong process, whereas indicators of bone turnover reflect short-term 
effects. To detect instability of TSH levels over the years, we calculated the slope of TSH 
levels for each patient. The slope of TSH levels was -0.0001 (range -0.004 to 0) per year, 
indicating stable TSH levels over the years. 
The TSH-Asp727Glu polymorphism is associated with lower TSH levels, but not with differences 
in thyroid hormone levels (8;9). We, therefore, hypothesized that DTC patients with uniform 
TSH and thyroid hormone levels would be a good model to study the relationship between 
the TSH-Asp727Glu polymorphism and bone metabolism. We found significantly higher BMD 
in carriers of this polymorphism. However, after correction for BMI this relationship was no 
longer significant, which may suggest that the effect of the polymorphism is mediated by 
BMI. This is consistent with the study of van der Deure et al.(10). 
Nonetheless, controversy exists about the net contribution of TSH on BMD and bone 
metabolism (11;12). Bassett et al. found that thyroid hormone receptor (TR)-α knockout 
mice have osteosclerosis with decreased osteoclastic bone resorption in the presence 
of normal thyroid hormone- and TSH levels. TR-β knockout mice were osteoporotic with 
increased bone resorption in the presence of elevated thyroid hormone- and TSH levels. 
T3 target gene expression showed skeletal hypothyroidism in TRα knockout mice, whereas 
TRβ mice showed skeletal hyperthyroidism. Furthermore, Bassett et al. reported that Pax 
-/-  mice and hyt/hyt mice, two mouse models of congenital hypothyroidism in which the 
feedback between TSH and thyroid hormones was intact or disrupted, both displayed delayed 
ossification, reduced cortical bone, a trabecular bone remodeling defect and reduced bone 
mineralization, indicating that the effects of congenital hypothyroidism on bone are also 
independent of TSH (13). Moreover, they showed that osteoblasts and osteoclasts express 
TSH-receptors, but TSH did not affect a cAMP response or the differentiation or function 
(14).
To investigate the consequences of controlled hypothyroidism on bone metabolism and 
to discriminate between potential effects mediated by decreased thyroid hormone levels 
versus those mediated by increased TSH levels, we studied eleven DTC patients during 
short-term thyroxin withdrawal and 8 weeks after thyroxin replacement therapy versus 
eleven age-, gender- and BMI-matched DTC patients after injection with recombinant human 
TSH (rhTSH) resulting in increased TSH levels preserving normal thyroid hormone levels 
(chapter 6). To our knowledge, this is the first study comparing these two situations in age-, 
gender- and BMI-matched patients. During hypothyroidism, a significant decrease in C-cross-
linking terminal telopeptide of type I collagen levels was found accompanied by increased 
levels of osteoprotegerin (OPG), indicating decreased bone resorption. This is in agreement 
with most studies. After rhTSH-injections, no differences in indicators of bone metabolism 
were observed. A recent study found only a weak expression of the TSH receptor in human 
osteoblasts (15). This might explain why we found no differences in parameters of bone 
turnover after rhTSH injection.
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D2 activity is found in osteoblasts, which might imply a role for D2 in bone metabolism. 
Because the D2 Thr-92Ala polymorphism has been associated with a decreased enzyme 
velocity, we studied the relationship between the D2-Thr92Ala polymorphism and BMD and 
indicators of bone turnover in DTC patients (chapter 7). We found a 6% lower BMD of the 
femoral neck in the homozygote carriers of the D2-THr92Ala polymorphism. Furthermore, 
increased levels of indicators of bone formation (P1NP) and indicators of bone resorption 
(Ctx and Ntx) were observed in homozygote carriers independent of other determinants of 
bone metabolism, such as age, gender, BMI, estrogen status, calcium and vitamin D and 
also independent of TSH. This association was also independent of thyroid hormone levels 
indicating a true effect of the D2-Thr92Alal polymorphism. No relationship between the D2-
Thr92Alal polymorphism and BMD of the lumbar spine was observed, which may be explained 
by the fact that BMD measurements of the lumbar spine are influenced by osteoarthritis 
and therefore cannot be correctly assessed. A recent study found an association between 
the D2-Thr92Alal polymorphism and osteoarthritis strengthening the role for D2 in bone 
metabolism. As the D2-Thr92Ala polymorphism is associated with a lower enzyme velocity in 
vitro in thyroid and skeletal muscle samples, and T3 stimulates osteoblastic proliferation and 
osteoblasts are the primary T3 target cells that regulate bone turnover (16-20), we expected 
to find decreased bone turnover in homozygote carriers of the D2-Thr92Ala polymorphism. 
We found, however, increased bone turnover in homozygote carriers of the D2-Thr92Ala 
polymorphism. D2 activity is found in mature osteoblasts, but not in osteoclasts (21). For this 
reason, the increased bone resorption could not be explained by direct effects on osteoclasts 
but more likely, indirectly, through alterations in the interaction between osteoblasts and 
osteoclasts.  This study shows that the relationship between local T3 availability through the 
action of D2 and bone metabolism is complex, and can not be explained from the traditionally 
observed direct effects of T3 on bone cells. Multiple known and unknown components of the 
bone microenvironment may be involved. We believe the findings need to be reconfirmed in 
another study. However, as we used regression analysis to investigate this correlation and 
we corrected for all covariates, we feel that this study may add important data to the role of 
D2 and the D2-Thr92Ala polymorphism in bone metabolism.
In conclusion, we found no effect of TSH suppressive replacement therapy on bone mineral 
density in men and premenopausal women. However, postmenopausal women are at risk 
for osteoporosis. Although we found an inverse relationship between TSH and indicators of 
bone turnover in DTC patients on thyroxin replacement therapy, we found no effect of TSH on 
bone metabolism during TSH stimulation. This is in line with the studies of Bassett in mice. A 
possible explanation could be that in the cross-sectional study investigating the relationship 
between thyroid hormone levels and indicators of bone turnover postmenopausal women 
were included, whereas in the hypothyroidism study only men and premenopausal women 
were studied. Another explanation could be differences in study design, since we studied 
the effects hypothyroidism after short-term withdrawal (4 weeks), whereas the cross-
sectional study included patients treated long-term (median (range) 9.3 (1.2-43) years) with 
TSH suppressive therapy. We believe that alterations in thyroid hormone levels are of more 
importance for bone turnover then TSH levels. We found that homozygote carriers of the 
D2-Thr92Ala polymorphism have lower BMD of the femora neck with increased indicators 
of bone turnover. These results point to a functional role of D2 in humans for the local 
availability of T3 in bone. However, this association is complex and is probably explained 
indirectly by the interaction between osteoclasts and osteoblasts.
Clinical implications
Our findings indicate a higher risk for bone loss in post-menopausal women on TSH 
suppressive therapy. In these patients screening at baseline and regular intervals during 
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TSH suppressive therapy is advised to allow timely intervention with bone protective agents. 
Since we have reported a relationship between TSH and indicators of bone turnover, we 
believe that restoration to euthyroidism should be propagated in patients with low-risk of 
recurrence or after long-term follow-up. 
V. Glucose metabolism 
There are only limited data available on the consequences of subclinical hyperthyroidism 
on glucose metabolism. For that reason, we performed a prospective randomized placebo-
controlled study to investigate the effects of restoration of euthyroidism after long-term 
subclinical hyperthyroidism on glucose metabolism (Chapter 8). We found no effects of 
restoration to euthyroidism on several parameters of glucose- and lipid metabolism. The 
percentage of patients with impaired glucose tolerance assessed by the oral glucose 
tolerance test in our study (15.4%) was comparable with previous studies in the Netherlands 
and the USA (10.3% and 15.6%) (22)). Yavuz et al. (23) found a decreased insulin sensitivity 
index after 6 months of exogenous subclinical hyperthyroidism compared to matched 
controls, which is at odds with our study. These differences in outcome might be explained 
by differences in the duration of subclinical hyperthyroidism. We studied a population, that 
was treated for over 10 years with TSH suppressive therapy which might result in adaptation, 
whereas Yavuz et al. studied 20 patients with multinodular goitre who were treated for 6 
months (24). It could also be that the “dose” (the extent of subclinical hyperthyroidism) in 
our study was not relevant to result in a “response” (glucose intolerance). However, this 
explanation is unlikely, because TSH values in our study were comparable to the values in 
the study of Yavuz et al. 
In conclusion, we observed no effect of restoration of euthyroidism on glucose- or 
lipidmetabolsim in patients treated with long-term (>10 years) TSH suppressive therapy, 
which might imply that adaptation of glucose metabolism occurs in long-term TSH suppressive 
therapy.
VI. Autonomic nervous system 
In the literature, the consequences of subclinical hyperthyroidism on the autonomic nervous 
system are not clear. In addition, most studies are performed in heterogeneous patient 
populations in which the duration and course of subclinical hyperthyroidism are not known. 
Furthermore, thyreostatic drugs and the use of β-blockers may influence the effects on the 
autonomic nervous system. Consequently, we performed the first prospective, placebo-
controlled randomized study to investigate the effects of restoration of euthyroidism on the 
autonomic nervous system in patients with long-term exogenous subclinical hyperthyroidism 
(chapter 9). 
We found that subclinical hyperthyroidism was associated with a lower degree of activation 
of the autonomic nervous system when compared to euthyroid controls, whereas activation 
was higher than in hyperthyroidism. Urinary catecholamine excretion was higher during 
subclinical hyperthyroidism compared to euthyroid controls, whereas it was lower compared 
to hyperthyroidism. 
Restoration to euthyroidism in patients with long-term subclinical hyperthyroidism due to 
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TSH suppression had no effect on the autonomic nervous system. No differences were 
observed in urinary catecholamine excretion, heart rate variability parameters and the 
response to a mental stress test between the patients who remained on TSH suppression 
and those in whom biochemical euthyroidism was restored. Although, in all patients in the 
intervention-group (restoration to euthyroidism) TSH levels became within the normal range 
with a decrease in FT4 and FT3, restoration of euthyroidism in patients treated for more 
then 10 years with TSH suppressive therapy did not result in changes in the activity of the 
autonomic nervous system. An explanation could be that during long-term TSH suppressive 
therapy irreversible changes or adaptation occur, like we observed in glucose metabolism, 
or that restoration of the autonomic nervous system set-point takes longer than 6 months. 
In our study, the LF component was significant higher in patients compared to controls, 
whereas there were no differences in the HF component and the LF/HF power ratio 
between the patients compared to healthy controls. Other studies reported sympathovagal 
imbalance with increased sympathetic activity and a decreased vagal tone during 
(subclinical) hyperthyroidism characterized by an increased LF component (expressed in 
normalized units) and a decreased HF component resulting in an increased LF/HF power 
ratio (25-31). Possible explanations for the fact that the HRV spectrum had characteristics 
of hyperthyroidism despite normal mean TSH levels could be that the patients in the 
present study were treated for a long period (5.0 ± 7.1 years) with TSH suppressive thyroxin 
replacement therapy preceding the present study and it is plausible that irreversible changes 
or adaptation of the autonomic nervous were present. This would concur with other recent 
findings of our group which showed that long-term subclinical hyperthyroidism affects the 
autonomic nervous system and that these changes persist even after a 6 months-period of 
restoration to euthyroidism (32). 
We noticed however, a substantial difference between the patients and the controls in 
VLF, which could well be that this difference in the contribution of the VLF frequency band 
influenced our findings on the LF and HF component.
The response to a challenge of the autonomic nervous system, which seems to reveal the 
most prominent differences in the autonomic nervous system, was also investigated. We 
found no differences in the response to the mental stress test, which is a validated test to 
study the autonomic nervous system, during thyroxin replacement therapy as compared to 
the values mentioned in healthy controls. 
The impact of hypothyroidism on the autonomic nervous system is inconclusive. Current 
literature shows conflicting results with either increased sympathetic activity, decreased 
sympathetic modulation or increased vagal tone. For that reason, we investigated the 
effect of controlled hypothyroidism and reinstitution of thyroxin replacement therapy on 
the autonomic nervous system in DTC patients by measuring heart rate variability at rest 
and in response to a mental stress test. (chapter 10). The LF/HF power ratio, representing 
sympathovagal balance with lower levels suggesting sympathetic withdrawal (33), was 
significant lower during hypothyroidism compared to thyroxin replacement therapy, indicating 
sympathovagal imbalance with sympathetic withdrawal. The LF component tended to be 
lower during hypothyroidism compared to thyroxin replacement therapy. Although the LF 
component is associated with both sympathetic and vagal activity (33), other studies report 
that the LF component, especially when expressed in normalized units, reflects sympathetic 
activity (27;33;34). This is in agreement with the literature. No differences were observed in 
the response to a mental stress test during hypothyroidism compared to values in healthy 
controls.
In summary, long-term exogenous subclinical hyperthyroidism affects the autonomic nervous 
system as measured by heart rate variability and urinary catecholamine excretion, whereas 6 
months after restoration of euthyroidism no differences were observed which points out that 
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long-term TSH suppressive therapy may result in irreversible changes or adaptation. Short-
term hypothyroidism in thyreoidectomized patients results in a sympathovagal imbalance 
with sympathetic withdrawal during hypothyroidism. The cardiovascular reflexes to (mental) 
stress were however preserved
Clinical implications
Our findings indicate an adaptation of the autonomic nervous system to long-term TSH 
suppressive therapy, which is not repaired within 6 months of restoration to euthyroidism. 
We therefore believe that the need for long-term TSH suppressive therapy should be 
reconsidered carefully in DTC patients.
VII. Quality of life
Quality of life may be affected in DTC patients by either the diagnosis with initial therapy or 
TSH suppressive therapy. Several studies have investigated this subject, but these results 
are inconclusive. For that reason, we studied quality of life (QOL) in a large cohort of cured 
DTC patients using multiple quality of life questionnaires and compared the results to those 
found in healthy matched controls (chapter 11). Our findings indicate decreased QOL in 
DTC patients, which may be restored after years of follow-up. Longer duration of cure was 
associated with better scores on different quality of life items. Advantages of our study 
are the large number of patients included in the study, the use of multiple quality of life 
questionnaires and comparison with matched health controls. 
The consequences of subclinical hyperthyroidism on QOL are less clear (35-37). Studies 
investigating this subject included selected groups of DTC patients or patients with 
endogenous subclinical hyperthyroidism in which the duration and course of subclinical 
hyperthyroidism are not known. In our study, QOL was not affected by alterations in TSH 
levels at time of the survey or over time since initial therapy. 
In summary, QOL is affected in a large cohort of cured DTC patients compared to healthy 
matched controls. Only long duration of cure could normalize these effects.
Clinical implications
Clinicians should be aware that despite the good prognosis psychological well-being of 
cured DTC patients can be affected for years and should provide professional support when 
necessary.
VIII. D2-Thr92Ala and thyroxin dose
Controversy exists on the functional implications of the D2-Thr92Alal polymorphism. We 
investigated the association between this D2-Thr92Ala polymorphism, thyroid hormone 
levels and thyroxin dose in 2 separate groups of patients: athyroid patients after treatment 
for DTC or patients with Hashimoto thyroiditis (chapter 12). The D2-Thr92Ala polymorphism 
was not associated with thyroid hormone parameters or thyroxin dosages in the 2 separate 
groups of patients included in our analyses, which is in agreement with previous studies. 
However, Torlontano et al. reported that homozygous DTC carriers of the D2-Ala92 allele 
need higher thyroxin dosages (38), which was present in the near-suppressed TSH group, 
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but not in the suppressed group. Limitations of their study were the absence of data on TSH 
levels in the near-suppressed group and the analysis strategy, which should be primarily 
based on regression analysis, rather than TSH categories.  It is noteworthy, that Torlontano 
et al. did not find any differences in thyroid hormone levels suggesting that patients with 
D2-Ala92 alleles need a higher thyroxin dose to reach the same serum FT4 level indicating 
that the Ala allele would affect T4 resorption instead of T4 feedback. Furthermore, the 
association between the D2-Thr92Ala polymorphism and thyroxin dose was only found in the 
TSH suppressive group, which is an ill-defined group with a wide plasma TSH range including 
patients with normal TSH levels. 
In conclusion, we found no association between the D2-Thr92Ala polymorphism and thyroxin 
dose in athyroid patients and Hashimoto thyroiditis patients.
193
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I. Inleiding
Patiënten met gedifferentieerd schildkliercarcinoom hebben een goede prognose. Dit is 
het gevolg van een combinatie van het biologische gedrag van de tumor en de effectiviteit 
van de initiële behandeling. Hoewel de implementatie van uniforme protocollen voor 
diagnose, behandeling en follow-up van gedifferentieerd schildkliercarcinoom is verbeterd 
door recente publicaties van Nederlandse, Europese en Amerikaanse richtlijnen, zijn 
er nog veel beperkingen aanwezig. Sommige beperkingen zijn het gevolg van het feit 
dat de prevalentie van gedifferentieerd schildkliercarcinoom laag is, wat het moeilijk 
maakt om gerandomiseerde trials uit te voeren. Andere beperkingen zijn het gevolg van 
het feit dat gedifferentieerd schildkliercarcinoom een bijzondere maligne ziekte is met 
fascinerende biologische fenomenen, zoals de pathofysiologie van het jodide-transport 
en (gecontroleerde) veranderingen in de schildklierhormoonwaarden. Deze zorgen er voor 
dat de meest algemene principes van de oncologie niet geëxtrapoleerd kunnen worden 
naar gedifferentieerd schildkliercarcinoom. Een ander probleem is de gedecentraliseerde 
aanpak van deze ziekte. Ondanks de lage incidentie behandelen vele centra patiënten met 
gedifferentieerd schildkliercarcinoom. 
Er bestaan veel onzekerheden over de optimale follow-up strategie van gedifferentieerd 
schildkliercarcinoom. Het meeste onderzoek wordt gedaan naar de detectie en behandeling 
van gedifferentieerd schildkliercarcinoom. In dit proefschrift hebben we de diagnostische 
en prognostische waarde van thyreoglobuline onderzocht. Echter, het grootste gedeelte 
van het proefschrift richt zich op de consequenties van een thyreoïdectomie en 
schildklierhormoonsubstitutie op metabole eindpunten en op de kwaliteit-van-leven in 
patiënten met gedifferentieerd schildkliercarcinoom. Patiënten met gedifferentieerd 
schildkliercarcinoom worden behandeld met een hoge dosis schildklierhormoon om het 
TSH te onderdrukken, omdat TSH de groei van eventueel achtergebleven tumorcellen kan 
stimuleren. Dit weerspiegelt in feite een status van subklinische hyperthyreoïdie en kan 
gevolgen hebben voor het botmetabolisme, glucosemetabolisme, het autonome zenuwstelsel 
en de kwaliteit-van-leven.
Tijdens de follow-up van gedifferentieerd schildkliercarcinoom wordt schildklierhormoon 
soms onthouden aan patiënten of wordt de patiënt behandeld met recombinant humaan 
TSH om een eventuele tumorrest of recidief te ontdekken. Tijdens het onthouden 
van schildklierhormoon worden patiënten hypothyreoot, wat het botmetabolisme, 
glucosemetabolisme en autonome zenuwstelsel ook kan beïnvloeden. 
Patiënten met gedifferentieerd schildkliercarcinoom vormen een uniek substitutiemodel 
om het effect van exogeen schildklierhormoon, overmaat en deficiëntie, op de hierboven 
genoemde systemen te onderzoeken. In dit proefschrift worden de effecten van exogene 
subklinische hyperthyreoïdie en het onthouden van schildklierhormoon op het botmetabolisme, 
glucosemetabolisme, autonome zenuwstelsel en kwaliteit-van-leven besproken. Tevens zal 
de deiodinase 2 activiteit in skeletspierweefsel tijdens hypothyreoïdie worden besproken. 
Verder zal het effect van het D2-Thr92Ala polymorfisme op het botmetabolisme en de 
gevolgen voor de toe te dienen schildklierhormoondosis worden bediscussieerd. 
II. Diagnostische & prognostische waarde van thyreoglobuline
Serum thyreoglobuline (Tg) metingen zijn de belangrijkste marker in de follow-up van 
gedifferentieerd schildkliercarcinoom. Een Europese consensus heeft geadviseerd om 
institutionele Tg afkapwaarden te definiëren. Daarnaast is de prognostische waarde van Tg 
nauwelijks onderzocht. 
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Daarom hebben we de prognostische en diagnostische waarde van Tg metingen voor 
recidief en overlijden onderzocht in een groot cohort van patiënten met gedifferentieerd 
schildkliercarcinoom met behulp van ROC curven (hoofdstuk 2). Onze resultaten tonen 
een hoge sensitiviteit (100 %) van Tg-waarden onder TSH stimulatie 6 maanden na initiële 
behandeling met een hogere Tg-afkapwaarde (10.0 µg/l) dan normaal wordt gebruikt. De 
specificiteit en de positief voorspellende waarde daalden aanzienlijk wanneer de meer 
gangbare Tg-afkapwaarde van 2.0 µg/l werd gebruikt. Voordelen van onze studie zijn de 
homogeniteit van de studiepopulatie met betrekking tot de initiële behandeling, het feit 
dat meerdere Tg metingen werden geanalyseerd op specifieke tijdstippen tijdens de follow-
up en het gebruik van ROC-curven tijdens de analyse. De hogere Tg-afkapwaarde kan 
verklaard worden door het lagere initiële I-131 ablatiepercentage in ons instituut vergeleken 
met andere instituten. Een Tg-waarde vóór de I-131 ablatie kleiner dan 27.5 µg/l voorspelt 
curatie onafhankelijk van andere prognostische factoren zoals stadium T4, folliculaire 
histologie, metastasen en hogere leeftijd. TSH gestimuleerde Tg metingen 6 maanden na 
initiële behandeling en 2 en 5 jaar na initiële behandeling waren onafhankelijke voorspellers 
van overlijden gerelateerd aan gedifferentieerd schildkliercarcinoom . We vonden een 
specificiteit van minder dan 100 %, welke verklaard kan worden door de beperkingen van de 
huidige beeldvormende technologieën om tumor recidief te ontdekken. Wij zijn het daarom 
eens met het beleid om patiënten met verhoogde Tg-waarden te behandelen met een hoge 
dosis I-131. Verder, geloven wij dat Tg zou moeten worden gezien als een risico-indicator en 
daarom zou moeten worden geïncludeerd in het panel van risicofactoren. Een beperking 
van onze studie is dat de analyses gebaseerd zijn op retrospectieve data. De prognostische 
waarde van Tg afkapwaarden moet daarom met voorzichtigheid worden geïnterpreteerd en 
hiernaar zal prospectief onderzoek moeten worden verricht.
Klinische implicaties
Onze studie toont aan dat het definiëren van institutionele Tg-afkapwaarden belangrijk is in 
de follow-up van gedifferentieerd schildkliercarcinoom. Een Tg-meting onder TSH stimulatie 
6 maanden na initiële behandeling heeft een uitstekende diagnostische waarde. Tevens zijn 
Tg-waarden onafhankelijke prognostische indicators van ziektevrije regressie en overlijden 
en door deze strategie te gebruiken kunnen groepen patiënten met een hoog risico worden 
geïdentificeerd als aanvulling op de conventioneel gebruikte prognostische indicatoren. 
Perspectief
De methodologische tekortkomingen en de inter-institutionele verschillen van de Tg-metingen 
creëren de behoefte aan nieuwe methodes om tumorrecidief te ontdekken. Naar onze 
mening moet harmonisatie van Tg-metingen tussen instituten, op nationaal en internationaal 
niveau, worden nagestreefd. RT-PCR die cellen die schildklier specifieke eiwitten, zoals 
TPO, produceren detecteert, zou een nieuwe marker kunnen zijn om tumorrecidieven te 
detecteren. Echter, meer onderzoek naar de rol van deze nieuwe methoden in de follow-up 
van gedifferentieerd schildkliercarcinoom is nodig. 
III. Deiodinase 2 activiteit in skeletspier tijdens hypothyreoïdie
Recentelijk is er beschreven dat D2 een grote rol speelt in de T3 productie tijdens 
euthyreoïdie en hierdoor kan D2 ook een belangrijke rol spelen tijdens hypothyreoïdie. De 
perifere conversie van T4 naar T3 is verhoogd tijdens hypothyreoïdie, wat het resultaat kan 
zijn van verhoogde D2-activiteit. 
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In ratten werd er een verhoogde conversie van T4 naar T3 door D2 aangetoond tijdens 
hypothyreoïdie. Dierenstudies tonen een significant verhoogde D2-activiteit in de cerebrale 
cortex en hypofyse aan tijdens hypothyreoïdie. Omdat D2-activiteit is gevonden in skeletspier 
van de mens, hebben we D2-activiteit en expressie van D2 en D3 mRNA in skeletspier 
tijdens hypothyreoïdie en na schildklierhormoonsubstitutie onderzocht in patiënten met 
gedifferentieerd schildkliercarcinoom (hoofdstuk 3). We vonden weinig D2-activiteit in 
skeletspier en geen verschillen tussen hypothyreoïdie en na schildklierhormoonsubstitutie. 
Om een interfererend effect van lidocaïne op D2-activiteit uit te sluiten, werd de D2-activiteit 
in D2-COS1-cellen bij stijgende lidocaïne concentraties gemeten. Er werden geen verschillen 
in D2-activiteit waargenomen. Desondanks kunnen we een locaal direct effect van lidocaïne, 
dat tot een verlaging van de D2-activiteit zou kunnen leiden, niet uitsluiten. Er werden 
geen verschillen gevonden tussen de expressie van D2 of D3 mRNA in skeletspier tijdens 
hypothyreoïdie en schildklierhormoonsubstitutie. Daarom is een verhoogde D2-activiteit in 
andere weefsels waarschijnlijk verantwoordelijk voor de verhoogde omzetting van T4 naar 
T3 in hypothyreote mensen. 
Samenvattend, D2-activiteit en -expressie worden niet beïnvloed door de 
schildklierhormoonstatus. De waargenomen lage D2-activiteit maakt de relevantie van D2-
activiteit in skeletspier van de mens op de T3 productie buiten de schildklier twijfelachtig.
IV. Botmetabolisme
Het effect van subklinische hyperthyreoïdie op het botmetabolisme is een relevant vraagstuk, 
want patiënten met gedifferentieerd schildkliercarcinoom hebben een goede prognose en 
worden daarom langdurig behandeld met TSH-onderdrukkend schildklierhormoonsubstitutie. 
Bestaande studies zijn inconsistent door gebreken in studieontwerp, de geïncludeerde 
patiëntengroepen, de gebruikte methodologie, de duur van de follow-up en de keuze van 
uitkomstparameters. Hoewel er meerdere studies over dit onderwerp zijn verschenen, 
zijn er geen studies geweest die deze studies categoriseren naar de hierboven genoemde 
parameters. Daarom bespreken wij systematisch alle studies die het effect van subklinische 
hyperthyreoïdie op het botmetabolisme onderzochten met het zwaartepunt op veranderingen 
in botdichtheid (hoofdstuk 4). 
De meeste studies in premenopausale vrouwen en mannen lieten geen veranderingen in 
de botdichtheid zien tijdens TSH onderdrukkende behandeling, terwijl enkele studies in 
postmenopausale vrouwen wel een verandering in botdichtheid aangeven. Dit kan erop 
wijzen dat er een klinisch effect is van TSH onderdrukkende behandeling op de botdichtheid 
in postmenopausale vrouwen. Andere studies laten geen verandering in de botdichtheid in 
postmenopausale vrouwen zien. Dit kan het gevolg zijn van de instabiliteit van TSH-waarden 
van jaar tot jaar of van verschillen in additionele determinanten van de botdichtheid 
zoals voedselinname, lichaamsbeweging, endogene factoren of genetische aanleg. Deze 
determinanten worden relevant als de bijdrage van de oestrogenen is verdwenen in 
postmenopausale vrouwen. Het gebrek aan oestrogenen resulteert in een verhoogde 
vrijlating van cytokines en daardoor een verhoogde productie van M-CSF en RANKL, welke 
essentiële cytokines zijn voor de botvorming en de activatie van osteoclasten. Subklinische 
hyperthyreoïdie kan dit effect vergroten. TSH kan de RANKL mRNA-waarden verlagen 
en de OPG mRNA-waarden verhogen, wat leidt tot een verlaagde osteoclastvorming en -
overleving. TSH wordt onderdrukt tijdens subklinische hyperthyreoïdie, wat kan leiden tot 
een verminderde remming van de botresorptie. 
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We onderzochten ook de relatie tussen TSH en indicators van het botmetabolisme in 148 
patiënten met gedifferentieerd schildkliercarcinoom (hoofdstuk 5). Het voordeel van een 
studie in patiënten met gedifferentieerd schildkliercarcinoom is dat deze patiënten meer 
uniforme schildklierhormoonwaarden hebben. We vonden een significante omgekeerde 
relatie tussen serum TSH-waarden en parameters van zowel botvorming (bot-specifiek 
alkalisch fosfatase (BAP) en procollageen type 1 aminoterminal propeptide (P1NP)) 
als parameters van botresorptie (C-cross-linkende terminal telopeptide van type 1 
collageen (Ctx) en N telopeptide van collageen cross-links (Ntx)), onafhankelijk van serum 
schildklierhormoonwaarden. Er werd geen relatie gevonden tussen TSH-waarden en 
botdichtheid. Dit kan verklaard worden door het feit dat botdichtheid bepaald wordt door 
levenslange processen, terwijl de parameters van het botmetabolisme de korte termijn 
effecten reflecteren. Om instabiliteit van de TSH-waarden van jaar tot jaar te ontdekken werd 
de gradiënt van de TSH-waarden per patiënt berekend. De gemiddelde gradiënt was -0.0001 
(bereik -0.0004 tot 0) per jaar, wat aantoont dat de TSH-waarden stabiel waren. Het TSH-
Asp727Glu polymorfisme wordt geassocieerd met lagere TSH-waarden zonder verschillen 
in schildklierhormoonwaarden. Omdat patiënten met gedifferentieerd schildkliercarcinoom 
meer uniforme TSH- en schildklierhormoonwaarden hebben, onderzochten we de relatie 
tussen het TSH-ASP727Glu polymorfisme en botmetabolisme. Een significant hogere 
botdichtheid werd gevonden in dragers van het polymorfisme. Echter, na correctie voor body 
mass index was deze relatie niet meer significant, wat suggereert dat het effect van het 
polymorfisme wordt gemedieerd via de body mass index. Dit is in overeenstemming met de 
studie van Van der Deure et al. 
Er bestaat echter onduidelijkheid over de bijdrage van TSH aan de botdichtheid en aan het 
botmetabolisme. Bassett et al. vonden dat muizen die geen schildklierhormoonreceptor-
α hebben (TRα knock-out) osteosclerose met een verminderde botresorptie door de 
osteoclasten hebben in de aanwezigheid van normale schildklierhormoon- en TSH-
waarden. Muizen die geen schildklierhormoonreceptor-β hadden (TRβ knock-out), waren 
osteoporotisch in de aanwezigheid van verhoogde schildklierhormoon- en TSH-waarden. T3-
gen-expressie toonde hypothyreoïdie in het skelet van de TRα knock-out muizen, terwijl de 
TRβ knock-out muizen hyperthyreoïdie van het skelet toonden. Bassett et al. beschreven ook 
dat Pax -/- muizen en hyt/hyt muizen -twee muizenmodellen voor congenitale hypothyreoïdie 
waarbij de feedback tussen TSH en schildklierhormoon intact of beschadigd is- beiden 
verlate verkalking, verminderd corticaal bot, een gebrek in de trabeculaire bothervorming 
en verminderde botmineralisatie vertoonden, wat er op wijst dat de effecten van congenitale 
hypothyreoïdie op het botmetabolisme onafhankelijk van TSH zijn. Verder toonden zij aan 
dat osteoblasten en osteoclasten een TSH-receptor hebben, maar TSH had geen effect op 
de cAMP response, differentiatie of functie. 
Om de effecten van gecontroleerde hypothyreoïdie op het botmetabolisme te onderzoeken 
en om onderscheid te maken tussen de effecten gemedieerd door de verlaagde 
schildklierhormoonwaarden versus de effecten gemedieerd door de hoge TSH-waarden, 
onderzochten we 11 patiënten met gedifferentieerd schildkliercarcinoom tijdens het 
korte termijn onthouden van schildklierhormoon en 8 weken na het herstarten van 
schildklierhormoonsubstitutie versus 11 leeftijd-, geslacht- en BMI- gematchte patiënten met 
gedifferentieerd schildkliercarcinoom na injectie met recombinant menselijk TSH (rhTSH), 
wat leidt tot hoge TSH-waarden met ongewijzigde schildklierhormoonwaarden (hoofdstuk 
6). Voor zo ver wij weten, is dit de eerste studie die beide situaties vergelijkt in leeftijd-, 
geslacht- en BMI-gematchte patiënten. Tijdens hypothyreoïdie werden er significant lagere 
Ctx-waarden gevonden met significant hogere OPG-waarden, wat wijst op een verminderde 
botresorptie. Dit stemt overeen met andere studies. Na injectie met rhTSH werden er geen 
verschillen in parameters van het botmetabolisme gevonden. Een recente studie vond een 
zwakke expressie van de TSH-receptor in menselijke osteoblasten. Dit kan onze bevindingen 
verklaren. 
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D2-activiteit is ook gevonden in osteoblasten, waardoor er een mogelijke rol voor D2 in 
het botmetabolisme kan zijn. Omdat het D2-Thr92Ala polymorfisme wordt geassocieerd 
met een verminderde enzymsnelheid, onderzochten wij de relatie tussen het D2-Thr92Ala 
polymorfisme en botmetabolisme in patiënten met gedifferentieerd schildkliercarcinoom 
(hoofdstuk 7). We vonden een 6% lagere botdichtheid van de heup in de homozygote 
dragers van het D2-Thr92Ala polymorfisme. Tevens werden er verhoogde parameters van 
botvorming (P1NP) en botresorptie (Ctx en Ntx) gevonden in de homozygote dragers van 
het polymorfisme onafhankelijk van andere determinanten van het botmetabolisme zoals 
leeftijd, geslacht, BMI, oestrogeen status, calcium- en vitamine D-intake en onafhankelijk 
van TSH. Deze relatie was ook onafhankelijk van de schildklierhormoonwaarden wat wijst 
op een reëel effect van het D2-Thr92Ala polymorfisme. 
Er werd geen relatie gevonden tussen het D2-Thr92Ala polymorfisme en de botdichtheid van 
de lumbale wervelkolom. Dit kan verklaard worden door het feit dat botdichtheidmetingen van 
de lumbale wervelkolom kunnen worden beïnvloed door artrose en daarom niet nauwkeurig 
kunnen worden bepaald. Een recente studie vond een relatie tussen het D2-Thr92ala 
polymorfisme en artrose, wat de rol van D2 in het botmetabolisme versterkt. We hadden 
verwacht een lagere bot-turnover te vinden in homozygote dragers van het D2-Thr92Alal 
polymorfisme, omdat het D2-Thr92Alal polymorfisme wordt geassocieerd met een lagere 
enzymsnelheid in vitro in de schildklier en skeletspier, omdat T3 de osteoblast proliferatie 
stimuleert en omdat T3 zich primair richt op de osteoblasten. We vonden echter een 
verhoogde bot-turnover in de homozygote dragers van het D2-thr92Ala polymorfisme. D2-
activiteit is gevonden in volgroeide osteoblasten, echter niet in osteoclasten. De verhoogde 
botresorptie kan daarom niet verklaard worden door een direct effect op osteoclasten, 
maar waarschijnlijk wel, indirect, door veranderingen in de interactie tussen osteoblasten 
en osteoclasten. Deze studie laat zien dat de relatie tussen de lokale T3-beschikbaarheid 
door D2-activiteit en botmetabolisme complex is en niet kan worden verklaard door de 
traditioneel waargenomen directe effecten van T3 op bot. Vele bekende en onbekende 
componenten van het micromilieu van het bot kunnen hierbij betrokken zijn. Wij geloven 
dat onze bevindingen in andere studies moeten worden herbevestigd. Echter, aangezien we 
multipele regressie analyses gebruiken om deze associatie te onderzoeken en aangezien 
we gecorrigeerd hebben voor alle covariaten geloven wij dat deze studie belangrijke data 
kan toevoegen met betrekking tot de rol van D2 en het D2-Thr92Ala polymorfisme op het 
botmetabolisme. 
We kunnen concluderen dat er geen effect werd gevonden van TSH suppressieve therapie op 
de botdichtheid in mannen en premenopausale vrouwen. Echter, postmenopausale vrouwen 
lopen een groter risico op osteoporose. Hoewel we een relatie tussen TSH en parameters 
van het botmetabolisme vonden in patiënten met gedifferentieerd schildkliercarcinoom, 
werd er geen effect gevonden van TSH op het botmetabolisme tijdens stimulatie met 
TSH. Dit is consistent met de studie van Bassett et al. in muizen. Een mogelijke verklaring 
voor dit verschil zou kunnen zijn dat in de cross-sectionele studie waarin we de relatie 
tussen schildklierhormoonwaarden en indicatoren van botmetabolisme onderzochten 
postmenopausale vrouwen werden geïncludeerd, terwijl in de hypothyreoïdie-studie maar 
2 postmenopausale vrouwen werden bestudeerd. Een andere verklaring zou het verschil 
in studieontwerp kunnen zijn, aangezien de effecten van hypothyreoïdie op korte-termijn (4 
weken) werden onderzocht, terwijl in de cross-sectionele studie patiënten met langdurige 
(mediaan (range) 9.3 (1.2-43) jaar) TSH suppressieve therapie werden behandeld. Wij 
geloven dat de veranderingen in schildklierhormoonwaarden een belangrijker effect hebben 
op het botmetabolisme dan veranderingen in TSH-waarden. We vonden dat homozygote 
dragers van het D2-Thr92Ala polymorfisme een lagere botdichtheid van de femur hadden 
met verhoogde parameters van de bot turnover. Deze resultaten tonen aan dat D2 een 
functionele rol heeft in mensen voor de locale beschikbaarheid van T3 in bot. Echter, deze 
associatie is complex en wordt waarschijnlijk indirect verklaard door een interactie tussen 
osteoclasten en osteoblasten. 
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Klinische implementatie
Onze bevindingen wijzen op een groter risico op osteoporose in postmenopausale vrouwen 
die behandeld worden met TSH suppressieve therapie. In deze patiënten is screening op 
baseline en tijdens regelmatige intervallen tijdens de TSH suppressieve therapie geadviseerd 
om vroegtijdig te kunnen behandelen met botbeschermers. Aangezien we een relatie tussen 
TSH en parameters van de bot-turnover hebben aangetoond, geloven wij dat herstel van 
euthyreoïdie moet worden gepropageerd in patiënten met een laag risico op recidief of na 
langdurige follow-up.
V. Glucose metabolisme
Er is maar weinig data beschikbaar over de gevolgen van subklinische hyperthyreoïdie op 
het glucosemetabolisme. Daarom hebben we een prospectieve, gerandomniseerde placebo-
gecontrolleerde studie uitgevoerd om de effecten van herstel van euthyreoïdie na langdurige 
subklinische hyperthyreoïdie op het glucosemetabolisme te onderzoeken (Hoofdstuk 
8). We vonden geen effect van herstel van euthyreoïdie op parameters van het glucose- 
en vetmetabolisme. Het percentage van patiënten met een gestoorde glucosetolerantie, 
gemeten met de orale glucose tolerantie test, was 15.4 % in onze studie, en is vergelijkbaar 
met vorige studies in Nederland en Amerika (10.3 % en 15.6%). Yavuz et al. vonden, in 
tegenstelling tot onze studie, een verminderde insuline gevoeligheid index na 6 maanden 
van exogene subklinische hyperthyreoïdie vergeleken met gematchte gezonde vrijwilligers. 
De verschillen in uitkomst zouden kunnen worden verklaard door verschillen in de duur 
van de hyperthyreoïdie. We onderzochten een populatie die meer dan 10 jaar behandeld 
was met subklinische hyperthyreoïdie, terwijl Yavuz et al. 20 patiënten onderzocht die 6 
maanden behandeld werden. Een andere verklaring zou kunnen zijn dat de “dosis”(de mate 
van subklinische hyperthyreoïdie) in onze studie niet hoog genoeg was om te resulteren in 
een “response” (glucose intolerantie). Echter, deze verklaring is onwaarschijnlijk, omdat de 
TSH-waarden in onze studie vergelijkbaar zijn met de waarden van Yavuz et al.
Concluderend, we vonden geen effect op glucose- en vetmetabolisme van herstel van 
euthyreoïdie in patiënten die langdurig (>10 jaar) behandeld werden met TSH suppressieve 
therapie, wat mogelijk kan wijzen op adaptatie van het glucosemetabolisme na langdurige 
TSH suppressieve therapie.
VI. Autonome zenuwstelsel
In de literatuur zijn de consequenties van subklinische hyperthyreoïdie op het autonome 
zenuwstelsel niet duidelijk. Bovendien zijn de meeste studies uitgevoerd in heterogene 
patiëntenpopulaties waarin de duur en het beloop van de subklinische hyperthyreoïdie niet 
bekend zijn. Verder kan het gebruik van thyreostatica en β-blokkers ook invloed hebben op 
het autonome zenuwstelsel. Daarom hebben wij de eerste prospectieve, gerandomniseerde, 
placebo-gecontrolleerde studie verricht naar het effect van het herstel van euthyreoïdie op het 
autonome zenuwstelsel in patiënten met langdurige exogene subklinische hyperthyreoïdie 
(hoofdstuk 9).
We vonden dat subklinische hyperthyreoïdie werd geassocieerd met een lagere activatie van 
het autonome zenuwstelsel vergeleken met gezonde vrijwilligers, terwijl de activatie hoger 
was vergeleken met patiënten met hyperthyreoïdie. 
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De cathecholamine-excretie in de urine was hoger tijdens subklinische hyperthyreoïdie 
vergeleken met gezonde vrijwilligers, terwijl deze lager was vergeleken met 
hyperthyreoïdie. 
Herstel van euthyreoïdie in patiënten met langdurige subklinische hyperthyreoïdie door TSH 
suppressieve therapie had geen effect op het autonome zenuwstelsel. Er werd geen verschil 
gezien in de cathecholamine-excretie in de urine, parameters van hartritme variabiliteit en 
de response op een mentale stress test tussen patiënten die TSH gesupprimeerd bleven 
en patiënten in wie euthyreoïdie werd hersteld. Hoewel de TSH-waarden van alle patiënten 
in de interventiegroep (herstel van euthyreoïdie) binnen de normale range kwamen met 
een daling van het FT4 en FT3, resulteerde het herstel van euthyreoïdie in patiënten die 
meer dan 10 jaar behandeld werden met TSH suppressieve therapie niet in veranderingen 
in de activatie van het autonome zenuwstelsel. Een verklaring zou kunnen zijn dat tijdens 
langdurige TSH suppressieve therapie irreversibele veranderingen of adaptatie ontstaat, 
zoals we hebben gezien in het glucosemetabolisme, of dat herstel van de setpoints van het 
autonome zenuwstelsel langer duurt dan 6 maanden.
In de patiënten die 8 weken behandeld zijn met schildklierhormoonsubstitutie na kortdurende 
hypothyreoïdie was het LF component significant hoger vergeleken met gezonde euthyreote 
vrijwilligers, terwijl er geen verschillen werden gevonden in het HF component of de LF/
HF ratio. Andere studies hebben een sympatovagale onevenwichtigheid getoond tijdens 
(subklinische) hyperthyreoïdie met een verhoogde sympaticus activiteit en een verlaagde 
vagale tonus gekenmerkt door een verhoogde LF component en een verlaagde HF component 
resulterend in een verhoogde LF/HF ratio. Een mogelijke verklaring voor het feit dat het HRV 
spectrum kenmerken heeft van hyperthyreoïdie terwijl de gemiddelde TSH-waarde binnen 
de referentiewaarden valt, zou kunnen zijn dat de patiënten langdurig zijn behandeld met 
TSH supprimerende schildklierhormoonsubstitutie en dit kan geleid hebben tot irreversibele 
veranderingen of adaptatie van het autonome zenuwstelsel. Dit komt overeen met onze 
eerder genoemde studie. We merkten echter ook op dat er een significant verschil was in 
de hele lage frequentie component tussen patiënten en gezonde vrijwilligers, wat ook onze 
bevindingen van de HF en LF component kan hebben beïnvloed. 
De response op een uitdaging van het autonome zenuwstelsel, die de meest prominente 
verschillen in het autonome zenuwstelsel lijkt te openbaren, werd ook onderzocht. We 
vonden geen verschil in de response op een mentale stress test, die een gevalideerde test 
is om het autonome zenuwstelsel te onderzoeken, tijdens schildklierhormoonsubstitutie 
vergeleken met gezonde vrijwilligers. 
De impact van hypothyreoïdie op het autonome zenuwstelsel is onduidelijk. De huidige literatuur 
laat tegenstrijdige resultaten zien met een verhoogde sympaticus activiteit, een verlaagde 
sympaticus modulatie of een verhoogde vagale tonus. Daarom hebben we het effect van 
kortdurende gecontroleerde hypothyreoïdie en herstarten van schildklierhormoonsubstitutie 
op het autonome zenuwstelsel onderzocht door hartritme variabiliteit te meten in rust en na 
een mentale stress test (Hoofdstuk 10). We vonden een verlaagde LF/HF ratio met een 
verlaagde LF component en een verhoogde HF component tijdens hypothyreoïdie vergeleken 
met schildklierhormoonsubstitutie, wijzende op een sympatovagale onevenwichtigheid met 
een verlaagde sympaticus activiteit en een verhoogde vagale tonus tijdens hypothyreoïdie 
vergeleken met schildklierhormoonsubstitutie. Dit komt overeen met de literatuur. Er werden 
geen verschillen gezien in de response op een mentale stress test tijdens hypothyreoïdie 
vergeleken met gezonde vrijwilligers.
Samengevat, langdurige exogene subklinische hyperthyreoïdie heeft invloed op het autonome 
zenuwstelsel, gemeten met hartritme variabiliteit en de urine excretie van catecholamines. 
Zes maanden herstel van euthyreoïdie toonde geen veranderingen in het autonome 
zenuwstelsel, wat er op wijst dat langdurige TSH suppressieve therapie kan resulteren in 
irreversibele veranderingen of adaptatie. 
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Kortdurende gecontroleerde hypothyreoïdie werd geassocieerd met een sympatovagale 
onevenwichtigheid met een verminderde sympathicus activiteit. De cardiovasculaire reflex 
op (mentale ) stress was echter onveranderd.
Klinische implementaties
Onze bevindingen wijzen op een adaptatie van het autonome zenuwstelsel na langdurige 
TSH suppressieve therapie, welke niet hersteld 6 maanden na herstel van euthyreoïdie. 
Daarom adviseren wij om de noodzaak van TSH suppressieve behandeling in patiënten met 
gedifferentieerd schildkliercarcinoom zorgvuldig te overwegen per patiënt.
VII. Kwaliteit-van-leven
Kwaliteit-van-leven kan beïnvloed zijn in patiënten met gedifferentieerd schildkliercarcinoom 
door enerzijds de diagnose en initiële behandeling en anderzijds de TSH suppressieve 
behandeling. Er zijn verscheidene studies gedaan naar dit onderwerp, echter de resultaten 
zijn niet eenduidig. Daarom hebben we kwaliteit-van-leven onderzocht in een groot cohort 
van genezen patiënten met gedifferentieerd schildkliercarcinoom gebruik makend van 
verschillende kwaliteit-van-leven vragenlijsten en hebben we deze resultaten vergeleken 
met de resultaten van gematchte gezonde vrijwilligers (hoofdstuk 11). 
Onze bevindingen tonen een verminderde kwaliteit-van-leven in patiënten met genezen 
gedifferentieerd schildkliercarcinoom, wat mogelijk hersteld kan worden na jaren van follow-
up. Een langere duur van genezing werd geassocieerd met betere scores op de verschillen 
kwaliteit-van-leven onderdelen. Voordelen van onze studie zijn het grote aantal patiënten 
geïncludeerd in de studie, het gebruik van verschillende kwaliteit-van-leven vragenlijsten en 
de vergelijking met gematchte gezonde vrijwilligers. 
De gevolgen van subklinische hyperthyreoïdie op de kwaliteit-van-leven zijn ook onduidelijk. 
De studies die dit onderwerp hebben bestudeerd includeerden geselecteerde groepen 
patiënten met gedifferentieerd schildkliercarcinoom of patiënten met endogene subklinische 
hyperthyreoïdie waarin de duur en het beloop van de subklinische hyperthyreoïdie niet 
bekend zijn. In onze studie was kwaliteit-van-leven niet beïnvloed door veranderingen in 
TSH-waarden ten tijde van het onderzoek of gedurende de tijd sinds initiële behandeling.
Samengevat, kwaliteit-van-leven wordt beïnvloed in een groot cohort van genezen patiënten 
met gedifferentieerd schildkliercarcinoom vergeleken met gematchte gezonde vrijwilligers. 
Alleen een langere duur van genezing kan deze effecten normaliseren.
Klinische implementaties
Artsen moeten er op bedacht zijn dat, ondanks de goede prognose, het psychologische 
welzijn van genezen patiënten met gedifferentieerd schildkliercarcinoom beïnvloed kan zijn 
en dat professionele hulp moet worden aangeboden wanneer deze noodzakelijk is. 
VIII. D2-Thr92Ala polymorfisme en schildklierhormoon
Er bestaat onenigheid over de functionele implicaties van het D2-Thr92Ala polymorfisme. Daarom 
hebben we de associatie tussen het D2-Thr92Ala polymorfisme, schildklierhormoonwaarden 
en de schildklierhormoon onderzocht in 2 separate groepen patiënten: patiënten zonder 
schildklier die behandeld zijn voor gedifferentieerd schildkliercarcinoom en patiënten met 
Hashimoto thyreoïditis (hoofdstuk 12). 
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Het D2-Thr92Ala polymorfisme was niet geassocieerd met schildklierhormoonwaarden en 
schildklierhormoon in de 2 separate groepen van patiënten in onze analyse, wat overeenkomt 
met de resultaten uit andere studies. Echter, Torlontano et al. berichtten dat homozygote 
dragers van het D2-Thr92Ala polymorfisme een hogere dosis schildklierhormoon nodig 
hebben. Dit verschil was aanwezig in de bijna-TSH suppressieve groep, maar niet in de TSH 
suppressieve groep. Beperkingen van deze studie zijn de afwezigheid van data over TSH-
waarden in de bijna-TSH suppressieve groep en de analyse strategie, die primair gericht zou 
moeten zijn regressie analyses in plaat van categorieën naar TSH-waarden. Het is opmerkelijk 
dat Torlontano et al. geen verschillen in schildklierhormoonwaarden vond, wat er op wijst dat 
patiënten met het D2-Thr92Ala polymorfisme een hogere schildklierhormoon nodig hebben 
om dezelfde FT4 waarden te bereiken wat suggereert dat het Ala allel de schildklierhormoon 
absorptie beïnvloed in plaats van de schildklierhormoon feedback. Bovendien werd deze 
associatie tussen het D2-Thr92Ala polymorfisme en schildklierhormoon alleen gevonden in 
de bijna-TSH suppressieve groep, wat een slecht gedefinieerde groep is met een wijde range 
in TSH-waarden waarin ook patiënten met normale TSH-waarden zitten. 
In conclusie, er werd geen associatie gevonden tussen het D2-Thr92Ala polymorfisme en 
schildklierhormoon in patiënten met gedifferentieerd schildkliercarcinoom zonder schildklier 
en in patiënten met Hashimoto thyreoïditis. 
14
 
N
ed
er
la
nd
se
 s
am
en
va
tt
in
g
208
List of publications
1.  W.E. Visser, K.A. Heemstra, S.M. Swagemakers, E.P. Corssmit, W.F. van IJcken, P.J. 
van der Spek, J.W. Smit, T.J. Visser. Physiological levels of thyroid hormone regulate 
a myriad of transcripts in human skeletal muscle. Journal of Clinical Endocrinology 
and Metabolism, in press.
2.  K.A. Heemstra, J. Burggraaf1, A.A. van der Klaauw, J.A. Romijn, J.W. Smit, E.P. 
Corssmit. Short-term overt hypothyroidism induces sympathovagal imbalance in 
thyroidectomized differentiated thyroid carcinoma patients. Clinical Endocrinology, 
in press.
3.  K.A. Heemstra, M.R. Soeters, E. Fliers, M.J. Serlie, J. Burggraaf, M.B. van Doorn, A.A. 
van der Klaauw, J.A. Romijn, J.W. Smit, E.P. Corssmit, T.J. Visser. Type 2 iodothyronine 
deiodinase in skeletal muscle: effects of hypothyroidism and fasting. Journal of 
Clinical Endocrinology and Metabolism. 2009;94(6):2144-50.
4.  H.C. Hoftijzer, J. J. Bax, K.A. Heemstra, G.B. Bleeker, A.A. van der Klaauw, J.A. Romijn, 
J.W.A. Smit, E.P.M. Corssmit. Short-term, overt hypothyroidism induces discrete 
diastolic dysfunction in patients treated for differentiated thyroid carcinoma. Journal 
of Clinical Investigation, in press.
5.  K.A. Heemstra, H.C. Hoftijzer, W.M. van der Deure, R.P. Peeters, E. Fliers, B.C. 
Appelhof, W.M. Wiersinga , E.P.M. Corssmit, T. J. Visser, J.W.A. Smit. The Thr92Ala 
polymorphism in the type 2 deiodinase is not associated with thyroxine dose in 
athyroid patients or patients with Hashimoto thyroiditis. Clinical Endocrinology, in 
press.
6.  K.A. Heemstra, R.E. Toes, J. Sepers, A.M. Pereira, E.P. Corssmit, T.W. Huizinga, 
J.A. Romijn, J.W. Smit. Rituximab in Relapsing Graves’ Disease, a Phase II Study. 
European Journal of Endocrinology 2008;159(5):609-15.
7.  K.A. Heemstra, W.M. van der Deure, R.P. Peeters, N.A. Hamdy, M.P. Stokkel, 
E.P. Corssmit, J.A. Romijn, T.J. Visser, J.W. Smit. Thyroid hormone independent 
associations between serum TSH levels and indicators of bone turnover in cured 
patients with differentiated thyroid carcinoma. European Journal of Endocrinology. 
2008;159(1):69-76.
8.  C.F.A. Eustatia-Rutten, E.P.M. Corssmit, K. A. Heemstra, J.W.A. Smit, R. C. Schoemaker, 
J.A. Romijn, J. Burggraaf. Autonomic nervous system function in chronic exogenous 
subclinical thyrotoxicosis and the effect of restoring euthyroidism. Journal of Clinical 
Endocrinology and Metabolism. 2008 Jul;93(7):2835-41.
9.  K.A. Heemstra, H.C. Hoftijzer , E.P. Corssmit, A.A. van der Klaauw, J.A. Romijn, J.W. 
Smit. Quality of life in cured patients with differentiated thyroid carcinoma. Journal 
of Clinical Endocrinology and Metabolism. 2008;93(1):200-3.
10.  G.C. Hovens, K.A. Heemstra, A.M. Buiting, M.P. Stokkel, M. Karperien, B.E.Ballieux, 
209
A.M. Pereira, J.A. Romijn, J.W. Smit. Induction of Stimulating Thyrotropin Receptor 
Antibodies after Radioiodine Therapy for Toxic Multinodular Goitre andGraves’ 
Disease Measured with a Novel Bioassay. Nuclear Medicine Communications. 
2007;28(2):123-7.
11.  K.A. Heemstra, Y.Y. Liu, M. Stokkel, J. Kievit, E.P.M. Corssmit, A.M. Pereira, J.A. Romijn, 
J.W. Smit. Serum Thyroglobulin Concentrations Predict Disease-freeRemission and 
Death in Differentiated Thyroid Carcinoma. Clinical Endocrinology. 2007;66(1):58-
64.
12.  K.A. Heemstra, J.W.A. Smit, C.F.A Eustatia-Rutten, A.C. Heijboer, M. Frölich, J.A.Romijn, 
E.P.M.Corssmit. Glucose Tolerance and Lipid Profile in Long-term Exogenous 
Subclinical Hyperthyroidism and the Effects of Restoration of Euthyroidism, a 
Randomised Controlled Trial.” Clinical Endocrinology. 2006;65(6):737-44.
13.  K.A. Heemstra, N.A.T. Hamdy, J.A. Romijn, J.W.A. Smit. The Effects of TSH Suppressive 
Therapy on Bone Metabolism in Patients with Well-Differentiated Thyroid Carcinoma 
(review). Thyroid. 2006;16(6):583-91.
Li
st
 o
f p
ub
lic
at
io
ns
210
211
Curriculum vitae
Karen Anne Heemstra werd geboren op 7 februari 1982 in Weert. Zij behaalde in 2000 
haar Gymnasium diploma aan de Philips van Horne Scholengemeenschap in Weert. Hierna 
verbleef zij een jaar in Bergen, Noorwegen op Fana Følkehøgskule, waar zij outdoor life 
en ecologie bestudeerde. In 2001 werd zij via de decentrale selectie geselecteerd om 
geneeskunde te mogen studeren aan de Universiteit Leiden. Tijdens deze studie volgde 
zij vakken aan het Karolinska Institutet in Stockholm, Zweden. In 2005 begon zij via het 
excellente studententraject met promotieonderzoek op de afdeling endocrinologie van het 
Leids Universitair Medisch Centrum onder begeleiding van Prof. Dr. J.W.A. Smit, Prof. Dr. 
J.A. Romijn, en Dr. E.P.M. van der Kleij-Corssmit. Zij verrichtte onderzoek naar de klinische 
effecten van schildklierhormoon op het metabolisme. In 2008 kreeg zij de Medical Student 
Achievement Award van de Endocrine Society. Tevens was zij winnaar van de S.E. de Jonghprijs. 
Zij behaalde haar artsenbul in maart 2008. Hierna werkte zij als arts-onderzoeker op de 
afdeling endocrinologie. Per 1 juli is zij begonnen met de opleiding tot arts-microbioloog 
in het Universitair Medisch Centrum Utrecht (Opleiders: Dr. A.J.L. Weersink, Prof. Dr. J. 
Verhoef).
Cu
rr
ic
ul
um
 v
ita
e
212
Nawoord
Een proefschrift ontstaat nooit door maar één persoon. 
Allereerst wil ik mijn promotoren Prof. Dr. J.W.A. Smit en Prof. Dr. J.A. Romijn bedanken. 
Beste Jan, ik kan me nog goed herinneren dat ik als student begon met statusonderzoek 
bij jou. Dat dit uiteindelijk heeft geleid tot dit proefschrift had ik toen nooit verwacht. 
Dank voor al je hulp bij het schrijven van dit boekje!
Beste Hans, jij was degene die mij de kans gaf te promoveren. Dank voor je vertrouwen 
in mij.
Tevens wil ik mijn co-promotor Dr. E.P.M. van de Kleij-Corssmit bedanken. Beste Noortje, 
je had altijd tijd voor me als ik iets wilde vragen. Dank voor al je steun en de fijne 
samenwerking.
Veel dank ben ik ook verschuldigd aan Prof. Dr. T.J. Visser. Beste Theo, een bezoek aan 
jouw lab werkte altijd inspirerend. Dank voor de fijne samenwerking! Ook Robin, Wendy 
en Edward wil ik bedanken voor al jullie hulp!
Koos Burggraaf, dank voor je hulp bij de bioptenstudie en HRV artikelen. Maarten, dank 
voor de samenwerking bij het bioptenstuk!
Dieke, toen ik co-schappen ging lopen heb jij een deel van mijn onderzoek overgenomen 
en ik na mijn arts-examen weer een deel van jouw onderzoek. Het was altijd fijn om met 
je te werken. Nu op naar jouw promotie!
Ook de andere AIO’s van de afdeling dank voor alle gezelligheid en  hulp bij (statistische) 
problemen. 
Zonder de secretaresses van de polikliniek en Eveline de Lange had ik nooit alle 
patiënten kunnen zien. Hiervoor veel dank! Ook mijn dank voor de secretaresses van het 
stafsecretariaat (Caroline, Marianne en Marjolein). Beb Ladan, bedankt voor al je hulp in 
het onderzoekscentrum.
Mijn paranymfen; Anna en Froukje: ik hoop dat onze vriendschappen nog lang mogen 
duren. Anna; na al jouw boeken, nu ook eens een boek van mij! Frouk, dank voor al 
je werk en tijd die je in het lay-outen van mijn boekje hebt gestopt. Je hebt het super 
gedaan!
Cordial W’elles (Anna, Eveline, Ilse, Irene, Jacquelien, Judith, Nina, Laure, Liselotte, 
Maartje en Palesa): de afgelopen jaren hebben we lief en leed gedeeld samen. Dank 
voor de maandagen vol lekker eten en gezelligheid. Lieve Ilse, helaas komt dit boekje te 
laat voor jou om mee te maken, maar in mijn hart ben je vandaag bij me. 
Alle andere vrienden en familie bedankt voor jullie interesse, afleiding, gezelligheid, 
weekendjes  en mooie salsa-avonden!
Mijn ouders:  dank voor jullie geloof en vertrouwen in mij! Harald en Lars, dank voor alle 
fijne gesprekken, gezelligheid en goede adviezen!
Als laatste Menno; ondanks dat we op hele andere vakgebieden onderzoek doen, begreep 
jij toch altijd mijn problemen als ik weer eens vast zat. Dank voor al je steun en liefde!
